0001213900-26-055369.txt : 20260513 0001213900-26-055369.hdr.sgml : 20260513 20260512214251 ACCESSION NUMBER: 0001213900-26-055369 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20260331 FILED AS OF DATE: 20260513 DATE AS OF CHANGE: 20260512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dominari Holdings Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 07 Trade & Services EIN: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41845 FILM NUMBER: 26970624 BUSINESS ADDRESS: STREET 1: 725 FIFTH AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 393-4540 MAIL ADDRESS: STREET 1: 725 FIFTH AVENUE STREET 2: 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: AIkido Pharma Inc. DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 10-Q 1 ea0289782-10q_dominari.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2026

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________to ________

 

Commission File Number: 001-41845

 

DOMINARI HOLDINGS INC.
(Exact name of registrant as specified in its charter)

 

Delaware   52-0849320
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer Identification No.)

 

725 5th Avenue, 23rd Floor, New York, NY 10022
(Address of principal executive offices and Zip Code)

 

(212) 393-4540
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock ($0.0001 par value per share)   DOMH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of May 12, 2026 there were 22,613,781 shares of the Company’s common stock issued and outstanding.

 

 

 

 

DOMINARI HOLDINGS INC.

 

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2026

 

TABLE OF CONTENTS

 

  Page
     
Part I - Financial Information  
     
Item 1. Financial Statements (Unaudited) 1
     
  Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025 1
     
  Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited) 2
     
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited) 3
     
  Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited) 4
     
  Notes to the Condensed Consolidated Financial Statements (Unaudited) 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 28
     
Item 4. Controls and Procedures 29
     
Part II - Other Information 30
     
Item 1. Legal Proceedings 30
     
Item 1A. Risk Factors 30
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30
     
Item 3. Defaults Upon Senior Securities 30
     
Item 4. Mine Safety Disclosures 30
     
Item 5. Other Information 30
     
Item 6. Exhibits 31
     
Signatures 32

 

i

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Balance Sheets

($ in thousands except share and per share amounts)

 

   March 31,   December 31, 
   2026   2025 
   (Unaudited)     
ASSETS        
Cash and cash equivalents  $27,477   $34,005 
Marketable securities   6,901    46,516 
Securities owned   11,118    9,756 
Receivable from clearing brokers   21,883    3,995 
Long-term equity investments   11,846    11,744 
Loans to employees   1,669    1,767 
Right-of-use assets   2,586    2,721 
Prepaid expenses and other assets   1,840    2,403 
Total assets  $85,320   $112,907 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Accounts payable and accrued expenses  $777   $611 
Accrued compensation and commissions   25,005    17,754 
Accrued dividends payable   364    10,335 
Contract liabilities   4,679    4,504 
Lease liability   2,744    2,841 
Income taxes payable   20,174    7,318 
Other liabilities   
-
    173 
Total liabilities   53,743    43,536 
           
Stockholders’ equity          
Preferred stock, $.0001 par value, 50,000,000 authorized   
 
    
 
 
Convertible Preferred Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding as of March 31, 2026 and December 31, 2025; liquidation value of $0.0001 per share   
-
    
-
 
Convertible Preferred Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding as of March 31, 2026 and December 31, 2025; liquidation value of $0.0001 per share   
-
    
-
 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 22,613,781 and 16,067,435 shares issued as of March 31, 2026, and December 31, 2025, respectively; 22,613,781 and 16,067,435 shares outstanding as of March 31, 2026 and December 31, 2025, respectively   2    
-
 
Additional paid-in capital   357,099    337,505 
Accumulated deficit   (325,492)   (268,134)
Total Dominari stockholders’ equity   31,609    69,371 
Non-controlling interests   (32)   
-
 
Total stockholders’ equity   31,577    69,371 
Total liabilities and stockholders’ equity  $85,320   $112,907 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

1

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Operations

($ in thousands except share and per share amounts)

(Unaudited)

 

   Three Months Ended 
   March 31, 
   2026   2025 
Revenues        
Underwriting services  $32,949   $5,606 
Carried interest   1,096    
-
 
Commissions   2,490    2,190 
Interest income   308    39 
Principal transactions   (1,532)   (910)
Other revenue   494    315 
Total revenue   35,805    7,240 
           
Operating costs and expenses          
Compensation and benefits   68,159    15,457 
Advisory fees   36    20,944 
Legal fees   1,485    704 
Professional and consulting fees   876    829 
Other expenses   2,871    2,188 
Total operating expenses   73,427    40,122 
Loss from operations   (37,622)   (32,882)
           
Other income (expenses)          
Other income   108    
-
 
Interest income   61    21 
Gain (loss) on marketable securities, net   (7,014)   (168)
Realized and unrealized gain loss on notes receivable, net   
-
    221 
Change in carrying value of investments   
-
    320 
Total other income (expenses)   (6,845)   394 
Net loss before income tax expense  $(44,467)  $(32,488)
Provision for income taxes   12,868    
-
 
Net loss   (57,335)   (32,488)
Less: Net income attributable to non-controlling interests   23    
-
 
Net loss attributable to common stockholders of Dominari Holdings Inc.  $(57,358)  $(32,488)
           
Net loss per share, basic and diluted          
Basic and Diluted  $(3.17)  $(3.02)
           
Weighted average number of shares outstanding, basic and diluted          
Basic and Diluted   18,068,269    10,775,219 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

2

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

($ in thousands except share and per share amounts)

(Unaudited)

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Accumulated   Dominari
Holding
Stockholders’
   Non-
Controlling
   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity   Interests   Equity 
Balance at December 31, 2025   4,659   $           -    16,067,435   $        -   $337,505   $(268,134)  $     69,371   $             -   $       69,371 
Stock-based compensation - employees   
-
    
-
    6,471,346    2    19,241    
-
    19,243    
-
    19,243 
Issuance of common stock from warrants exercised   
-
    
-
    75,000    
-
    317    
-
    317    
-
    317 
Stock-based compensation- advisors   -    
-
    -    
-
    36    
-
    36    
 
    36 
Distributions to non-controlling interest   -    
-
    -    
-
    
-
    
-
    
-
    (55)   (55)
Net loss   -    
-
    -    
-
    
-
    (57,358)   (57,358)   23    (57,335)
Balance at March 31, 2026   4,659   $
-
    22,613,781   $2   $357,099   $(325,492)  $31,609   $(32)  $31,577 

 

   Preferred Stock   Common Stock   Additional
Paid-in
   Treasury Stock   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Shares   Amount   Deficit   Equity 
Balance at December 31, 2024   4,659   $
         -
    7,037,022   $
         -
   $263,820    60,148   $(501)  $(223,466)  $      39,853 
Stock-based compensation   
-
    
-
    1,240,969    
-
    7,682    -    
-
    
-
    7,682 
Issuance of common stock   
-
    
-
    3,876,054    
-
    13,517    -    
-
    
-
    13,517 
Advisory shares issued   
-
    
-
    2,550,000    
-
    20,944    -    
-
    
-
    20,944 
Dividends issued   -    
-
    -    
-
    
-
    -    
-
    (7,080)   (7,080)
Net loss   -    
-
    -    
-
    
-
    -    
-
    (32,488)   (32,488)
Balance at March 31, 2025   4,659   $-    14,704,045   $-   $305,963    60,148   $(501)  $(263,034)  $42,428 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

 

DOMINARI HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

($ in thousands)

(Unaudited)

 

   Three Months Ended 
   March 31, 
   2026   2025 
Cash flows from operating activities        
Net loss  $(57,335)  $(32,488)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of right-of-use assets   135    52 
Depreciation   26    26 
Change in carrying value of long-term investment   
-
    (320)
Non-cash underwriting revenues   (10,080)   (697)
Non-cash commission expense   7,610    
-
 
Stock-based compensation – employees   19,243    28,626 
Stock-based compensation – advisors   36    
-
 
Realized (gain) loss on securities owned   (590)   714 
Unrealized loss on securities owned   2,122    259 
Realized loss on marketable securities   6,949    670 
Unrealized (gain) loss on marketable securities   115    (468)
Realized and unrealized (gain) loss on note receivable   
-
    (221)
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   537    (2,401)
Receivable from clearing brokers   (17,888)   4,848 
           
Accounts payable and accrued expenses   165    520 
Accrued compensation and commissions   7,251    1,210 
Right of use asset and liability, net   (97)   (122)
Contract liabilities   175    632 
Income taxes payable   12,856    
-
 
Other liabilities   (173)   395 
Net cash (used in) provided by operating activities   (28,942)   1,235 
           
Cash flows from investing activities          
Purchase of marketable securities   (9,185)   (9,035)
Sale of marketable securities   41,736    1,776 
Purchase of securities owned   (1,666)   
 
 
Sale of securities owned   1,242    
-
 
Purchase of long-term investments   (102)   
-
 
Redemption of long-term investments   
-
    538 
Collection of principal on note receivable   
 
    1,143 
Collection of loans to employees   98    142 
Net cash provided by (used in) investing activities   32,123    (5,436)
           
Cash flows from financing activities          
Cash paid for dividends   (9,971)   (7,080)
Distributions to non-controlling interest   (55)   
-
 
Cash from issuance common stock, net of offering cost   
-
    13,517 
Cash from issuance common stock for exercised warrants   317    
-
 
Net cash (used in) provided by financing activities   (9,709)   6,437 
           
Net increase in cash and cash equivalents   (6,528)   2,236 
Cash and cash equivalents, beginning of period   34,005    4,079 
Cash and cash equivalents, end of period  $27,477   $6,315 
           
Cash paid for interest and taxes  $17   $
-
 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

DOMINARI HOLDINGS INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). The registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financials’ acquisition of FPS’ Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

 

On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”), which are both wholly owned subsidiaries and whose operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”). The Company holds a ninety percent (90%) Membership Interest in each, and their operations are included within the condensed consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

Note 2. Liquidity and Capital Resources

 

The Company monitors its liquidity position on a regular basis The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to fund its activities through managing current cash on hand from the Company’s past equity offerings.

 

As of March 31, 2026, the Company has approximately $27.5 million of cash and cash equivalents and $6.9 million of marketable securities as well as $11.1 million of securities owned. Additionally, the Company had approximately $21.9 million in receivable from clearing brokers. Additionally, the Company’s working capital balance at March 31, 2026, totaled $21.9 million. Unless otherwise noted, all such funds are available to fund the Company’s operations. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities, together with the anticipated cash flow to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

 

5

 

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2025 Annual Report.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheets as of March 31, 2026, condensed consolidated statements of operations for the three months ended March 31, 2026 and 2025, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2026 and 2025, and the condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026 or for any future interim period. The condensed consolidated balance sheets as of December 31, 2025 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial Inc., Dominari IM LLC, Dominari Manager LLC and Dominari Securities along with American Ventures IM LLC and American Ventures Manager LLC, both of which are owned 90% by the Company. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Joint Ventures

 

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its unaudited condensed consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of March 31, 2026, there has been no material activity in DFHS.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, marketable securities, securities owned, the valuation of long-term equity investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Securities owned

 

Securities owned consist of equity securities including, common stock and warrants of publicly traded companies which are held by Dominari Securities. Securities owned and securities sold, but not yet purchased are recorded in the balance sheet at fair value, with the change in fair value and any realized gains or losses upon purchase or sale recorded within the statement of operations as principal transactions.

 

Dominari Securities may receive securities, including common or preferred stock and stock purchase warrants, from companies as part of its compensation for underwriting services. These instruments are stated at fair value in accordance with GAAP, and recorded within the balance sheet as securities owned. Such securities that the Company receives may be subject to contractual or instrument specific restrictions which prevent Dominari Securities from reselling the securities within the open market. Under ASC 820 only those restrictions which are an attribute of the instrument, and do not arise from any contractual agreement, are considered when determining fair value.

 

6

 

A portion of the Company’s equity securities, which are held by Dominari Securities, are subject to restrictions as disclosed in Note 7. Equities that have periods of contractual trading restrictions, discounts were considered in determining fair value The Company’s significant unobservable inputs, included the implied probability of 15% of certain marketplace transactions and events occurring, which would permit the sale of equities held. These equities are included in securities owned.

 

Warrant Investments

 

Warrant fair values are primarily determined using a Black Scholes option pricing model, which includes the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value. Warrants held by Dominari Securities are included in securities owned and other warrants are included in marketable securities.

 

The following inputs are considered for determining the fair values of warrants:

 

The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.

 

The expected remaining term is equal to the time to expiration of the warrant investment.

 

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.

 

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.

 

Marketability discounts are applied for warrants that have sales restrictions (or lock-up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.

 

Receivable from Clearing Brokers

 

Receivable from Dominari Securities’ clearing brokers totaling $21.9 million consisted of approximately $0.5 million of liquid insured deposits $3.7 million of commission receivable and $17.7 million of liquid deposits maintained by the Company with its clearing brokers as of March 31, 2026. Receivable from Dominari Securities’ clearing brokers consisted of approximately $1.4 million of liquid insured deposits, $2.1 million of commissions receivable and $0.5 million of liquid deposits maintained by the Company with its clearing brokers as of December 31, 2025. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of March 31, 2026 and December 31, 2025 an allowance for credit losses was deemed not necessary.

 

Long-term Equity Investments and marketable securities

 

The Company holds certain strategic investments that are not part of its broker-dealer trading activities. The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying unaudited condensed consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are accounted for under ASC 321 using the measurement alternative. Equity method investments and other long-term investments that are not part of our broker-dealer trading activities are included in “long term equity investment” on the unaudited condensed consolidated balance sheet. These investments are generally strategic in nature and are not actively traded. Unrealized gains and losses on these investments are recognized in earnings when impairment is identified or when observable price changes occur and are classified in other income (loss) in the unaudited condensed consolidated statement of operations.

 

7

 

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 9 - Leases).

 

Revenue

 

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

 

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

 

Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized. The Company records such Non-Cash Consideration on the date at which its performance obligation is fulfilled using the date of contract inception as the fair value measurement date, as required by FASB ASC 606-10-32-21 and recorded as underwriting revenues. Any changes resulting from the form of the consideration after contract inception (e.g. fair value) are not included in the transaction price and, therefore, are included in principal transactions. To the extent changes in the noncash consideration occur for reasons other than the form of the consideration (e.g., notional quantity of instruments provided is based upon the Company’s performance), the Company applies relevant guidance on variable consideration, constraining such amounts until the associated uncertainty is resolved. Similarly, any commissions or compensation expense from providing non-cash consideration provided to employees and is recognized at fair value in accordance with ASC 820 on the same date.

 

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying unaudited condensed consolidated balance sheet.

 

8

 

Carried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high-water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Carried Interest Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to claw back or reversal.

 

Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:

 

oThe Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.

 

oManagement fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.

 

Principal transactions are recorded on a trade-date basis (as if they had settled). Realized and unrealized gains and losses arising from all securities transactions entered into for the account and risk of the Company are recorded in principal transactions in the accompanying statement of operations. These gains and losses are not in scope for ASC 606 as they are not generated from contracts with customers.

 

Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management As of March 31, 2026, the Company recognized $4.7 million of contract liabilities of which $1.1 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2031. During the three months ended March 31, 2026, the Company recognized revenue of $0.3 million that was included in contract liabilities as of March 31, 2026.

 

Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b-1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.

 

Compensation and benefits

 

Compensation and benefits includes fixed salaries, commissions (paid in either cash or in securities), related benefits and stock-based compensation incurred on an accrual basis. The Company has a defined contribution 401(k) plan that covers all employees and allows an employer contribution of up to 50% of the first 3% of each participating employee’s eligible compensation contributed to the plan and 50% of the next two percent of each participating employee’s eligible compensation. Participants are 100% vested in these matching contributions when they are made. Eligible employees may elect to defer pre-tax contributions regulated under Section 401(k) of the Internal Revenue Code. The Company’s matching contributions are included in compensation and benefits in the unaudited condensed consolidated statements of operations. Please see “Stock based compensation” section below for additional information on stock-based compensation accounting policies.

 

Stock-based Compensation

 

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on either the simplified method, if applicable, which is the half-life from vesting to the end of its contractual term or when applicable, probability estimates of expected exercises of such options.

 

9

 

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

 

The Company accounts for forfeitures as they occur.

 

Income Taxes

 

Income tax expense for interim periods is calculated in accordance with ASC 740, Income Taxes, and ASC 740 270, Interim Reporting. Interim periods are treated as integral parts of the annual reporting period, and income tax expense is recognized using estimates that reflect management’s best assessment of the expected annual tax position, including discrete items recognized in the period incurred.

 

Effect of new accounting pronouncements to be adopted in future periods

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity discloses more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its financial statements.

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

 

Reclassification of prior year amounts

 

Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or stockholders’ equity.

 

Note 4. Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2026 and 2025, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended 
   March 31, 
   2026   2025 
Realized gain / (loss)  $(6,949)  $(732)
Unrealized gain / (loss)   (115)   468 
Interest and dividend income   50    96 
Total  $(7,014)  $(168)

 

10

 

Note 5. Long-Term Equity Investments

 

The Company holds interests in several privately held companies as long-term investments. The following table presents the Company’s long-term investments as of March 31, 2026, and December 31, 2025 ($ in thousands):

 

   March 31, 2026   December 31, 2025 
       Carrying       Carrying 
   Cost Basis   Value   Cost Basis   Value 
Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a.                    
Masterclass)*   170    170    170    170 
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a.Kraken)* *   597    364    597    364 
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.)**   1,240    1,240    1,240    1,240 
                     
Investment in Discord Inc.   476    476    476    476 
                     
Investment in Automation Anywhere, Inc.   476    397    476    397 
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
Investment in AdvEn Inc.   750    750    750    750 
Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..)   102    102    -    - 
Total  $10,601   $11,846   $10,499   $11,744 

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investment made in these companies are through both an SPV and direct investments.

 

The Company had no changes to the carrying values for the three months ended March 31, 2026, and recorded an increase in the carrying values of approximately $0.3 million for the three months ended March 31, 2025. Please see below details of the changes in carrying value by investment.

 

Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)

 

On July 25, 2024, the Company entered into an agreement (the “Groq Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XII Groq Units for $25 thousand. As of March 31, 2026, there was no change to the carrying value. On April 6, 2026, the Company received a payment of $58 thousand as a payment related to the Company’s investment.

 

Investment in TracX.

 

On January 13, 2026, the Company entered into an agreement (the “TracX Agreement”) with American Ventures LLC whereby the Company agreed to purchase Series XX TracX Logis units for $102 thousand.

 

Note 6. Notes Receivable

 

As of March 31, 2026, and December 31, 2025, the Company had no notes receivable.

 

American Innovative Robotics, LLC

 

The Company recorded interest income of approximately $20,000, and a realized gain on the note of approximately $221,000 on the American Innovative Robotics Promissory Note in the 31, 2025. The note was fully paid off as of March 24, 2025, with proceeds totaling $1.1 million, resulting in an ending value of $0.

 

11

 

Note 7. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued expenses and accrued compensation and commissions are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2026 and December 31, 2025 ($ in thousands):

 

   Fair value measured as of March 31, 2026 
       Quoted   Significant     
   Total at   prices in
Active
   other
observable
   Significant
unobservable
 
   March 31,   Markets   inputs   inputs 
   2026   (Level 1)   (Level 2)   (Level 3) 
Assets                
Securities owned  $11,118   $
   $9,467   $1,651 
Marketable securities  $6,901   $5,494   $1,407   $
 

 

   Fair value measured as of December 31, 2025 
       Quoted   Significant     
   Total at   prices in active   other observable   Significant unobservable 
   December 31,   markets   inputs   inputs 
   2025   (Level 1)   (Level 2)   (Level 3) 
Assets                
Securities owned  $9,756   $
   $8,014   $1,742 
Marketable securities  $46,516   $45,049   $1,467   $
 

 

The fair value of level 3 securities owned totaling $1.7 million shown above at March 31, 2026 are subject to an initial lock-up period until approximately June 30, 2026, and further restrictions to which the Company cannot liquidate its investment until such restrictions are met. Additionally, approximately $1.1 million of fair value of level 2 securities owned shown above at March 31, 2026 represents warrants that are subject to lock-up periods that will end by June 30, 2026 and another $4.3 million of fair value of warrant securities with lock-up periods that will end by September 30, 2026 as well.

 

12

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Securities owned at fair value as of December 31, 2025  $1,741 
      
Unrealized loss included in principal transactions  $(90)
Securities owned at fair value as of March 31, 2026  $1,651 

 

The Company’s Level 3 fair value measurements at March 31, 2026 were determined by the following quantitative inputs:

 

The underlying stock price of $10.01 per share as of the measurement date.

 

Implied success rates of similar type instruments from other comparable entities’ recent historical results of 15% of the underlying value of the stock price.

 

Note 8. Prepaid expenses and other assets

 

Other assets consist of the following as of March 31, 2026, and December 31, 2025 ($ in thousands):

 

   March 31,
2026
   December 31,
2025
 
Prepaid expenses  $480   $805 
Security deposits   483    483 
Property and equipment, net   108    135 
Other   769    980 
Total  $1,840   $2,403 

 

Note 9. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “23rd Floor Premises”). Dominari Financial currently uses the 23rd Floor Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the 23rd Floor Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the 23rd Floor Premises in February 2023.

 

13

 

On September 2, 2025, the Company entered into a Lease Agreement (the “Company’s Florida Lease”) with Blue Diamond Towers, LLC, a Delaware limited liability company. Under the Company’s Florida Lease, the Company rents a portion of the first floor designated as Suite 103 of the North Building at 3835 PGA Boulevard in Palm Beach Gardens, Florida, (the “Florida Premises”). The Company will use the Florida Premises as Executive Offices. The initial term of the Company’s Florida Lease is two (2) years commencing on October 1, 2025. Under the Company’s Florida Lease, the Company is required to pay monthly rent, commencing on October 1, 2025, equal to $10,000. Effective for the second year of the Company’s Florida Lease, the rent shall increase to $10,300. The Company took possession of Florida Premises in October 2025.

 

The tables below represent the Company’s lease assets and liabilities as of March 31, 2026:

 

   March 31, 
   2026 
Assets:    
Operating lease right-of-use-assets  $2,586 
Liabilities:     
Current     
Operating  $568 
Long-term     
Operating   2,176 
   $2,744 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   March 31, 
   2026 
Weighted-average remaining lease term - operating leases (in years)   4.0 
Weighted-average discount rate - operating leases   10.0%

 

During the years ended March 31, 2026 and 2025, the Company recorded approximately $0.2 million and $0.2 million, respectively, of lease expense to current period operations.

 

   Three Months Ended
March 31,
 
   2026   2025 
Operating leases        
Operating lease cost  $205   $178 
Short-term lease rent expense   3    22 
Net rent expense  $208   $200 

 

As of March 31, 2026, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining period Ended December 31, 2026  $638 
Year Ended December 31, 2027   801 
Year Ended December 31, 2028   766 
Year Ended December 31, 2029   784 
Year Ended December 31, 2030   377 
Thereafter   
-
 
Total   3,366 
Less present value discount   (622)
Operating lease liabilities  $2,744 

 

14

 

Note 10. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.

 

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended March 31, 2026, and 2025 are as follows:

 

   As of March 31, 
   2026   2025 
Convertible preferred stock   34    34 
Warrants to purchase common stock   6,362,098    8,175,188 
Restricted stock awards   396,346    50,000 
Options to purchase common stock   10,072,646    346,654 
Total   16,831,124    8,571,876 

 

Note 11. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

As of March 31, 2026, there are 22,613,781 shares of common stock issued and outstanding This includes 316,346 unvested shares issued that are subject to forfeiture through September 30, 2026, and 80,000 unvested shares issued that are subject to forfeiture through December 11, 2026.

 

On February 10, 2025, the Company entered into securities purchase agreements with certain accredited investors for the sale by the Company of 1,439,467 registered shares of its common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants in a direct offering. In a concurrent private placement, the Company entered into securities purchase agreements with certain accredited investors for the sale of 2,436,587 unregistered shares of common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants (the “February 2025 Financings”). The Series A warrants are exercisable immediately upon issuance at an exercise price of $3.72 per share and will expire five years from the date of issuance. The Series B warrants are exercisable immediately upon issuance at an exercise price of $4.22 per share and will expire five years from the date of issuance. The net proceeds to the Company from the February 2025 Financings were approximately $13.5 million.

 

On February 10, 2025, the Company entered into advisory agreements with various individuals who were issued shares of common stock. The agreements are for a term of two years but are cancellable by either party. As part of these agreements, 2,550,000 shares of common stock were issued on February 18, 2025. An additional 850,000 shares may be issued under the terms of the agreements when certain provisions are met, which as of the date of grant is probable. These shares are nonforfeitable and thus were fully expensed by the Company at the time of grant. The Company used a Monte Carlo simulation to calculate the grant date fair value of the common stock. The fair value of issued shares amounted to $20.9 million and is presented in advisory fees expense on the unaudited condensed consolidated statement of operations.

 

The securities in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered shares, the warrants, and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

 

15

 

Certain officers, directors, employees and members of the Company’s advisory board participated in the February 2025 Financings on the same terms as the other investors.

 

During the period January 1, 2026 to March 31, 2026, various individuals exercised warrants, resulting in the additional issuance of 75,000 shares of common stock and cash proceeds of $0.3 million, which were recorded in additional paid-in capital and are reflected in the unaudited condensed consolidated statements of changes in stockholders’ equity.

 

Series D Convertible Preferred Stock

 

In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

 

As of March 31, 2026, and December 31, 2025, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

 

Series D-1 Convertible Preferred Stock

 

The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

 

As of March 31, 2026 and December 31, 2025, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

 

Dividends

 

On February 11, 2025, the board of directors approved a special cash dividend of $0.32 per share payable on March 3, 2025, to holders of common stock and certain warrant holders as of close of business on February 24, 2025. On September 9, 2025, the board of directors approved a special cash dividend of $0.22 per share payable on September 26, 2025, to holders of common stock and certain warrant holders as of close of business on September 3, 2025. On December 11, 2025, the board of directors approved a special cash dividend of $0.432 per share payable on January 26, 2026, to holders of common stock and certain warrant holders as of close of business on January 5, 2026, Cash dividends declared in 2025 totaled $22.2 million and have been charged to accumulated deficit. Dividends paid for the three months ended March 31, 2025, totaled $7.0 million, and dividends paid for the three months ended September 30, 2025, totaled $4.9 million. Dividends declared totaled $10.3 million during the three months ended December 31, 2025, of which $9.9 million were paid during the three months ended March 31, 2026, resulting in a dividend payable of $0.4 million as of March 31, 2026.

 

16

 

Warrants

 

A summary of warrant activity for the three months ended March 31, 2026, is presented below:

 

               Weighted 
       Weighted       Average 
       Average       Remaining 
       Exercise   Total Intrinsic   Contractual 
   Warrants   Price   Value ($000s)   Life (in years) 
Outstanding as of December 31, 2025   6,690,768   $5.38   $6,186    3.9 
Granted   
-
    
-
    
-
    
-
 
Expired   (253,670)  $34.00    
-
    
-
 
Exercised   (75,000)  $4.22    
-
    - 
Outstanding as of March 31, 2026   6,362,098   $4.25   $
              -
    3.8 

 

Restricted Stock Awards and Stock Options

 

On October 7, 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”). The 2022 Plan provided for the issuance of up to 1,100,000 shares in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2022 Plan expires on January 1, 2032, and is administered by the Dominari Holdings’ board of directors.

 

On February 10, 2025, the Company issued 50,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $308,000.

 

On February 10, 2025, the Company issued 351,851 shares of the Company’s common stock to Messrs. Christopher Devall under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $2.1 million.

 

On February 12, 2025 in connection with the closing of the PIPE, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant to Messrs. Anthony Hayes. Pursuant to the Committee’s decision, he received 500,000 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $3.4 million.

 

On March 11, 2025, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $1.7 million.

 

On December 10, 2025, the Company issued 316,346 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. These shares will vest on September 30, 2026; provided that in the event of a change in control prior to any such vesting date, the shares, which have not yet vested shall vest and become nonforfeitable upon the effective date of such change in control, with a total fair value of $1.3 million.

 

On December 11, 2025, the Company issued 80,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. These shares will vest on the one-year anniversary of the grant date; provided that in the event of a change in control prior to any such vesting date, the shares, which have not yet vested shall vest and become nonforfeitable upon the effective date of such change in control, with a total fair value of $381 thousand.

 

On January 9, 2026, the Company issued 75,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan to members of the board of directors. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of $320 thousand.

 

On March 4, 2026, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant of 3.0 million shares of the Company’s common stock each to Messrs. Anthony Hayes and Kyle Wool, pursuant to shareholder approval to increase the shares of common stock reserved for issuance under the Company’s 2022 Equity Incentive Plan, which was approved on March 4, 2026 at a Special Meeting of Shareholders Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $18.4 million.

 

17

 

See Restricted Stock roll-forward below.

 

A summary of restricted stock awards activity for the three months ended March 31, 2026, is presented below:

 

       Weighted 
   Number of   Average 
   Restricted   Grant Day 
   Stock Awards   Fair Value 
Nonvested at December 31, 2025   396,346   $4.29 
Granted   6,075,000   $3.08 
Vested   (6,075,000)  $3.08 
Forfeited   
-
   $
-
 
Nonvested at March 31, 2026   396,346   $4.29 

 

Stock-based compensation associated with restricted stock awards was approximately $19.2 million and $7.6 million for the three months ended March 31, 2026, and 2025, respectively. All stock compensation was recorded as a component of compensation and benefits expenses. The 396,346 nonvested restricted stock units that were approved in December 2025 in the table above are reflected as being issued in the unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026.

 

As of March 31, 2026, there is approximately $1.1 million unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

On February 10, 2025, the Company granted an additional 5.0 million fully vested nonqualified stock options (each, a “Performance Award” and collectively, the “Performance Awards”) each to Anthony Hayes and Kyle Wool conditioned upon either the Company’s shareholders approving the Performance Awards or approving an increase in the share reserve of the Company’s 2022 Equity Incentive Plan (the “Plan”) such that the full number of shares underlying the Performance Awards could be delivered under the Plan. On April 1, 2025, following a special meeting of shareholders, the Company’s shareholders voted to approve an increase in the Plan’s share reserve allowing the Performance Awards to be delivered under the Plan. The Company recorded an expense of $26.1 million for the Performance Awards during the second quarter of 2025.

 

On December 1, 2025, the Company entered into an advisory agreement with a certain individual who was issued 50,000 nonqualified stock options (“Advisor Options”). Each party reserves the right to terminate the agreement at any time, with or without cause, upon five (5) days prior written notice to the other party. One half of the Advisor Options shall vest and become exercisable during its term on December 1, 2025, and one half of the Advisor Options shall vest and become exercisable during its term on June 1, 2026, in the manner and subject to the terms and conditions of the Plan and the Stock Option Grant Agreement (the “Option Grant Agreement”). The Company used a Black Scholes valuation to calculate the grant date fair value of the Advisor Options. The fair value of the Advisor Options amounted to $146 thousand and the Company recorded an expense of $36 thousand during the three months ended 2026 related to such options.

 

A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2026, is presented below:

 

                Weighted 
       Weighted        Average 
       Average   Total   Remaining  
   Number of
Shares
   Exercise
Price
   Intrinsic
Value
   Contractual Life (in years) 
Outstanding as of December 31, 2025   10,072,646   $6.16   $26    9.1 
Employee options granted   
-
   $
-
   $-    - 
Employee options exercised   
-
   $
-
   $-    - 
Employee options forfeited   
-
   $
-
   $-    - 
Outstanding as of March 31, 2026   10,072,646   $6.16   $-    8.8 
Options vested and exercisable   10,064,313   $6.17   $-    8.8 

 

Stock-based compensation associated with stock options was approximately $36 thousand and $38 thousand for the three months ended March 31, 2026, and 2025, respectively. All stock compensation was recorded as a component of compensation and benefits expenses.

 

18

 

Estimated future stock-based compensation expense relating to unvested stock options is approximately $24 thousand.

 

Non-controlling Interest

 

As previously discussed, the Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of March 31, 2026, the revenue attributable to non-controlling interest was $23 thousand of which the Company owes $21 thousand at March 31, 2026. During the three months ended March 31, 2026, the Company distributed $55 thousand to non-controlling interests.

 

Note 12. Revenue

 

Disaggregation of Revenue

 

For the three months ended March 31, 2026, and 2025 total revenue and revenue related to contracts with customers within the scope of Topic 606 were ($ in thousands):

 

   Three Months Ended 
   March 31, 
Revenues  2026   2025 
Underwriting services  $32,949   $5,606 
Carried interest   1,096    
-
 
Commissions   2,490    2,190 
Interest income – customers   72    39 
Other revenue   230    249 
Management fees   265    66 
Total revenue from contracts with customers   37,102   $8,150 
Principal transactions   (1,532)   (910)
Interest income – noncustomer   235    
-
 
Total revenue  $35,805   $7,240 

 

Revenue Recognized at a Point in Time

 

The Company recognizes revenue that is transactional in nature and such revenue is earned at a point in time. For the three months ended March 31, 2026, revenue that was recognized at a point in time includes underwriting services of $32.9. million, carried interest of $1.1 million, commissions of $2.5 million and principal transactions losses of $1.5 million consisting of $0.6 million of realized gains and $2.1 million of unrealized losses. For the three months ended March 31, 2025, revenue that is recognized at a point in time includes underwriting services of $5.6 million, commissions of $2.2 million, and principal transactions losses of $0.9 million consisting of $0.3 million of realized gains and $1.2 million of unrealized losses.

 

Revenue Recognized Over Time

 

The Company recognizes revenue over a period of time, generally monthly on a straight-line basis, as services are performed, and performance obligations are satisfied. For the three months ended March 31, 2026, revenue that is recognized over time includes other revenue of $230 thousand, management fees of $265 thousand, interest income from customers of $72 thousand, and interest income-noncustomers of $235 thousand. For the three months ended March 31, 2025, revenue that was recognized over time includes other revenue of $233 thousand, management fees of $66 thousand, and interest income from customers of $53 thousand.

 

19

 

Note 13. Commitments and Contingencies

 

Legal Proceedings

 

The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be. Notwithstanding this uncertainty, the Company does not believe that the results of these potential claims are likely to have a material effect on its financial position or results of operations.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

 

Note 14. Income Taxes

 

The Company’s income tax expense (benefit) for the three months ended March 31, 2026 is as follows ($ in thousands):

 

U.S. Federal  $8,537 
State   4,331 
Foreign   
-
 
Current income tax expense (benefit)  $12,868 
U.S. Federal   
-
 
State   
-
 
Foreign   
-
 
Deferred income tax expense (benefit)   
-
 
Total income tax expense (benefit)  $12,868 

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. For interim periods, the Company applies the estimated annual effective tax rate (“AETR”) method in accordance with ASC 740-270. Under this method, income tax expense for interim periods is computed by applying the estimated annual effective tax rate to year-to-date ordinary pretax income (loss) and adjusting for the tax effects of discrete items recognized in the period.

 

For the three months ended March 31, 2026, the Company recorded income tax expense despite reporting a pretax loss. This result is primarily attributable to a significant permanent difference related to the limitation on the deductibility of certain executive compensation under Internal Revenue Code Section 162(m). The Company currently expects that a substantial portion of executive compensation will not be deductible for income tax purposes for the full fiscal year. As a result, the Company’s estimated annual taxable income is forecasted to be positive, despite an expected pretax book loss. Accordingly, the Company’s estimated annual effective tax rate is negative, as the projected annual income tax expense is divided by an expected pretax book loss. The application of this negative AETR to year-to-date ordinary pretax loss results in the recognition of income tax expense in the interim period, rather than a tax benefit that would otherwise be expected based on the pretax loss.

 

In addition, the Company recognized the tax effect of a discrete item during the three months ended March 31, 2026, which further impacted income tax expense in the period. Discrete items are excluded from the determination of the AETR and are recorded in the period in which they occur. During the period, the Company recognized a book loss of approximately $6.9 million related to the sale of the Company’s marketable securities in American Bitcoin Corp (“ABTC”) stock. For income tax purposes, the majority of the approximate $32.5 million of proceeds from the sale of the Company’s ABTC stock resulted in a $32.5 million were taxable ordinary income which is treated as a discrete item in the interim period. The income tax effect of this transaction increased current income tax expense by approximately $9.5 million.

 

The Company’s effective tax rate for the three months ended March 31, 2026, was (9.0%). The primary drivers of the variance from the statutory rate were state taxes, Sec. 162m disallowed compensation, and valuation allowance. The Company will continue to assess its estimated annual effective tax rate each reporting period. Changes in forecasted pretax income, the amount of non-deductible compensation under Section 162(m), or other factors could result in significant adjustments to the Company’s interim income tax provision in future periods.

 

During the three months ended March 31, 2025, the Company did not record any income tax expense or benefit.

 

20

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company’s history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of all deferred tax assets. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets of approximately $49.4 million as of March 31, 2026 and $38.3 million as of December 31, 2025. For the three-month period ended March 31, 2026, the change in valuation allowance is approximately $11.1 million.

 

As of March 31, 2026, the Company has federal, state post-apportioned, and foreign net operating loss (“NOL”) carryforwards of approximately $76.7 million, $74.5 million, and $0, respectively. Of the federal amount, $29.8 million have a limited carryforward period and will begin to expire in 2026, and $47.0 million will have an indefinite carryforward period. Of the state post-apportioned amount, $74.5 million have a limited carryforward period and will begin to expire in 2038.

 

Utilization of the U.S. NOL carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.

 

The Company completed a Section 382 study through December 31, 2025, and concluded that it underwent ownership changes as defined by the Code on September 10, 2013, March 31, 2014, May 24, 2016, December 5, 2019, March 31, 2020, March 31, 2021, and February 10, 2025. The Company had a net unrealized built-in loss (“NUBIL”) position at each ownership change date. As a result, the Company’s utilization of certain tax attributes, including amortization of acquired intangible assets, is subject to the Section 382 limitation. The Company has approximately $76 million of acquired intangible assets capitalized between 2013 and 2023 that are subject to this limitation.

 

Any future ownership changes that may occur after December 31, 2025, may limit the Company’s ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company’s effective tax rate.

 

Note 15. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is Dominari Securities is subject to SEC Uniform Net Capital Rule (Rule 15c3-1), which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule15c3-1. As of March 31, 2026, Dominari Securities had net capital of approximately $23.4 million in excess of minimum net capital requirement of $0.7 million.

 

Dominari Securities customers’ securities transactions are introduced on a fully-disclosed basis with its clearing broker/dealers. The clearing broker/dealers are responsible for execution, collection of and payment of funds and, receipt and delivery of securities relative to customer transactions. Off-balance-sheet risk exists with respect to these transactions due to the possibility that customers may be unable to fulfill their contractual commitments. The clearing broker/dealers may charge any losses it incurs on customers to Dominari Securities. The Company seeks to minimize this risk through procedures designed at Dominari Securities to monitor the creditworthiness of its customers and to ensure that customer transactions are executed properly by the clearing brokers, by monitoring all customer activity and reviewing information it receives from its clearing broker on a daily basis.

 

Note 16. Related Party Transactions

 

In 2021, the Dominari Holdings engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, Chief Executive Officer and one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023 and held approximately 30% of Revere’s outstanding equity until May, 2025. From time to time, the Company participates in offerings of securities as an underwriter in transactions in which Revere also participates as an underwriter. For the three months ended March 31, 2026, there were no such transactions. The Company earned $368,000 in the three months ended March 31, 2025 in transactions, which Revere also participated as an underwriter. As of May 20, 2025, Kyle Wool no longer holds an equity interest in Revere.

 

During the year December 31, 2024, the Company entered into employee loans with various employees totaling $2.4 million. The terms of the loan agreements range from 3 years to 7 years, with an average annual interest rate of approximately 3.2%. The total interest received for the three months ended March 31, 2026 and 2025 was approximately $17 thousand and $21 thousand, respectively. As of March 31, 2026 and 2025, the total outstanding balance of the employee loans was $1.7 million and $2.0 million, respectively and are included in loans to employees on the accompanying unaudited condensed consolidated balance sheets.

 

21

 

Certain of the Company’s investments are made through related party special purpose vehicles (the “Series Funds”). Those Company investments in the Series Funds without readily determinable fair values are accounted for using the measurement alternative and are are classified as long-term equity investments. Approximate carrying values of such related party long-term equity investments was $261 thousand and $150 thousand as of March 31, 2026 and December 31, 2025 respectively. Those Company investments in the Series Funds which have readily determinable fair values are classified as marketable securities with an approximate fair value of $2.3 million as March 31, 2026 and December 31, 2025.

 

The Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of March 31, 2026, the amount attributable to non-controlling interest was $23 thousand. There is $21 thousand payable to non-controlling interests as of March 31, 2026.

 

The Company earns revenues for managing certain pooled investment vehicles which are related parties. These include the entirety of the management fee revenues totaling $0.3 million and $0.1 million for the three months ended March 31, 2026 and 2025, respectively and are classified as management fees in Note 12 and included in other revenue within the statement of operations. The total amount of contract liabilities disclosed in Note 2 represented amounts received in advance of revenue earned on managing such related party investment vehicles and are listed as contract liabilities in the unaudited condensed statement of financial condition totaling $4.7 million as of March 31, 2026 and $4.5 million as of December 2025.

 

In the normal course of business, Dominari Securities provides underwriting and brokerage services to the Series Funds. As a result of services provided, the Company recognized approximately $0.4 million in underwriting revenue, $1.1 million in carried interest revenue, and $1.0 million of commission revenue during the three months ended 2026.

 

Note 17. Segment Reporting

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy Aikido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy Aikido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy Aikido.

 

The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies”.

 

22

 

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net income (loss), as presented within the table below and reconciled to the unaudited condensed consolidated statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.

 

   Three Months Ended March 31, 2026 
   Dominari
Financial
   Legacy
Holding Co.
   Consolidated 
Revenue  $35,805   $
-
   $35,805 
Operating Costs               
Compensation and benefits   23,891    44,268    68,159 
Professional and consulting fees   291    585    876 
Other operating expenses   3,063    1,329    4,392 
Income / (loss) from operations   8,560    (46,182)   (37,622)
                
Other (expenses) income               
Other income   
-
    108    108 
Interest income   
-
    61    61 
Loss on marketable securities   
-
    (7,014)   (7,014)
Total other income   
-
    (6,845)   (6,845)
Net income (/loss) before income taxes   8,560    (53,027)   (44,467)
Provision for income taxes   
-
    12,868    12,868 
Net income (loss)  $8,560   $(65,895)  $(57,335)
Non-controlling interests   
-
    23    23 
Net loss attributable to stockholders  $8,560    (65,918)  $(57,358)
Total assets  $25,104   $60,216   $85,320 

 

    Three Months Ended March 31, 2025  
    Dominari
Financial
    Legacy
Holding Co.
    Consolidated  
Revenue   $          7,240     $ -     $ 7,240  
Operating Costs                        
Compensation,  benefits and advisory fees     7,595       28,806       36,401  
Professional and consulting fees     54       775       829  
                         
Other expenses     1,544       1,348       2,892  
Loss from operations     (1,953 )     (30,929 )     (32,882 )
                         
Other (expenses) income                        
Interest income     -       21       21  
Gain on marketable securities     -       (168 )     (168 )
Unrealized loss on note receivable     -       221       221  
Change in carrying value of investments     -       320       320  
Total other (expenses) income     -       394       394  
Net loss   $ (1,953 )   $ (30,535 )   $ (32,488 )
                         
Total assets   $ 19,202     $ 33,103     $ 52,335  

 

Note 19. Subsequent Events

 

Dividend

 

On May 4, 2026, the Company’s board of directors authorized a special cash dividend of, in aggregate, approximately $9.0 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to the Company’s common stock shareholders and certain warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2026.

23

 

Item 2. Management’s Discussion and analysis of Financial Condition and Results of Operations

 

You should read this discussion together with the Financial Statements, related Notes and other financial information included elsewhere in this Form 10-Q. All references to “we,”“us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation and its consolidated subsidiaries unless the context requires otherwise.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (“Quarterly Report”) contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company’s business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Quarterly Report, words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

 

Overview

 

Dominari Holdings Inc. (“Dominari”)is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominari and its subsidiaries are collectively referred to herein as “Company,” “we,” “our” or “us.”

 

Dominari Financial Inc. (“Dominari Financial”),a wholly owned subsidiary of Dominari Holdings Inc., executes the Company’s growth strategy in the financial services industry. In addition to organic growth, Dominari Financial seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the financial services industry, the acquisition of 100% of a dually registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust (“Fieldpoint”), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser was renamed Dominari Securities LLC (“Dominari Securities”) and is a wholly owned subsidiary of Dominari Financial.

 

On October 13, 2023, the Company entered into two separate Limited Liability Company Agreements with Dominari Manager LLC (“Manager”) and Dominari IMLLC (“Investment Manager”), which are both wholly owned subsidiaries and whose operations are included within the unaudited condensed consolidated financial statements of Dominari. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”) and was assigned ninety percent (90%) Membership Interest in each, which are both ninety percent (90%)majority owned subsidiaries of the Company and whose operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

24

 

Critical Accounting Estimates

 

We prepare our unaudited condensed consolidated financial statements in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Our actual results could differ significantly from these estimates under different assumptions and conditions.

 

There have been no material changes to our critical accounting estimates as compared to the critical accounting estimates discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

Refer to Note 3 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, for a discussion of our significant accounting policies.

 

Recently Issued Accounting Pronouncements

 

See Note 3 to the unaudited condensed consolidated financial statements for a discussion of recent accounting standards.

 

Results of Operations

 

Three months ended March 31, 2026, compared to the three months ended March 31, 2025

 

   Three Months Ended 
   March 31, 
   2026   2025 
Revenues        
Underwriting services  $32,949   $5,606 
Carried interest   1,096    - 
Commissions   2,490    2,190 
Interest income   308    39 
Principal transactions   (1,532)   (910)
Other revenue   494    315 
Total revenue   35,805    7,240 
           
Operating costs and expenses          
Compensation and benefits   68,159    15,457 
Advisory fees   36    20,944 
Legal fees   1,485    704 
Professional and consulting fees   876    829 
Other expenses   2,871    2,188 
Total operating expenses   73,427    40,122 
Loss from operations   (37,622)   (32,882)
           
Other income (expenses)          
Other income   108    - 
Interest income   61    21 
Loss on marketable securities, net   (7,014)   (168)
Realized and unrealized gain loss on notes receivable, net   -    221 
Change in carrying value of investments   -    320 
Total other income (expenses)   (6,845)   394 
Net loss before income tax expense  $(44,467)  $(32,488)
Provision for income taxes   12,868    - 
Net loss   (57,335)   (32,488)
Less: Net income attributable to non-controlling interests   23    - 
Net loss attributable to common stockholders of Dominari Holdings Inc.  $(57,358)  $(32,488)

 

25

 

During the three months ended March 31, 2026, we recognized approximately $35.8 million in revenue from operations, an increase of approximately $28.6 million or 395% as compared to the three months ended March 31, 2025, primarily driven by the increase in our activities of Dominari Securities. The increase in revenue was primarily attributable to the following:

 

i.Underwriting service revenue increased by $27.3 million or 488% from $5.6 million to $32.9 million in the three months ended March 31, 2026 as compared to the comparable period 2025, reflecting the impact of it increased efforts in both private placement and registered offering underwriting activities and deal flow.

 

ii.Carried interest revenue totaled $1.1 million in first quarter of 2026 as compared to no such revenue in the first quarter of 2025 as a result of receiving variable consideration from investment management customers.

 

iii.Commission revenues increased by $0.3 million, or 14% in the first three months of 2026 as compared to the same period in 2025, as a result of the increased customer trading activity.

 

During the three months ended March 31, 2026, we recognized $73.4 million in operating costs and expenses representing an increase of $33.3 million or 83% as compared to the three months ended March 31, 2026. The increase in operating costs and expenses is primarily a result of the following:

 

i.Compensation and benefits increased by $52.7 million or 341%for the three months ended March 31, 2026 as compared to the same period in 2025 primarily as a result of increased commissions expenses of approximately $17.1 million and increases in bonus expense of approximately $34.1 million (of which $18.2 million of stock based compensation is included). Increases in compensation and benefits costs were primarily incurred to compensate employees for generation of the significantly increased revenues.

 

ii.The Company recorded $36 thousand of advisory fees in three months ending March 31, 2026, as compared to $20.9 million in the comparable period in 2025 primarily as a result of the issuance of approximately 2.55 million shares of common stock to certain advisors in February 2025.

 

During the three months ended March 31, 2026, , other expense was approximately $(6.8) million as compared to other income of $394 thousand for the three months ended March 31, 2025. The 2026 other expense primarily is as a result of the loss on the sale of the Company’s ABTC stock for cash proceeds of approximately $32.5 million in January 2026 which was lower than the approximate December 31, 2025, book value of $39.4 million. During the three months ending March 31, 2025, the Company recorded a realized gain of approximately $0.2 million on a note that was satisfied during the period and an approximate $0.3 million increase in the carrying value of its long-term investments.

 

During the three months ended March 31, 2026, the Company recorded income tax expense of $12.9 million as compared to $0 in comparable period in 2025 primarily as a result of the increased revenues, taxable gain on the sale of the Company’s ABTC stock in January 2026, and certain income tax limitations under Internal Revenue Code Sections 162(m) and 382 the tax impact of certain expenses related to compensation that are not allowable which limit available deductions for income tax purposes.

 

Net loss of $57.3 million in the three months ended March 31, 2026, was $24.8 million or 76% higher than the $32.5 million loss reported in the comparable period of 2025. In the first three months of 2026, non-controlling interest of $23 thousand was recorded slightly increasing the net loss attributable to common stockholders’ of the Company.

 

26

 

Non-GAAP Comparison of Results for the Three Months Ended March 31, 2026, and March 31, 2025

 

To supplement its consolidated financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the table below summarizes the additional non-GAAP financial measures of loss from operations, net income (loss) applicable to common stockholders’ of Dominari Holdings and earnings per share as adjusted from excluding non-cash stock-based compensation. Such noncash stock-based compensation represents charges included in compensation and benefits expense and advisory expense as reported on the Company’s consolidated statement of operations. The Company believes that these non-GAAP financial measures are appropriate to enhance understanding of its past performance as well as prospects for future performance. The non-GAAP financial measures should be considered in addition to, not as a substitute for, measures of financial performance prepared in accordance with U.S. GAAP. A reconciliation of the differences between these non-GAAP financial measures with the most directly comparable financial measure calculated in accordance with GAAP is shown in the table below ($ thousands):

 

   Three Months Ended   Three Months Ended 
   March 31,
2026
   March  31,
2025
 
Loss from operations  $(37,622)  $(32,882)
Non-cash stock-based compensation   19,279    28,626 
Adjusted loss from operations  $(18,343)  $(4,256)
           
Net loss attributable to common stockholders’ of Dominari Holdings  $(57,358)  $(32,488)
Non-cash stock-based compensation   19,279    28,626 
Adjusted net loss before income tax expense  $(38,079)  $(3,862)
Adjustment to the provision for income taxes   -    4,427 
Adjusted net loss to common stockholders’ of Dominari Holdings   (38,079)   (8,289)
Adjusted net loss per share, basic  $(2.11)  $(0.77)
Weighted average number of shares outstanding, basic   18,068,269    10,775,219 

 

Liquidity and Capital Resources

 

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

 

managing current cash and cash equivalents on hand from our past debt and equity offerings;

 

seeking additional funds raised through the sale of additional securities in the future; and

 

seeking additional liquidity through credit facilities or other debt arrangements.

 

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our business plan to support our transition into the financial services industry. Our working capital amounted to approximately $21.9 million as of March 31, 2026. As of March 31, 2026, we had approximately $27.5 million of cash and cash equivalents, $6.9 million of marketable securities and $11.1 million of securities owned. Additionally, we had approximately $21.9 million in receivable from clearing brokers. All of such funds are available to fund our operations. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from continuing operations.

 

27

 

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity securities could result in significant dilution to stockholders.

 

The following table summarizes our net cash flows from operating, investing and financing activities for the periods indicated (in thousands):

 

   As of March 31, 
   2026   2025 
Cash provided by (used in)        
Operating activities  $(28,942)  $1,235 
Investing activities   32,123    (5,436)
Financing activities   (9,709)   6,437 
Net increase (decrease) in cash  $(6,528)  $2,236 

  

Cash Flows from Operating Activities

 

For the three months ended March 31, 2026, net cash (used in) operations was approximately $(28.9) million as compared to net cash provided by operations of $1.2 million for the three months ended March 31, 2025. The cash used in operating activities for the three months ending March 31, 2026, is primarily attributable to net loss of approximately $55.7 million, increases in receivable from clearing brokers of approximately $17.9 million and non-cash underwriting revenue of approximately $10.1 million, offset primarily by non-cash commission expense of approximately $7.6 million, increases in income taxes payable of approximately $12.9 million and stock-based compensation of approximately $19.3 million, and a realized gain on marketable securities of approximately $6.9 million. The cash provided by operating activities for the three months ended March 31, 2025, was primarily attributable to decreases in receivable from clearing brokers of $4.8 million, increase in accrued commissions of approximately $1.2 million, increase in stock based compensation of approximately $28.6 million, changes in operating assets and liabilities of approximately $3.7 million, realized loss on marketable securities of approximately $0.7 million, offset by a net loss of approximately $32.4 million.

 

Cash Flows from Investing Activities

 

For the three months ended March 31, 2026 and 2025, net cash provided by (used in) investing activities was approximately $32.1 million and $(5.4) million, respectively. The cash provided by investing activities for the three months ended March 31, 2026, primarily resulted from our sale of marketable securities of approximately $41.7 that included the sale of the Company’s ABTC shares for $32.4 million in net proceeds, partially offset by our purchase of marketable securities of approximately $10.0 million. The cash used in investing activities for the three months ended March 31, 2025, primarily resulted from our purchases of marketable securities of approximately $9.0 million, partially offset by sale of marketable securities of approximately $1.8 million and collection of principal on notes receivable of $1.1 million.

 

Cash Flows from Financing Activities

 

For the three months ended March 31, 2026 and 2025, net cash (used in) provided by financing activities was approximately $(9.7) million and $6.4 million, respectively. The cash used in financing activities for the three months ended March 31, 2026, was resulted from dividends paid of approximately $9.9 million and distributions to non-controlling interest of approximately $55 thousand, offset by the issuance of common stock for warrants exercised of approximately $0.3 million. The cash provided by financing activities for the three months ended March 31, 2025, was primarily driven by fund raising related to issuance of common stock of $13.5 million, partially offset by payment of dividends $(7.1) million.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not Applicable

  

28

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act are accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e)under the Exchange Act. Based upon that evaluation, as of March 31, 2026, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective due to the material weakness in our internal controls.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Material Weaknesses in Internal Controls

 

During the period ended March 31, 2026, due to staffing and resource constraints, the Company required significant additional effort to close the books and records, and record appropriate account adjustments. As such, information technology, business processes and financial reporting controls were deemed to be ineffective due to (a) the lack of personnel to ensure the books and records are closed accurately and on a timely basis, (b) lack of sufficient review over the accounting for certain transactions recorded at fair value, (c) the lack of appropriate segregation of duties, (d) certain general information technology control deficiencies regarding user access provisioning and administrative access review, and (e) insufficient documentation to support and evidence the design and implementation of controls.

 

Remedial Actions

 

As a result, our management performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with accounting principles generally accepted in the United States of America. Management understands that the accounting standards applicable to our financial statements are complex and will seek to enhance controls over its experienced third-party professionals with whom management can consult with respect to accounting issues and remediate this material weakness. The Company has engaged an outside consulting firm to assist in the closing process to ensure that steps are taken to remediate the control environment and to specifically improve the timeliness and accuracy of its financial reporting process. Additionally, the Company is planning to implement certain information technology related changes over the year ending December 31, 2026.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting for the quarter ended March 31, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls

 

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

29

 

Part II – Other Information

 

Item 1. Legal Proceedings

 

Many aspects of the Company’s business involve substantial risks of liability. In the ordinary course of business, the Company may be named as defendant or co-defendant in various legal actions, including arbitrations, class actions and other litigation, which could create substantial exposure and periodic expenses. The Company may also be involved, from time to time, in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding the Company’s business, which may result in expenses, adverse judgments, settlements, fines, penalties, injunctions or other relief. In the past in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company’s subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

Item 1A. Risk Factors

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Our current risk factors are set forth in our Annual Report on Form 10-K, which was filed with the SEC on March 31, 2026. Any of our previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

30

 

Item 6. Exhibits

 

31.1*   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Principal Executive Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certification of Principal Financial Officer of Dominari Holdings Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002  
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*Filed herewith.

 

**Furnished herewith.

 

31

 

Signatures

 

Pursuant to the requirements of the Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DOMINARI HOLDINGS INC.
     
Date: May 12, 2026 By: /s/ Anthony Hayes
    Anthony Hayes
    Chief Executive Officer
     
Date: May 12, 2026 By:  /s/ Tim Ledwick
    Tim Ledwick
  Chief Financial Officer

 

32

 

http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 0000012239 false Q1 --12-31 0000012239 2026-01-01 2026-03-31 0000012239 2026-05-12 0000012239 2026-03-31 0000012239 2025-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2026-03-31 0000012239 us-gaap:SeriesDPreferredStockMember 2025-12-31 0000012239 domh:SeriesD1PreferredStockMember 2026-03-31 0000012239 domh:SeriesD1PreferredStockMember 2025-12-31 0000012239 2025-01-01 2025-03-31 0000012239 us-gaap:PreferredStockMember 2025-12-31 0000012239 us-gaap:CommonStockMember 2025-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000012239 us-gaap:RetainedEarningsMember 2025-12-31 0000012239 us-gaap:ParentMember 2025-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2025-12-31 0000012239 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000012239 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000012239 us-gaap:ParentMember 2026-01-01 2026-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0000012239 us-gaap:PreferredStockMember 2026-03-31 0000012239 us-gaap:CommonStockMember 2026-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000012239 us-gaap:RetainedEarningsMember 2026-03-31 0000012239 us-gaap:ParentMember 2026-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2026-03-31 0000012239 us-gaap:PreferredStockMember 2024-12-31 0000012239 us-gaap:CommonStockMember 2024-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-12-31 0000012239 us-gaap:RetainedEarningsMember 2024-12-31 0000012239 2024-12-31 0000012239 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000012239 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000012239 us-gaap:PreferredStockMember 2025-03-31 0000012239 us-gaap:CommonStockMember 2025-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2025-03-31 0000012239 us-gaap:RetainedEarningsMember 2025-03-31 0000012239 2025-03-31 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2026-03-31 0000012239 domh:AmericanVenturesLLCMember 2025-06-17 0000012239 domh:AmericanVenturesIMLLCAndAmericanVenturesManagerLLCMember 2026-03-31 0000012239 domh:DominariFinancialHeritageStrategiesLLCMember 2024-05-21 0000012239 srt:MaximumMember 2026-01-01 2026-03-31 0000012239 srt:MinimumMember 2026-01-01 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2024-07-25 2024-07-25 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2026-01-01 2026-03-31 0000012239 us-gaap:SubsequentEventMember 2026-04-06 2026-04-06 0000012239 domh:InvestmentInTracXMember 2026-01-13 2026-01-13 0000012239 domh:InvestmentInKernaHealthIncMember 2026-03-31 0000012239 domh:InvestmentInKernaHealthIncMember 2025-12-31 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2026-03-31 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2025-12-31 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2026-03-31 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2025-12-31 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2026-03-31 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2025-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2026-03-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2025-12-31 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2026-03-31 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2025-12-31 0000012239 domh:InvestmentInDiscordIncMember 2026-03-31 0000012239 domh:InvestmentInDiscordIncMember 2025-12-31 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2026-03-31 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2025-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2025-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2025-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2025-12-31 0000012239 domh:InvestmentInAdvEnIncMember 2026-03-31 0000012239 domh:InvestmentInAdvEnIncMember 2025-12-31 0000012239 domh:InvestmentInAmericanVenturesLLCSeriesXXTracXLogisPteLtdMember 2026-03-31 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-01-01 2025-12-31 0000012239 2025-03-24 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-03-24 2025-03-24 0000012239 us-gaap:FairValueInputsLevel3Member 2026-03-31 0000012239 us-gaap:FairValueInputsLevel2Member 2026-01-01 2026-03-31 0000012239 srt:ScenarioForecastMember 2026-09-30 2026-09-30 0000012239 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0000012239 us-gaap:FairValueInputsLevel1Member 2026-03-31 0000012239 us-gaap:FairValueInputsLevel2Member 2026-03-31 0000012239 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 2025-10-01 0000012239 2025-10-01 2025-10-01 0000012239 domh:ConvertiblePreferredOptionMember 2026-01-01 2026-03-31 0000012239 domh:ConvertiblePreferredOptionMember 2025-01-01 2025-03-31 0000012239 us-gaap:WarrantMember 2026-01-01 2026-03-31 0000012239 us-gaap:WarrantMember 2025-01-01 2025-03-31 0000012239 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0000012239 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000012239 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000012239 srt:ScenarioForecastMember 2026-09-30 0000012239 srt:ScenarioForecastMember 2026-12-11 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 2025-02-10 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-02-10 2025-02-10 0000012239 2025-02-10 0000012239 domh:SeriesAWarrantsMember 2025-02-10 0000012239 domh:SeriesBWarrantsMember 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-02-10 2025-02-10 0000012239 us-gaap:CommonStockMember domh:AdvisoryAgreementsMember 2025-02-18 2025-02-18 0000012239 domh:AdvisoryAgreementsMember 2025-02-10 2025-02-10 0000012239 us-gaap:MajorityShareholderMember us-gaap:SeriesDPreferredStockMember 2013-09-30 0000012239 us-gaap:SeriesDPreferredStockMember 2013-09-30 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2026-03-31 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2025-12-31 0000012239 2025-03-03 2025-03-03 0000012239 2025-09-26 2025-09-26 0000012239 2026-01-26 2026-01-26 0000012239 2025-01-01 2025-12-31 0000012239 2025-07-01 2025-09-30 0000012239 2025-10-01 2025-12-31 0000012239 domh:RestrictedStockAwardsMember domh:EquityIncentivePlanMember 2022-10-07 0000012239 domh:EquityIncentivePlanMember 2025-02-10 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember 2025-02-10 2025-02-10 0000012239 domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 2025-02-10 0000012239 domh:MessrAnthonyHayesMember 2025-02-12 2025-02-12 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:MessrAnthonyHayesMember 2025-02-12 2025-02-12 0000012239 domh:EquityIncentivePlanMember domh:AnthonyHayesAndKyleWoolMember us-gaap:CommonStockMember 2025-03-11 2025-03-11 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember domh:AnthonyHayesAndKyleWoolMember us-gaap:CommonStockMember 2025-03-11 2025-03-11 0000012239 domh:EquityIncentivePlanMember 2025-12-10 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember 2025-12-10 2025-12-10 0000012239 domh:EquityIncentivePlanMember 2025-12-11 0000012239 domh:EquityIncentivePlanMember 2025-12-11 2025-12-11 0000012239 domh:RestrictedStockAwardsMember domh:EquityIncentivePlanMember us-gaap:CommonStockMember 2026-01-09 2026-01-09 0000012239 2024-06-11 2024-06-11 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember us-gaap:CommonStockMember 2026-03-04 2026-03-04 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember 2026-03-04 2026-03-04 0000012239 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember 2025-12-31 0000012239 domh:AnthonyHayesAndKyleWoolMember 2025-02-10 2025-02-10 0000012239 2025-01-01 2025-06-30 0000012239 2025-12-01 2025-12-01 0000012239 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000012239 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000012239 domh:AVManagerMember 2026-03-31 0000012239 domh:AVInvestmentManagerMember 2026-03-31 0000012239 us-gaap:WarrantMember 2025-12-31 0000012239 us-gaap:WarrantMember 2025-12-31 2025-12-31 0000012239 us-gaap:WarrantMember 2026-01-01 2026-03-31 0000012239 us-gaap:WarrantMember 2026-03-31 0000012239 us-gaap:RestrictedStockMember 2025-12-31 0000012239 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:RestrictedStockMember 2026-03-31 0000012239 us-gaap:StockOptionMember 2025-12-31 0000012239 us-gaap:StockOptionMember 2025-12-31 2025-12-31 0000012239 us-gaap:StockOptionMember 2026-01-01 2026-03-31 0000012239 us-gaap:StockOptionMember 2026-03-31 0000012239 domh:UnderwritingServicesMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:CarriedInterestMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:CommissionsMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:PrincipalTransactionLossesMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:RealizedGainsMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:UnrealizedLossesMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:CarriedInterestMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:CommissionsMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:PrincipalTransactionLossesMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:RealizedGainsMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:UnrealizedLossesMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:OtherRevenueMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:ManagementFeesMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeFromCustomersMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeNonCustomersMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:OtherRevenueMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000012239 domh:ManagementFeesMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000012239 domh:InterestIncomeFromCustomersMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000012239 domh:UnderwritingServicesMember 2026-01-01 2026-03-31 0000012239 domh:UnderwritingServicesMember 2025-01-01 2025-03-31 0000012239 domh:CarriedInterestMember 2026-01-01 2026-03-31 0000012239 domh:CarriedInterestMember 2025-01-01 2025-03-31 0000012239 domh:CommissionsMember 2026-01-01 2026-03-31 0000012239 domh:CommissionsMember 2025-01-01 2025-03-31 0000012239 domh:InterestIncomeCustomersMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeCustomersMember 2025-01-01 2025-03-31 0000012239 domh:OtherMember 2026-01-01 2026-03-31 0000012239 domh:OtherMember 2025-01-01 2025-03-31 0000012239 domh:ManagementFeesMember 2026-01-01 2026-03-31 0000012239 domh:ManagementFeesMember 2025-01-01 2025-03-31 0000012239 domh:PrincipalTransactionsRevenueMember 2026-01-01 2026-03-31 0000012239 domh:PrincipalTransactionsRevenueMember 2025-01-01 2025-03-31 0000012239 domh:InterestIncomeNoncustomerMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeNoncustomerMember 2025-01-01 2025-03-31 0000012239 domh:ABTCStockMember 2026-01-01 2026-03-31 0000012239 srt:MinimumMember 2026-03-31 0000012239 srt:MaximumMember 2026-03-31 0000012239 domh:Section382LimitationMember 2026-03-31 0000012239 domh:DominariSecuritiesMember 2026-03-31 0000012239 2023-06-30 2023-06-30 0000012239 2024-01-01 2024-12-31 0000012239 srt:MinimumMember 2024-01-01 2024-12-31 0000012239 srt:MaximumMember 2024-01-01 2024-12-31 0000012239 us-gaap:RelatedPartyMember 2026-03-31 0000012239 us-gaap:RelatedPartyMember 2025-12-31 0000012239 domh:NoncontrollingInterestsMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2026-01-01 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2026-01-01 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2026-01-01 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-01-01 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2025-01-01 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-01-01 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-03-31 0000012239 domh:ABTCMember us-gaap:SubsequentEventMember 2026-05-04 2026-05-04 0000012239 domh:ABTCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-05-04 2026-05-04 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure domh:Segments
EX-31.1 2 ea028978201ex31-1.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

RULE 13A-14(A)/15(D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEYACT OF 2002

 

I, Anthony Hayes, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2026

 

  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

 

EX-31.2 3 ea028978201ex31-2.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION OFPRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER PURSUANT TO

RULE 13A-14(A)/15(D)-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Tim Ledwick, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Dominari Holdings Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the period presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 12, 2026

 

  /s/ Tim Ledwick
  Tim Ledwick
  Chief Financial Officer
  (Principal Financial Officer and Accounting Officer)

 

EX-32.1 4 ea028978201ex32-1.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission (the “Report”), I, Anthony Hayes, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

Date: May 12, 2026

 

  /s/ Anthony Hayes
  Anthony Hayes
  Chief Executive Officer
  (Principal Executive Officer)

 

EX-32.2 5 ea028978201ex32-2.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dominari Holdings Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2026, as filed with the Securities and Exchange Commission (the “Report”), I, Tim Ledwick, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

 

Date: May 12, 2026

 

  /s/ Tim Ledwick
  Tim Ledwick
  Chief Financial Officer
  (Principal Financial Officer and Accounting Officer)

 

EX-101.SCH 6 domh-20260331.xsd XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Organization and Description of Business and Recent Developments link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Liquidity and Capital Resources link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Marketable Securities link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Long-Term Equity Investments link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Notes Receivable link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Prepaid Expenses and Other Assets link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 995316 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock link:presentationLink link:definitionLink link:calculationLink 995317 - Disclosure - Revenue link:presentationLink link:definitionLink link:calculationLink 995318 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995319 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 995320 - Disclosure - Regulatory link:presentationLink link:definitionLink link:calculationLink 995321 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 995322 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 995323 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Marketable Securities (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Long-Term Equity Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Prepaid Expenses and Other Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Revenue (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Organization and Description of Business and Recent Developments (Details) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Long-Term Equity Investments (Details) link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Long-Term Equity Investments - Schedule of Long-Term Investments (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Notes Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Prepaid Expenses and Other Assets - Schedule of Other Assets (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Leases - Schedule of Future Minimum Payments (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilute Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock (Details) link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Stockholders’ Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company’s Stock Option Plan (Details) link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Revenue (Details) link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Regulatory (Details) link:presentationLink link:definitionLink link:calculationLink 996035 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 996036 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 996037 - Disclosure - Segment Reporting - Schedule of CODM Views the Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 996038 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 domh-20260331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 domh-20260331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 domh-20260331_lab.xml XBRL LABEL FILE EX-101.PRE 10 domh-20260331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover - shares
3 Months Ended
Mar. 31, 2026
May 12, 2026
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Mar. 31, 2026  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q1  
Entity Information [Line Items]    
Entity Registrant Name DOMINARI HOLDINGS INC.  
Entity Central Index Key 0000012239  
Entity File Number 001-41845  
Entity Tax Identification Number 52-0849320  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 725 5th Avenue  
Entity Address, Address Line Two 23rd Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10022  
Entity Phone Fax Numbers [Line Items]    
City Area Code (212)  
Local Phone Number 393-4540  
Entity Listings [Line Items]    
Title of 12(b) Security Common Stock ($0.0001 par value per share)  
Trading Symbol DOMH  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   22,613,781
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
ASSETS    
Cash and cash equivalents $ 27,477 $ 34,005
Marketable securities 6,901 46,516
Securities owned 11,118 9,756
Receivable from clearing brokers 21,883 3,995
Long-term equity investments 11,846 11,744
Loans to employees 1,669 1,767
Right-of-use assets 2,586 2,721
Prepaid expenses and other assets 1,840 2,403
Total assets 85,320 112,907
LIABILITIES AND STOCKHOLDERS’ EQUITY    
Accounts payable and accrued expenses 777 611
Accrued compensation and commissions 25,005 17,754
Accrued dividends payable 364 10,335
Contract liabilities 4,679 4,504
Lease liability 2,744 2,841
Income taxes payable 20,174 7,318
Other liabilities 173
Total liabilities 53,743 43,536
Stockholders’ equity    
Preferred stock, value
Common stock, $0.0001 par value, 100,000,000 shares authorized; 22,613,781 and 16,067,435 shares issued as of March 31, 2026, and December 31, 2025, respectively; 22,613,781 and 16,067,435 shares outstanding as of March 31, 2026 and December 31, 2025, respectively 2
Additional paid-in capital 357,099 337,505
Accumulated deficit (325,492) (268,134)
Total Dominari stockholders’ equity 31,609 69,371
Non-controlling interests (32)
Total stockholders’ equity 31,577 69,371
Total liabilities and stockholders’ equity 85,320 112,907
Series D Convertible Preferred Stock    
Stockholders’ equity    
Preferred stock, value
Series D-1 Convertible Preferred Stock    
Stockholders’ equity    
Preferred stock, value
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Mar. 31, 2026
Dec. 31, 2025
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in Shares) 50,000,000 50,000,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in Shares) 100,000,000 100,000,000
Common stock, shares issued (in Shares) 22,613,781 16,067,435
Common stock, shares outstanding (in Shares) 22,613,781 16,067,435
Series D Convertible Preferred Stock    
Preferred stock, shares authorized (in Shares) 5,000,000 5,000,000
Preferred stock, shares issued (in Shares) 3,825 3,825
Preferred stock, shares outstanding (in Shares) 3,825 3,825
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
Series D-1 Convertible Preferred Stock    
Preferred stock, shares authorized (in Shares) 5,000,000 5,000,000
Preferred stock, shares issued (in Shares) 834 834
Preferred stock, shares outstanding (in Shares) 834 834
Liquidation preference (in Dollars per share) $ 0.0001 $ 0.0001
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues    
Underwriting services $ 32,949 $ 5,606
Carried interest 1,096
Commissions 2,490 2,190
Interest income 308 39
Principal transactions (1,532) (910)
Other revenue 494 315
Total revenue 35,805 7,240
Operating costs and expenses    
Compensation and benefits 68,159 15,457
Advisory fees 36 20,944
Legal fees 1,485 704
Professional and consulting fees 876 829
Other expenses 2,871 2,188
Total operating expenses 73,427 40,122
Loss from operations (37,622) (32,882)
Other income (expenses)    
Other income 108
Interest income 61 21
Gain (loss) on marketable securities, net (7,014) (168)
Realized and unrealized gain loss on notes receivable, net 221
Change in carrying value of investments 320
Total other income (expenses) (6,845) 394
Net loss before income tax expense (44,467) (32,488)
Provision for income taxes 12,868
Net loss (57,335) (32,488)
Less: Net income attributable to non-controlling interests 23
Net loss attributable to common stockholders of Dominari Holdings Inc. $ (57,358) $ (32,488)
Net loss per share, basic and diluted    
Basic (in Dollars per share) $ (3.17) $ (3.02)
Diluted (in Dollars per share) $ (3.17) $ (3.02)
Weighted average number of shares outstanding, basic and diluted    
Basic (in Shares) 18,068,269 10,775,219
Diluted (in Shares) 18,068,269 10,775,219
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Dominari Holding Stockholders’ Equity
Non- Controlling Interests
Treasury Stock
Total
Balance at Dec. 31, 2024 $ 263,820 $ (223,466)     $ (501) $ 39,853
Balance (in Shares) at Dec. 31, 2024 4,659 7,037,022            
Balance (in Shares) at Dec. 31, 2024             60,148  
Stock-based compensation 7,682     7,682
Stock-based compensation (in Shares) 1,240,969            
Issuance of common stock 13,517     13,517
Issuance of common stock (in Shares) 3,876,054            
Advisory shares issued 20,944     20,944
Advisory shares issued (in Shares) 2,550,000            
Dividends issued (7,080)     (7,080)
Net loss (32,488)     (32,488)
Balance at Mar. 31, 2025 305,963 (263,034)     $ (501) 42,428
Balance (in Shares) at Mar. 31, 2025 4,659 14,704,045            
Balance (in Shares) at Mar. 31, 2025             60,148  
Balance at Dec. 31, 2025 337,505 (268,134) $ 69,371   69,371
Balance (in Shares) at Dec. 31, 2025 4,659 16,067,435            
Stock-based compensation - employees $ 2 19,241 19,243   19,243
Stock-based compensation - employees (in Shares) 6,471,346            
Issuance of common stock from warrants exercised 317 317   317
Issuance of common stock from warrants exercised (in Shares) 75,000            
Stock-based compensation- advisors 36 36   36
Distributions to non-controlling interest (55)   (55)
Net loss (57,358) (57,358) 23   (57,335)
Balance at Mar. 31, 2026 $ 2 $ 357,099 $ (325,492) $ 31,609 $ (32)   $ 31,577
Balance (in Shares) at Mar. 31, 2026 4,659 22,613,781            
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities    
Net loss $ (57,335) $ (32,488)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of right-of-use assets 135 52
Depreciation 26 26
Change in carrying value of long-term investment (320)
Non-cash underwriting revenues (10,080) (697)
Non-cash commission expense 7,610
Stock-based compensation – employees 19,243 28,626
Stock-based compensation – advisors 36
Realized (gain) loss on securities owned (590) 714
Unrealized loss on securities owned 2,122 259
Realized loss on marketable securities 6,949 670
Unrealized (gain) loss on marketable securities 115 (468)
Realized and unrealized (gain) loss on note receivable (221)
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 537 (2,401)
Receivable from clearing brokers (17,888) 4,848
Accounts payable and accrued expenses 165 520
Accrued compensation and commissions 7,251 1,210
Right of use asset and liability, net (97) (122)
Contract liabilities 175 632
Income taxes payable 12,856
Other liabilities (173) 395
Net cash (used in) provided by operating activities (28,942) 1,235
Cash flows from investing activities    
Purchase of marketable securities (9,185) (9,035)
Sale of marketable securities 41,736 1,776
Purchase of securities owned (1,666)
Sale of securities owned 1,242
Purchase of long-term investments (102)
Redemption of long-term investments 538
Collection of principal on note receivable 1,143
Collection of loans to employees 98 142
Net cash provided by (used in) investing activities 32,123 (5,436)
Cash flows from financing activities    
Cash paid for dividends (9,971) (7,080)
Distributions to non-controlling interest (55)
Cash from issuance common stock, net of offering cost 13,517
Cash from issuance common stock for exercised warrants 317
Net cash (used in) provided by financing activities (9,709) 6,437
Net increase in cash and cash equivalents (6,528) 2,236
Cash and cash equivalents, beginning of period 34,005 4,079
Cash and cash equivalents, end of period 27,477 6,315
Cash paid for interest and taxes $ 17
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.26.1
Organization and Description of Business and Recent Developments
3 Months Ended
Mar. 31, 2026
Organization and Description of Business and Recent Developments [Abstract]  
Organization and Description of Business and Recent Developments

Note 1. Organization and Description of Business and Recent Developments

 

Organization and Description of Business

 

Dominari Holdings Inc. (the “Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

 

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). The registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financials’ acquisition of FPS’ Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.

 

On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”), which are both wholly owned subsidiaries and whose operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

 

On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”). The Company holds a ninety percent (90%) Membership Interest in each, and their operations are included within the condensed consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.26.1
Liquidity and Capital Resources
3 Months Ended
Mar. 31, 2026
Liquidity and Capital Resources [Abstract]  
Liquidity and Capital Resources

Note 2. Liquidity and Capital Resources

 

The Company monitors its liquidity position on a regular basis The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to fund its activities through managing current cash on hand from the Company’s past equity offerings.

 

As of March 31, 2026, the Company has approximately $27.5 million of cash and cash equivalents and $6.9 million of marketable securities as well as $11.1 million of securities owned. Additionally, the Company had approximately $21.9 million in receivable from clearing brokers. Additionally, the Company’s working capital balance at March 31, 2026, totaled $21.9 million. Unless otherwise noted, all such funds are available to fund the Company’s operations. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities, together with the anticipated cash flow to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2026
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

 

There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2025 Annual Report.

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheets as of March 31, 2026, condensed consolidated statements of operations for the three months ended March 31, 2026 and 2025, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2026 and 2025, and the condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026 or for any future interim period. The condensed consolidated balance sheets as of December 31, 2025 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.

 

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial Inc., Dominari IM LLC, Dominari Manager LLC and Dominari Securities along with American Ventures IM LLC and American Ventures Manager LLC, both of which are owned 90% by the Company. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Joint Ventures

 

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its unaudited condensed consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of March 31, 2026, there has been no material activity in DFHS.

 

Use of Estimates

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, marketable securities, securities owned, the valuation of long-term equity investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

 

Securities owned

 

Securities owned consist of equity securities including, common stock and warrants of publicly traded companies which are held by Dominari Securities. Securities owned and securities sold, but not yet purchased are recorded in the balance sheet at fair value, with the change in fair value and any realized gains or losses upon purchase or sale recorded within the statement of operations as principal transactions.

 

Dominari Securities may receive securities, including common or preferred stock and stock purchase warrants, from companies as part of its compensation for underwriting services. These instruments are stated at fair value in accordance with GAAP, and recorded within the balance sheet as securities owned. Such securities that the Company receives may be subject to contractual or instrument specific restrictions which prevent Dominari Securities from reselling the securities within the open market. Under ASC 820 only those restrictions which are an attribute of the instrument, and do not arise from any contractual agreement, are considered when determining fair value.

A portion of the Company’s equity securities, which are held by Dominari Securities, are subject to restrictions as disclosed in Note 7. Equities that have periods of contractual trading restrictions, discounts were considered in determining fair value The Company’s significant unobservable inputs, included the implied probability of 15% of certain marketplace transactions and events occurring, which would permit the sale of equities held. These equities are included in securities owned.

 

Warrant Investments

 

Warrant fair values are primarily determined using a Black Scholes option pricing model, which includes the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value. Warrants held by Dominari Securities are included in securities owned and other warrants are included in marketable securities.

 

The following inputs are considered for determining the fair values of warrants:

 

The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.

 

The expected remaining term is equal to the time to expiration of the warrant investment.

 

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.

 

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.

 

Marketability discounts are applied for warrants that have sales restrictions (or lock-up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.

 

Receivable from Clearing Brokers

 

Receivable from Dominari Securities’ clearing brokers totaling $21.9 million consisted of approximately $0.5 million of liquid insured deposits $3.7 million of commission receivable and $17.7 million of liquid deposits maintained by the Company with its clearing brokers as of March 31, 2026. Receivable from Dominari Securities’ clearing brokers consisted of approximately $1.4 million of liquid insured deposits, $2.1 million of commissions receivable and $0.5 million of liquid deposits maintained by the Company with its clearing brokers as of December 31, 2025. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of March 31, 2026 and December 31, 2025 an allowance for credit losses was deemed not necessary.

 

Long-term Equity Investments and marketable securities

 

The Company holds certain strategic investments that are not part of its broker-dealer trading activities. The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying unaudited condensed consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are accounted for under ASC 321 using the measurement alternative. Equity method investments and other long-term investments that are not part of our broker-dealer trading activities are included in “long term equity investment” on the unaudited condensed consolidated balance sheet. These investments are generally strategic in nature and are not actively traded. Unrealized gains and losses on these investments are recognized in earnings when impairment is identified or when observable price changes occur and are classified in other income (loss) in the unaudited condensed consolidated statement of operations.

Leases

 

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 9 - Leases).

 

Revenue

 

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

 

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

 

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

 

Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized. The Company records such Non-Cash Consideration on the date at which its performance obligation is fulfilled using the date of contract inception as the fair value measurement date, as required by FASB ASC 606-10-32-21 and recorded as underwriting revenues. Any changes resulting from the form of the consideration after contract inception (e.g. fair value) are not included in the transaction price and, therefore, are included in principal transactions. To the extent changes in the noncash consideration occur for reasons other than the form of the consideration (e.g., notional quantity of instruments provided is based upon the Company’s performance), the Company applies relevant guidance on variable consideration, constraining such amounts until the associated uncertainty is resolved. Similarly, any commissions or compensation expense from providing non-cash consideration provided to employees and is recognized at fair value in accordance with ASC 820 on the same date.

 

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying unaudited condensed consolidated balance sheet.
Carried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high-water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Carried Interest Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to claw back or reversal.

 

Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:

 

oThe Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.

 

oManagement fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.

 

Principal transactions are recorded on a trade-date basis (as if they had settled). Realized and unrealized gains and losses arising from all securities transactions entered into for the account and risk of the Company are recorded in principal transactions in the accompanying statement of operations. These gains and losses are not in scope for ASC 606 as they are not generated from contracts with customers.

 

Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management As of March 31, 2026, the Company recognized $4.7 million of contract liabilities of which $1.1 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2031. During the three months ended March 31, 2026, the Company recognized revenue of $0.3 million that was included in contract liabilities as of March 31, 2026.

 

Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b-1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.

 

Compensation and benefits

 

Compensation and benefits includes fixed salaries, commissions (paid in either cash or in securities), related benefits and stock-based compensation incurred on an accrual basis. The Company has a defined contribution 401(k) plan that covers all employees and allows an employer contribution of up to 50% of the first 3% of each participating employee’s eligible compensation contributed to the plan and 50% of the next two percent of each participating employee’s eligible compensation. Participants are 100% vested in these matching contributions when they are made. Eligible employees may elect to defer pre-tax contributions regulated under Section 401(k) of the Internal Revenue Code. The Company’s matching contributions are included in compensation and benefits in the unaudited condensed consolidated statements of operations. Please see “Stock based compensation” section below for additional information on stock-based compensation accounting policies.

 

Stock-based Compensation

 

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on either the simplified method, if applicable, which is the half-life from vesting to the end of its contractual term or when applicable, probability estimates of expected exercises of such options.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

 

The Company accounts for forfeitures as they occur.

 

Income Taxes

 

Income tax expense for interim periods is calculated in accordance with ASC 740, Income Taxes, and ASC 740 270, Interim Reporting. Interim periods are treated as integral parts of the annual reporting period, and income tax expense is recognized using estimates that reflect management’s best assessment of the expected annual tax position, including discrete items recognized in the period incurred.

 

Effect of new accounting pronouncements to be adopted in future periods

 

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity discloses more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its financial statements.

 

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

 

Reclassification of prior year amounts

 

Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or stockholders’ equity.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.26.1
Marketable Securities
3 Months Ended
Mar. 31, 2026
Marketable Securities [Abstract]  
Marketable Securities

Note 4. Marketable Securities

 

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2026 and 2025, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended 
   March 31, 
   2026   2025 
Realized gain / (loss)  $(6,949)  $(732)
Unrealized gain / (loss)   (115)   468 
Interest and dividend income   50    96 
Total  $(7,014)  $(168)
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.26.1
Long-Term Equity Investments
3 Months Ended
Mar. 31, 2026
Long-Term Equity Investments [Abstract]  
Long-Term Equity Investments

Note 5. Long-Term Equity Investments

 

The Company holds interests in several privately held companies as long-term investments. The following table presents the Company’s long-term investments as of March 31, 2026, and December 31, 2025 ($ in thousands):

 

   March 31, 2026   December 31, 2025 
       Carrying       Carrying 
   Cost Basis   Value   Cost Basis   Value 
Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a.                    
Masterclass)*   170    170    170    170 
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a.Kraken)* *   597    364    597    364 
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.)**   1,240    1,240    1,240    1,240 
                     
Investment in Discord Inc.   476    476    476    476 
                     
Investment in Automation Anywhere, Inc.   476    397    476    397 
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
Investment in AdvEn Inc.   750    750    750    750 
Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..)   102    102    -    - 
Total  $10,601   $11,846   $10,499   $11,744 

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investment made in these companies are through both an SPV and direct investments.

 

The Company had no changes to the carrying values for the three months ended March 31, 2026, and recorded an increase in the carrying values of approximately $0.3 million for the three months ended March 31, 2025. Please see below details of the changes in carrying value by investment.

 

Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)

 

On July 25, 2024, the Company entered into an agreement (the “Groq Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XII Groq Units for $25 thousand. As of March 31, 2026, there was no change to the carrying value. On April 6, 2026, the Company received a payment of $58 thousand as a payment related to the Company’s investment.

 

Investment in TracX.

 

On January 13, 2026, the Company entered into an agreement (the “TracX Agreement”) with American Ventures LLC whereby the Company agreed to purchase Series XX TracX Logis units for $102 thousand.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.26.1
Notes Receivable
3 Months Ended
Mar. 31, 2026
Notes Receivable [Abstract]  
Notes Receivable

Note 6. Notes Receivable

 

As of March 31, 2026, and December 31, 2025, the Company had no notes receivable.

 

American Innovative Robotics, LLC

 

The Company recorded interest income of approximately $20,000, and a realized gain on the note of approximately $221,000 on the American Innovative Robotics Promissory Note in the 31, 2025. The note was fully paid off as of March 24, 2025, with proceeds totaling $1.1 million, resulting in an ending value of $0.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value of Financial Assets and Liabilities
3 Months Ended
Mar. 31, 2026
Fair Value of Financial Assets and Liabilities [Abstract]  
Fair Value of Financial Assets and Liabilities

Note 7. Fair Value of Financial Assets and Liabilities

 

Financial instruments, including cash and cash equivalents, accounts payable and accrued expenses and accrued compensation and commissions are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

 

The Company uses three levels of inputs that may be used to measure fair value:

 

Level 1 - quoted prices in active markets for identical assets or liabilities

 

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2026 and December 31, 2025 ($ in thousands):

 

   Fair value measured as of March 31, 2026 
       Quoted   Significant     
   Total at   prices in
Active
   other
observable
   Significant
unobservable
 
   March 31,   Markets   inputs   inputs 
   2026   (Level 1)   (Level 2)   (Level 3) 
Assets                
Securities owned  $11,118   $
   $9,467   $1,651 
Marketable securities  $6,901   $5,494   $1,407   $
 

 

   Fair value measured as of December 31, 2025 
       Quoted   Significant     
   Total at   prices in active   other observable   Significant unobservable 
   December 31,   markets   inputs   inputs 
   2025   (Level 1)   (Level 2)   (Level 3) 
Assets                
Securities owned  $9,756   $
   $8,014   $1,742 
Marketable securities  $46,516   $45,049   $1,467   $
 

 

The fair value of level 3 securities owned totaling $1.7 million shown above at March 31, 2026 are subject to an initial lock-up period until approximately June 30, 2026, and further restrictions to which the Company cannot liquidate its investment until such restrictions are met. Additionally, approximately $1.1 million of fair value of level 2 securities owned shown above at March 31, 2026 represents warrants that are subject to lock-up periods that will end by June 30, 2026 and another $4.3 million of fair value of warrant securities with lock-up periods that will end by September 30, 2026 as well.

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Securities owned at fair value as of December 31, 2025  $1,741 
      
Unrealized loss included in principal transactions  $(90)
Securities owned at fair value as of March 31, 2026  $1,651 

 

The Company’s Level 3 fair value measurements at March 31, 2026 were determined by the following quantitative inputs:

 

The underlying stock price of $10.01 per share as of the measurement date.

 

Implied success rates of similar type instruments from other comparable entities’ recent historical results of 15% of the underlying value of the stock price.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.26.1
Prepaid Expenses and Other Assets
3 Months Ended
Mar. 31, 2026
Prepaid Expenses and Other Assets [Abstract]  
Prepaid expenses and other assets

Note 8. Prepaid expenses and other assets

 

Other assets consist of the following as of March 31, 2026, and December 31, 2025 ($ in thousands):

 

   March 31,
2026
   December 31,
2025
 
Prepaid expenses  $480   $805 
Security deposits   483    483 
Property and equipment, net   108    135 
Other   769    980 
Total  $1,840   $2,403 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.26.1
Leases
3 Months Ended
Mar. 31, 2026
Leases [Abstract]  
Leases

Note 9. Leases

 

On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22nd Floor Premises”). The Company currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

 

On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “23rd Floor Premises”). Dominari Financial currently uses the 23rd Floor Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the 23rd Floor Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the 23rd Floor Premises in February 2023.

On September 2, 2025, the Company entered into a Lease Agreement (the “Company’s Florida Lease”) with Blue Diamond Towers, LLC, a Delaware limited liability company. Under the Company’s Florida Lease, the Company rents a portion of the first floor designated as Suite 103 of the North Building at 3835 PGA Boulevard in Palm Beach Gardens, Florida, (the “Florida Premises”). The Company will use the Florida Premises as Executive Offices. The initial term of the Company’s Florida Lease is two (2) years commencing on October 1, 2025. Under the Company’s Florida Lease, the Company is required to pay monthly rent, commencing on October 1, 2025, equal to $10,000. Effective for the second year of the Company’s Florida Lease, the rent shall increase to $10,300. The Company took possession of Florida Premises in October 2025.

 

The tables below represent the Company’s lease assets and liabilities as of March 31, 2026:

 

   March 31, 
   2026 
Assets:    
Operating lease right-of-use-assets  $2,586 
Liabilities:     
Current     
Operating  $568 
Long-term     
Operating   2,176 
   $2,744 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   March 31, 
   2026 
Weighted-average remaining lease term - operating leases (in years)   4.0 
Weighted-average discount rate - operating leases   10.0%

 

During the years ended March 31, 2026 and 2025, the Company recorded approximately $0.2 million and $0.2 million, respectively, of lease expense to current period operations.

 

   Three Months Ended
March 31,
 
   2026   2025 
Operating leases        
Operating lease cost  $205   $178 
Short-term lease rent expense   3    22 
Net rent expense  $208   $200 

 

As of March 31, 2026, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining period Ended December 31, 2026  $638 
Year Ended December 31, 2027   801 
Year Ended December 31, 2028   766 
Year Ended December 31, 2029   784 
Year Ended December 31, 2030   377 
Thereafter   
-
 
Total   3,366 
Less present value discount   (622)
Operating lease liabilities  $2,744 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.26.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2026
Net Loss Per Share [Abstract]  
Net Loss per Share

Note 10. Net Loss per Share

 

Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.

 

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended March 31, 2026, and 2025 are as follows:

 

   As of March 31, 
   2026   2025 
Convertible preferred stock   34    34 
Warrants to purchase common stock   6,362,098    8,175,188 
Restricted stock awards   396,346    50,000 
Options to purchase common stock   10,072,646    346,654 
Total   16,831,124    8,571,876 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders’ Equity and Convertible Preferred Stock
3 Months Ended
Mar. 31, 2026
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Stockholders’ Equity and Convertible Preferred Stock

Note 11. Stockholders’ Equity and Convertible Preferred Stock

 

Common Stock

 

As of March 31, 2026, there are 22,613,781 shares of common stock issued and outstanding This includes 316,346 unvested shares issued that are subject to forfeiture through September 30, 2026, and 80,000 unvested shares issued that are subject to forfeiture through December 11, 2026.

 

On February 10, 2025, the Company entered into securities purchase agreements with certain accredited investors for the sale by the Company of 1,439,467 registered shares of its common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants in a direct offering. In a concurrent private placement, the Company entered into securities purchase agreements with certain accredited investors for the sale of 2,436,587 unregistered shares of common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants (the “February 2025 Financings”). The Series A warrants are exercisable immediately upon issuance at an exercise price of $3.72 per share and will expire five years from the date of issuance. The Series B warrants are exercisable immediately upon issuance at an exercise price of $4.22 per share and will expire five years from the date of issuance. The net proceeds to the Company from the February 2025 Financings were approximately $13.5 million.

 

On February 10, 2025, the Company entered into advisory agreements with various individuals who were issued shares of common stock. The agreements are for a term of two years but are cancellable by either party. As part of these agreements, 2,550,000 shares of common stock were issued on February 18, 2025. An additional 850,000 shares may be issued under the terms of the agreements when certain provisions are met, which as of the date of grant is probable. These shares are nonforfeitable and thus were fully expensed by the Company at the time of grant. The Company used a Monte Carlo simulation to calculate the grant date fair value of the common stock. The fair value of issued shares amounted to $20.9 million and is presented in advisory fees expense on the unaudited condensed consolidated statement of operations.

 

The securities in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered shares, the warrants, and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

Certain officers, directors, employees and members of the Company’s advisory board participated in the February 2025 Financings on the same terms as the other investors.

 

During the period January 1, 2026 to March 31, 2026, various individuals exercised warrants, resulting in the additional issuance of 75,000 shares of common stock and cash proceeds of $0.3 million, which were recorded in additional paid-in capital and are reflected in the unaudited condensed consolidated statements of changes in stockholders’ equity.

 

Series D Convertible Preferred Stock

 

In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

 

As of March 31, 2026, and December 31, 2025, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.

 

Series D-1 Convertible Preferred Stock

 

The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.

 

As of March 31, 2026 and December 31, 2025, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

 

Dividends

 

On February 11, 2025, the board of directors approved a special cash dividend of $0.32 per share payable on March 3, 2025, to holders of common stock and certain warrant holders as of close of business on February 24, 2025. On September 9, 2025, the board of directors approved a special cash dividend of $0.22 per share payable on September 26, 2025, to holders of common stock and certain warrant holders as of close of business on September 3, 2025. On December 11, 2025, the board of directors approved a special cash dividend of $0.432 per share payable on January 26, 2026, to holders of common stock and certain warrant holders as of close of business on January 5, 2026, Cash dividends declared in 2025 totaled $22.2 million and have been charged to accumulated deficit. Dividends paid for the three months ended March 31, 2025, totaled $7.0 million, and dividends paid for the three months ended September 30, 2025, totaled $4.9 million. Dividends declared totaled $10.3 million during the three months ended December 31, 2025, of which $9.9 million were paid during the three months ended March 31, 2026, resulting in a dividend payable of $0.4 million as of March 31, 2026.

Warrants

 

A summary of warrant activity for the three months ended March 31, 2026, is presented below:

 

               Weighted 
       Weighted       Average 
       Average       Remaining 
       Exercise   Total Intrinsic   Contractual 
   Warrants   Price   Value ($000s)   Life (in years) 
Outstanding as of December 31, 2025   6,690,768   $5.38   $6,186    3.9 
Granted   
-
    
-
    
-
    
-
 
Expired   (253,670)  $34.00    
-
    
-
 
Exercised   (75,000)  $4.22    
-
    - 
Outstanding as of March 31, 2026   6,362,098   $4.25   $
              -
    3.8 

 

Restricted Stock Awards and Stock Options

 

On October 7, 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”). The 2022 Plan provided for the issuance of up to 1,100,000 shares in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2022 Plan expires on January 1, 2032, and is administered by the Dominari Holdings’ board of directors.

 

On February 10, 2025, the Company issued 50,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $308,000.

 

On February 10, 2025, the Company issued 351,851 shares of the Company’s common stock to Messrs. Christopher Devall under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $2.1 million.

 

On February 12, 2025 in connection with the closing of the PIPE, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant to Messrs. Anthony Hayes. Pursuant to the Committee’s decision, he received 500,000 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $3.4 million.

 

On March 11, 2025, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $1.7 million.

 

On December 10, 2025, the Company issued 316,346 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. These shares will vest on September 30, 2026; provided that in the event of a change in control prior to any such vesting date, the shares, which have not yet vested shall vest and become nonforfeitable upon the effective date of such change in control, with a total fair value of $1.3 million.

 

On December 11, 2025, the Company issued 80,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. These shares will vest on the one-year anniversary of the grant date; provided that in the event of a change in control prior to any such vesting date, the shares, which have not yet vested shall vest and become nonforfeitable upon the effective date of such change in control, with a total fair value of $381 thousand.

 

On January 9, 2026, the Company issued 75,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan to members of the board of directors. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of $320 thousand.

 

On March 4, 2026, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant of 3.0 million shares of the Company’s common stock each to Messrs. Anthony Hayes and Kyle Wool, pursuant to shareholder approval to increase the shares of common stock reserved for issuance under the Company’s 2022 Equity Incentive Plan, which was approved on March 4, 2026 at a Special Meeting of Shareholders Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $18.4 million.

See Restricted Stock roll-forward below.

 

A summary of restricted stock awards activity for the three months ended March 31, 2026, is presented below:

 

       Weighted 
   Number of   Average 
   Restricted   Grant Day 
   Stock Awards   Fair Value 
Nonvested at December 31, 2025   396,346   $4.29 
Granted   6,075,000   $3.08 
Vested   (6,075,000)  $3.08 
Forfeited   
-
   $
-
 
Nonvested at March 31, 2026   396,346   $4.29 

 

Stock-based compensation associated with restricted stock awards was approximately $19.2 million and $7.6 million for the three months ended March 31, 2026, and 2025, respectively. All stock compensation was recorded as a component of compensation and benefits expenses. The 396,346 nonvested restricted stock units that were approved in December 2025 in the table above are reflected as being issued in the unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026.

 

As of March 31, 2026, there is approximately $1.1 million unrecognized stock-based compensation expense related to restricted stock awards.

 

Stock Options

 

On February 10, 2025, the Company granted an additional 5.0 million fully vested nonqualified stock options (each, a “Performance Award” and collectively, the “Performance Awards”) each to Anthony Hayes and Kyle Wool conditioned upon either the Company’s shareholders approving the Performance Awards or approving an increase in the share reserve of the Company’s 2022 Equity Incentive Plan (the “Plan”) such that the full number of shares underlying the Performance Awards could be delivered under the Plan. On April 1, 2025, following a special meeting of shareholders, the Company’s shareholders voted to approve an increase in the Plan’s share reserve allowing the Performance Awards to be delivered under the Plan. The Company recorded an expense of $26.1 million for the Performance Awards during the second quarter of 2025.

 

On December 1, 2025, the Company entered into an advisory agreement with a certain individual who was issued 50,000 nonqualified stock options (“Advisor Options”). Each party reserves the right to terminate the agreement at any time, with or without cause, upon five (5) days prior written notice to the other party. One half of the Advisor Options shall vest and become exercisable during its term on December 1, 2025, and one half of the Advisor Options shall vest and become exercisable during its term on June 1, 2026, in the manner and subject to the terms and conditions of the Plan and the Stock Option Grant Agreement (the “Option Grant Agreement”). The Company used a Black Scholes valuation to calculate the grant date fair value of the Advisor Options. The fair value of the Advisor Options amounted to $146 thousand and the Company recorded an expense of $36 thousand during the three months ended 2026 related to such options.

 

A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2026, is presented below:

 

                Weighted 
       Weighted        Average 
       Average   Total   Remaining  
   Number of
Shares
   Exercise
Price
   Intrinsic
Value
   Contractual Life (in years) 
Outstanding as of December 31, 2025   10,072,646   $6.16   $26    9.1 
Employee options granted   
-
   $
-
   $-    - 
Employee options exercised   
-
   $
-
   $-    - 
Employee options forfeited   
-
   $
-
   $-    - 
Outstanding as of March 31, 2026   10,072,646   $6.16   $-    8.8 
Options vested and exercisable   10,064,313   $6.17   $-    8.8 

 

Stock-based compensation associated with stock options was approximately $36 thousand and $38 thousand for the three months ended March 31, 2026, and 2025, respectively. All stock compensation was recorded as a component of compensation and benefits expenses.

Estimated future stock-based compensation expense relating to unvested stock options is approximately $24 thousand.

 

Non-controlling Interest

 

As previously discussed, the Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of March 31, 2026, the revenue attributable to non-controlling interest was $23 thousand of which the Company owes $21 thousand at March 31, 2026. During the three months ended March 31, 2026, the Company distributed $55 thousand to non-controlling interests.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue
3 Months Ended
Mar. 31, 2026
Revenue [Abstract]  
Revenue

Note 12. Revenue

 

Disaggregation of Revenue

 

For the three months ended March 31, 2026, and 2025 total revenue and revenue related to contracts with customers within the scope of Topic 606 were ($ in thousands):

 

   Three Months Ended 
   March 31, 
Revenues  2026   2025 
Underwriting services  $32,949   $5,606 
Carried interest   1,096    
-
 
Commissions   2,490    2,190 
Interest income – customers   72    39 
Other revenue   230    249 
Management fees   265    66 
Total revenue from contracts with customers   37,102   $8,150 
Principal transactions   (1,532)   (910)
Interest income – noncustomer   235    
-
 
Total revenue  $35,805   $7,240 

 

Revenue Recognized at a Point in Time

 

The Company recognizes revenue that is transactional in nature and such revenue is earned at a point in time. For the three months ended March 31, 2026, revenue that was recognized at a point in time includes underwriting services of $32.9. million, carried interest of $1.1 million, commissions of $2.5 million and principal transactions losses of $1.5 million consisting of $0.6 million of realized gains and $2.1 million of unrealized losses. For the three months ended March 31, 2025, revenue that is recognized at a point in time includes underwriting services of $5.6 million, commissions of $2.2 million, and principal transactions losses of $0.9 million consisting of $0.3 million of realized gains and $1.2 million of unrealized losses.

 

Revenue Recognized Over Time

 

The Company recognizes revenue over a period of time, generally monthly on a straight-line basis, as services are performed, and performance obligations are satisfied. For the three months ended March 31, 2026, revenue that is recognized over time includes other revenue of $230 thousand, management fees of $265 thousand, interest income from customers of $72 thousand, and interest income-noncustomers of $235 thousand. For the three months ended March 31, 2025, revenue that was recognized over time includes other revenue of $233 thousand, management fees of $66 thousand, and interest income from customers of $53 thousand.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies [Abstract]  
Commitments and Contingencies

Note 13. Commitments and Contingencies

 

Legal Proceedings

 

The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be. Notwithstanding this uncertainty, the Company does not believe that the results of these potential claims are likely to have a material effect on its financial position or results of operations.

 

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

 

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes
3 Months Ended
Mar. 31, 2026
Income Taxes [Abstract]  
Income Taxes

Note 14. Income Taxes

 

The Company’s income tax expense (benefit) for the three months ended March 31, 2026 is as follows ($ in thousands):

 

U.S. Federal  $8,537 
State   4,331 
Foreign   
-
 
Current income tax expense (benefit)  $12,868 
U.S. Federal   
-
 
State   
-
 
Foreign   
-
 
Deferred income tax expense (benefit)   
-
 
Total income tax expense (benefit)  $12,868 

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. For interim periods, the Company applies the estimated annual effective tax rate (“AETR”) method in accordance with ASC 740-270. Under this method, income tax expense for interim periods is computed by applying the estimated annual effective tax rate to year-to-date ordinary pretax income (loss) and adjusting for the tax effects of discrete items recognized in the period.

 

For the three months ended March 31, 2026, the Company recorded income tax expense despite reporting a pretax loss. This result is primarily attributable to a significant permanent difference related to the limitation on the deductibility of certain executive compensation under Internal Revenue Code Section 162(m). The Company currently expects that a substantial portion of executive compensation will not be deductible for income tax purposes for the full fiscal year. As a result, the Company’s estimated annual taxable income is forecasted to be positive, despite an expected pretax book loss. Accordingly, the Company’s estimated annual effective tax rate is negative, as the projected annual income tax expense is divided by an expected pretax book loss. The application of this negative AETR to year-to-date ordinary pretax loss results in the recognition of income tax expense in the interim period, rather than a tax benefit that would otherwise be expected based on the pretax loss.

 

In addition, the Company recognized the tax effect of a discrete item during the three months ended March 31, 2026, which further impacted income tax expense in the period. Discrete items are excluded from the determination of the AETR and are recorded in the period in which they occur. During the period, the Company recognized a book loss of approximately $6.9 million related to the sale of the Company’s marketable securities in American Bitcoin Corp (“ABTC”) stock. For income tax purposes, the majority of the approximate $32.5 million of proceeds from the sale of the Company’s ABTC stock resulted in a $32.5 million were taxable ordinary income which is treated as a discrete item in the interim period. The income tax effect of this transaction increased current income tax expense by approximately $9.5 million.

 

The Company’s effective tax rate for the three months ended March 31, 2026, was (9.0%). The primary drivers of the variance from the statutory rate were state taxes, Sec. 162m disallowed compensation, and valuation allowance. The Company will continue to assess its estimated annual effective tax rate each reporting period. Changes in forecasted pretax income, the amount of non-deductible compensation under Section 162(m), or other factors could result in significant adjustments to the Company’s interim income tax provision in future periods.

 

During the three months ended March 31, 2025, the Company did not record any income tax expense or benefit.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company’s history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of all deferred tax assets. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets of approximately $49.4 million as of March 31, 2026 and $38.3 million as of December 31, 2025. For the three-month period ended March 31, 2026, the change in valuation allowance is approximately $11.1 million.

 

As of March 31, 2026, the Company has federal, state post-apportioned, and foreign net operating loss (“NOL”) carryforwards of approximately $76.7 million, $74.5 million, and $0, respectively. Of the federal amount, $29.8 million have a limited carryforward period and will begin to expire in 2026, and $47.0 million will have an indefinite carryforward period. Of the state post-apportioned amount, $74.5 million have a limited carryforward period and will begin to expire in 2038.

 

Utilization of the U.S. NOL carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.

 

The Company completed a Section 382 study through December 31, 2025, and concluded that it underwent ownership changes as defined by the Code on September 10, 2013, March 31, 2014, May 24, 2016, December 5, 2019, March 31, 2020, March 31, 2021, and February 10, 2025. The Company had a net unrealized built-in loss (“NUBIL”) position at each ownership change date. As a result, the Company’s utilization of certain tax attributes, including amortization of acquired intangible assets, is subject to the Section 382 limitation. The Company has approximately $76 million of acquired intangible assets capitalized between 2013 and 2023 that are subject to this limitation.

 

Any future ownership changes that may occur after December 31, 2025, may limit the Company’s ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company’s effective tax rate.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.26.1
Regulatory
3 Months Ended
Mar. 31, 2026
Regulatory [Abstract]  
Regulatory

Note 15. Regulatory

 

Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is Dominari Securities is subject to SEC Uniform Net Capital Rule (Rule 15c3-1), which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule15c3-1. As of March 31, 2026, Dominari Securities had net capital of approximately $23.4 million in excess of minimum net capital requirement of $0.7 million.

 

Dominari Securities customers’ securities transactions are introduced on a fully-disclosed basis with its clearing broker/dealers. The clearing broker/dealers are responsible for execution, collection of and payment of funds and, receipt and delivery of securities relative to customer transactions. Off-balance-sheet risk exists with respect to these transactions due to the possibility that customers may be unable to fulfill their contractual commitments. The clearing broker/dealers may charge any losses it incurs on customers to Dominari Securities. The Company seeks to minimize this risk through procedures designed at Dominari Securities to monitor the creditworthiness of its customers and to ensure that customer transactions are executed properly by the clearing brokers, by monitoring all customer activity and reviewing information it receives from its clearing broker on a daily basis.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.26.1
Related Party Transactions
3 Months Ended
Mar. 31, 2026
Related Party Transactions [Abstract]  
Related Party Transactions

Note 16. Related Party Transactions

 

In 2021, the Dominari Holdings engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, Chief Executive Officer and one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023 and held approximately 30% of Revere’s outstanding equity until May, 2025. From time to time, the Company participates in offerings of securities as an underwriter in transactions in which Revere also participates as an underwriter. For the three months ended March 31, 2026, there were no such transactions. The Company earned $368,000 in the three months ended March 31, 2025 in transactions, which Revere also participated as an underwriter. As of May 20, 2025, Kyle Wool no longer holds an equity interest in Revere.

 

During the year December 31, 2024, the Company entered into employee loans with various employees totaling $2.4 million. The terms of the loan agreements range from 3 years to 7 years, with an average annual interest rate of approximately 3.2%. The total interest received for the three months ended March 31, 2026 and 2025 was approximately $17 thousand and $21 thousand, respectively. As of March 31, 2026 and 2025, the total outstanding balance of the employee loans was $1.7 million and $2.0 million, respectively and are included in loans to employees on the accompanying unaudited condensed consolidated balance sheets.

Certain of the Company’s investments are made through related party special purpose vehicles (the “Series Funds”). Those Company investments in the Series Funds without readily determinable fair values are accounted for using the measurement alternative and are are classified as long-term equity investments. Approximate carrying values of such related party long-term equity investments was $261 thousand and $150 thousand as of March 31, 2026 and December 31, 2025 respectively. Those Company investments in the Series Funds which have readily determinable fair values are classified as marketable securities with an approximate fair value of $2.3 million as March 31, 2026 and December 31, 2025.

 

The Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of March 31, 2026, the amount attributable to non-controlling interest was $23 thousand. There is $21 thousand payable to non-controlling interests as of March 31, 2026.

 

The Company earns revenues for managing certain pooled investment vehicles which are related parties. These include the entirety of the management fee revenues totaling $0.3 million and $0.1 million for the three months ended March 31, 2026 and 2025, respectively and are classified as management fees in Note 12 and included in other revenue within the statement of operations. The total amount of contract liabilities disclosed in Note 2 represented amounts received in advance of revenue earned on managing such related party investment vehicles and are listed as contract liabilities in the unaudited condensed statement of financial condition totaling $4.7 million as of March 31, 2026 and $4.5 million as of December 2025.

 

In the normal course of business, Dominari Securities provides underwriting and brokerage services to the Series Funds. As a result of services provided, the Company recognized approximately $0.4 million in underwriting revenue, $1.1 million in carried interest revenue, and $1.0 million of commission revenue during the three months ended 2026.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting

Note 17. Segment Reporting

 

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.

 

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy Aikido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy Aikido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy Aikido.

 

The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “Summary of Significant Accounting Policies”.

The measures of segment profitability that are most relied upon by the CODM are gross revenue and net income (loss), as presented within the table below and reconciled to the unaudited condensed consolidated statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.

 

   Three Months Ended March 31, 2026 
   Dominari
Financial
   Legacy
Holding Co.
   Consolidated 
Revenue  $35,805   $
-
   $35,805 
Operating Costs               
Compensation and benefits   23,891    44,268    68,159 
Professional and consulting fees   291    585    876 
Other operating expenses   3,063    1,329    4,392 
Income / (loss) from operations   8,560    (46,182)   (37,622)
                
Other (expenses) income               
Other income   
-
    108    108 
Interest income   
-
    61    61 
Loss on marketable securities   
-
    (7,014)   (7,014)
Total other income   
-
    (6,845)   (6,845)
Net income (/loss) before income taxes   8,560    (53,027)   (44,467)
Provision for income taxes   
-
    12,868    12,868 
Net income (loss)  $8,560   $(65,895)  $(57,335)
Non-controlling interests   
-
    23    23 
Net loss attributable to stockholders  $8,560    (65,918)  $(57,358)
Total assets  $25,104   $60,216   $85,320 

 

    Three Months Ended March 31, 2025  
    Dominari
Financial
    Legacy
Holding Co.
    Consolidated  
Revenue   $          7,240     $ -     $ 7,240  
Operating Costs                        
Compensation,  benefits and advisory fees     7,595       28,806       36,401  
Professional and consulting fees     54       775       829  
                         
Other expenses     1,544       1,348       2,892  
Loss from operations     (1,953 )     (30,929 )     (32,882 )
                         
Other (expenses) income                        
Interest income     -       21       21  
Gain on marketable securities     -       (168 )     (168 )
Unrealized loss on note receivable     -       221       221  
Change in carrying value of investments     -       320       320  
Total other (expenses) income     -       394       394  
Net loss   $ (1,953 )   $ (30,535 )   $ (32,488 )
                         
Total assets   $ 19,202     $ 33,103     $ 52,335  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.26.1
Subsequent Events
3 Months Ended
Mar. 31, 2026
Subsequent Events [Abstract]  
Subsequent Events

Note 19. Subsequent Events

 

Dividend

 

On May 4, 2026, the Company’s board of directors authorized a special cash dividend of, in aggregate, approximately $9.0 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to the Company’s common stock shareholders and certain warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2026.

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.26.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Pay vs Performance Disclosure    
Net Income (Loss) $ (57,358) $ (32,488)
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.26.1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Accounting Policies, by Policy (Policies)
3 Months Ended
Mar. 31, 2026
Summary of Significant Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheets as of March 31, 2026, condensed consolidated statements of operations for the three months ended March 31, 2026 and 2025, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2026 and 2025, and the condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026 or for any future interim period. The condensed consolidated balance sheets as of December 31, 2025 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.

The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial Inc., Dominari IM LLC, Dominari Manager LLC and Dominari Securities along with American Ventures IM LLC and American Ventures Manager LLC, both of which are owned 90% by the Company. All significant intercompany balances and transactions have been eliminated in consolidation.

Joint Ventures

Joint Ventures

On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its unaudited condensed consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of March 31, 2026, there has been no material activity in DFHS.

Use of Estimates

Use of Estimates

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, marketable securities, securities owned, the valuation of long-term equity investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Securities owned

Securities owned

Securities owned consist of equity securities including, common stock and warrants of publicly traded companies which are held by Dominari Securities. Securities owned and securities sold, but not yet purchased are recorded in the balance sheet at fair value, with the change in fair value and any realized gains or losses upon purchase or sale recorded within the statement of operations as principal transactions.

Dominari Securities may receive securities, including common or preferred stock and stock purchase warrants, from companies as part of its compensation for underwriting services. These instruments are stated at fair value in accordance with GAAP, and recorded within the balance sheet as securities owned. Such securities that the Company receives may be subject to contractual or instrument specific restrictions which prevent Dominari Securities from reselling the securities within the open market. Under ASC 820 only those restrictions which are an attribute of the instrument, and do not arise from any contractual agreement, are considered when determining fair value.

A portion of the Company’s equity securities, which are held by Dominari Securities, are subject to restrictions as disclosed in Note 7. Equities that have periods of contractual trading restrictions, discounts were considered in determining fair value The Company’s significant unobservable inputs, included the implied probability of 15% of certain marketplace transactions and events occurring, which would permit the sale of equities held. These equities are included in securities owned.

Warrant Investments

Warrant Investments

Warrant fair values are primarily determined using a Black Scholes option pricing model, which includes the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value. Warrants held by Dominari Securities are included in securities owned and other warrants are included in marketable securities.

The following inputs are considered for determining the fair values of warrants:

The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.
The expected remaining term is equal to the time to expiration of the warrant investment.
Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.
The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.
Marketability discounts are applied for warrants that have sales restrictions (or lock-up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.
Receivable from Clearing Brokers

Receivable from Clearing Brokers

Receivable from Dominari Securities’ clearing brokers totaling $21.9 million consisted of approximately $0.5 million of liquid insured deposits $3.7 million of commission receivable and $17.7 million of liquid deposits maintained by the Company with its clearing brokers as of March 31, 2026. Receivable from Dominari Securities’ clearing brokers consisted of approximately $1.4 million of liquid insured deposits, $2.1 million of commissions receivable and $0.5 million of liquid deposits maintained by the Company with its clearing brokers as of December 31, 2025. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of March 31, 2026 and December 31, 2025 an allowance for credit losses was deemed not necessary.

Long-term Equity Investments and marketable securities

Long-term Equity Investments and marketable securities

The Company holds certain strategic investments that are not part of its broker-dealer trading activities. The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying unaudited condensed consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are accounted for under ASC 321 using the measurement alternative. Equity method investments and other long-term investments that are not part of our broker-dealer trading activities are included in “long term equity investment” on the unaudited condensed consolidated balance sheet. These investments are generally strategic in nature and are not actively traded. Unrealized gains and losses on these investments are recognized in earnings when impairment is identified or when observable price changes occur and are classified in other income (loss) in the unaudited condensed consolidated statement of operations.

Leases

Leases

The Company accounts for its leases under ASC 842, Leases (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 9 - Leases).

Revenue

Revenue

The Company recognizes revenue under ASC 606 - Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:

Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.

Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized. The Company records such Non-Cash Consideration on the date at which its performance obligation is fulfilled using the date of contract inception as the fair value measurement date, as required by FASB ASC 606-10-32-21 and recorded as underwriting revenues. Any changes resulting from the form of the consideration after contract inception (e.g. fair value) are not included in the transaction price and, therefore, are included in principal transactions. To the extent changes in the noncash consideration occur for reasons other than the form of the consideration (e.g., notional quantity of instruments provided is based upon the Company’s performance), the Company applies relevant guidance on variable consideration, constraining such amounts until the associated uncertainty is resolved. Similarly, any commissions or compensation expense from providing non-cash consideration provided to employees and is recognized at fair value in accordance with ASC 820 on the same date.

Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying unaudited condensed consolidated balance sheet.
Carried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high-water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Carried Interest Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to claw back or reversal.
Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:
oThe Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.
oManagement fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.

Principal transactions are recorded on a trade-date basis (as if they had settled). Realized and unrealized gains and losses arising from all securities transactions entered into for the account and risk of the Company are recorded in principal transactions in the accompanying statement of operations. These gains and losses are not in scope for ASC 606 as they are not generated from contracts with customers.

Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management As of March 31, 2026, the Company recognized $4.7 million of contract liabilities of which $1.1 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2031. During the three months ended March 31, 2026, the Company recognized revenue of $0.3 million that was included in contract liabilities as of March 31, 2026.
Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b-1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.
Compensation and benefits

Compensation and benefits

Compensation and benefits includes fixed salaries, commissions (paid in either cash or in securities), related benefits and stock-based compensation incurred on an accrual basis. The Company has a defined contribution 401(k) plan that covers all employees and allows an employer contribution of up to 50% of the first 3% of each participating employee’s eligible compensation contributed to the plan and 50% of the next two percent of each participating employee’s eligible compensation. Participants are 100% vested in these matching contributions when they are made. Eligible employees may elect to defer pre-tax contributions regulated under Section 401(k) of the Internal Revenue Code. The Company’s matching contributions are included in compensation and benefits in the unaudited condensed consolidated statements of operations. Please see “Stock based compensation” section below for additional information on stock-based compensation accounting policies.

Stock-based Compensation

Stock-based Compensation

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award.

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on either the simplified method, if applicable, which is the half-life from vesting to the end of its contractual term or when applicable, probability estimates of expected exercises of such options.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

The Company accounts for forfeitures as they occur.

Income Taxes

Income Taxes

Income tax expense for interim periods is calculated in accordance with ASC 740, Income Taxes, and ASC 740 270, Interim Reporting. Interim periods are treated as integral parts of the annual reporting period, and income tax expense is recognized using estimates that reflect management’s best assessment of the expected annual tax position, including discrete items recognized in the period incurred.

Effect of new accounting pronouncements to be adopted in future periods

Effect of new accounting pronouncements to be adopted in future periods

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity discloses more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its financial statements.

The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.

Reclassification of prior year amounts

Reclassification of prior year amounts

Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or stockholders’ equity.

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.26.1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2026
Marketable Securities [Abstract]  
Schedule of Gains and (Losses) on Marketable Securities

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2026 and 2025, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):

 

   Three Months Ended 
   March 31, 
   2026   2025 
Realized gain / (loss)  $(6,949)  $(732)
Unrealized gain / (loss)   (115)   468 
Interest and dividend income   50    96 
Total  $(7,014)  $(168)
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.26.1
Long-Term Equity Investments (Tables)
3 Months Ended
Mar. 31, 2026
Long-Term Equity Investments [Abstract]  
Schedule of Long-Term Investments The following table presents the Company’s long-term investments as of March 31, 2026, and December 31, 2025 ($ in thousands):
   March 31, 2026   December 31, 2025 
       Carrying       Carrying 
   Cost Basis   Value   Cost Basis   Value 
Investment in Kerna Health  $2,140   $4,940   $2,140   $4,940 
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*   1,000    1,000    1,000    1,000 
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a.                    
Masterclass)*   170    170    170    170 
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a.Kraken)* *   597    364    597    364 
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*   3,500    2,248    3,500    2,248 
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.)**   1,240    1,240    1,240    1,240 
                     
Investment in Discord Inc.   476    476    476    476 
                     
Investment in Automation Anywhere, Inc.   476    397    476    397 
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*   100    109    100    109 
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*   25    25    25    25 
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*   25    25    25    25 
Investment in AdvEn Inc.   750    750    750    750 
Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..)   102    102    -    - 
Total  $10,601   $11,846   $10,499   $11,744 

 

*Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

 

**Investment made in these companies are through both an SPV and direct investments.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value of Financial Assets and Liabilities (Tables)
3 Months Ended
Mar. 31, 2026
Fair Value of Financial Assets and Liabilities [Abstract]  
Schedule of Assets and Liabilities that are Measured at Fair Value

The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2026 and December 31, 2025 ($ in thousands):

 

   Fair value measured as of March 31, 2026 
       Quoted   Significant     
   Total at   prices in
Active
   other
observable
   Significant
unobservable
 
   March 31,   Markets   inputs   inputs 
   2026   (Level 1)   (Level 2)   (Level 3) 
Assets                
Securities owned  $11,118   $
   $9,467   $1,651 
Marketable securities  $6,901   $5,494   $1,407   $
 

 

   Fair value measured as of December 31, 2025 
       Quoted   Significant     
   Total at   prices in active   other observable   Significant unobservable 
   December 31,   markets   inputs   inputs 
   2025   (Level 1)   (Level 2)   (Level 3) 
Assets                
Securities owned  $9,756   $
   $8,014   $1,742 
Marketable securities  $46,516   $45,049   $1,467   $
 
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):

 

Securities owned at fair value as of December 31, 2025  $1,741 
      
Unrealized loss included in principal transactions  $(90)
Securities owned at fair value as of March 31, 2026  $1,651 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.26.1
Prepaid Expenses and Other Assets (Tables)
3 Months Ended
Mar. 31, 2026
Prepaid Expenses and Other Assets [Abstract]  
Schedule of Other Assets

Other assets consist of the following as of March 31, 2026, and December 31, 2025 ($ in thousands):

 

   March 31,
2026
   December 31,
2025
 
Prepaid expenses  $480   $805 
Security deposits   483    483 
Property and equipment, net   108    135 
Other   769    980 
Total  $1,840   $2,403 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.26.1
Leases (Tables)
3 Months Ended
Mar. 31, 2026
Leases [Abstract]  
Schedule of Lease Assets and Liabilities

The tables below represent the Company’s lease assets and liabilities as of March 31, 2026:

 

   March 31, 
   2026 
Assets:    
Operating lease right-of-use-assets  $2,586 
Liabilities:     
Current     
Operating  $568 
Long-term     
Operating   2,176 
   $2,744 

 

The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:

 

   March 31, 
   2026 
Weighted-average remaining lease term - operating leases (in years)   4.0 
Weighted-average discount rate - operating leases   10.0%
   Three Months Ended
March 31,
 
   2026   2025 
Operating leases        
Operating lease cost  $205   $178 
Short-term lease rent expense   3    22 
Net rent expense  $208   $200 
Schedule of Future Minimum Payments

As of March 31, 2026, future minimum payments during the next five years and thereafter are as follows:

 

   Operating 
   Leases 
Remaining period Ended December 31, 2026  $638 
Year Ended December 31, 2027   801 
Year Ended December 31, 2028   766 
Year Ended December 31, 2029   784 
Year Ended December 31, 2030   377 
Thereafter   
-
 
Total   3,366 
Less present value discount   (622)
Operating lease liabilities  $2,744 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.26.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2026
Net Loss Per Share [Abstract]  
Schedule of Potentially Dilute Loss Per Share

Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended March 31, 2026, and 2025 are as follows:

 

   As of March 31, 
   2026   2025 
Convertible preferred stock   34    34 
Warrants to purchase common stock   6,362,098    8,175,188 
Restricted stock awards   396,346    50,000 
Options to purchase common stock   10,072,646    346,654 
Total   16,831,124    8,571,876 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders’ Equity and Convertible Preferred Stock (Tables)
3 Months Ended
Mar. 31, 2026
Stockholders’ Equity and Convertible Preferred Stock [Abstract]  
Schedule of Warrant Activity

A summary of warrant activity for the three months ended March 31, 2026, is presented below:

 

               Weighted 
       Weighted       Average 
       Average       Remaining 
       Exercise   Total Intrinsic   Contractual 
   Warrants   Price   Value ($000s)   Life (in years) 
Outstanding as of December 31, 2025   6,690,768   $5.38   $6,186    3.9 
Granted   
-
    
-
    
-
    
-
 
Expired   (253,670)  $34.00    
-
    
-
 
Exercised   (75,000)  $4.22    
-
    - 
Outstanding as of March 31, 2026   6,362,098   $4.25   $
              -
    3.8 
Schedule of Restricted Stock Awards Activity

A summary of restricted stock awards activity for the three months ended March 31, 2026, is presented below:

 

       Weighted 
   Number of   Average 
   Restricted   Grant Day 
   Stock Awards   Fair Value 
Nonvested at December 31, 2025   396,346   $4.29 
Granted   6,075,000   $3.08 
Vested   (6,075,000)  $3.08 
Forfeited   
-
   $
-
 
Nonvested at March 31, 2026   396,346   $4.29 
Schedule of Option Activity Under the Company’s Stock Option Plan

A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2026, is presented below:

 

                Weighted 
       Weighted        Average 
       Average   Total   Remaining  
   Number of
Shares
   Exercise
Price
   Intrinsic
Value
   Contractual Life (in years) 
Outstanding as of December 31, 2025   10,072,646   $6.16   $26    9.1 
Employee options granted   
-
   $
-
   $-    - 
Employee options exercised   
-
   $
-
   $-    - 
Employee options forfeited   
-
   $
-
   $-    - 
Outstanding as of March 31, 2026   10,072,646   $6.16   $-    8.8 
Options vested and exercisable   10,064,313   $6.17   $-    8.8 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2026
Revenue [Abstract]  
Schedule of Total Revenue Disaggregated by Revenue Type

For the three months ended March 31, 2026, and 2025 total revenue and revenue related to contracts with customers within the scope of Topic 606 were ($ in thousands):

 

   Three Months Ended 
   March 31, 
Revenues  2026   2025 
Underwriting services  $32,949   $5,606 
Carried interest   1,096    
-
 
Commissions   2,490    2,190 
Interest income – customers   72    39 
Other revenue   230    249 
Management fees   265    66 
Total revenue from contracts with customers   37,102   $8,150 
Principal transactions   (1,532)   (910)
Interest income – noncustomer   235    
-
 
Total revenue  $35,805   $7,240 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes (Tables)
3 Months Ended
Mar. 31, 2026
Income Taxes [Abstract]  
Schedule of Income Tax Expense (Benefit)

The Company’s income tax expense (benefit) for the three months ended March 31, 2026 is as follows ($ in thousands):

 

U.S. Federal  $8,537 
State   4,331 
Foreign   
-
 
Current income tax expense (benefit)  $12,868 
U.S. Federal   
-
 
State   
-
 
Foreign   
-
 
Deferred income tax expense (benefit)   
-
 
Total income tax expense (benefit)  $12,868 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of CODM Views the Expenses Additionally, the CODM views the expenses listed below to be significant in their analysis.
   Three Months Ended March 31, 2026 
   Dominari
Financial
   Legacy
Holding Co.
   Consolidated 
Revenue  $35,805   $
-
   $35,805 
Operating Costs               
Compensation and benefits   23,891    44,268    68,159 
Professional and consulting fees   291    585    876 
Other operating expenses   3,063    1,329    4,392 
Income / (loss) from operations   8,560    (46,182)   (37,622)
                
Other (expenses) income               
Other income   
-
    108    108 
Interest income   
-
    61    61 
Loss on marketable securities   
-
    (7,014)   (7,014)
Total other income   
-
    (6,845)   (6,845)
Net income (/loss) before income taxes   8,560    (53,027)   (44,467)
Provision for income taxes   
-
    12,868    12,868 
Net income (loss)  $8,560   $(65,895)  $(57,335)
Non-controlling interests   
-
    23    23 
Net loss attributable to stockholders  $8,560    (65,918)  $(57,358)
Total assets  $25,104   $60,216   $85,320 

 

    Three Months Ended March 31, 2025  
    Dominari
Financial
    Legacy
Holding Co.
    Consolidated  
Revenue   $          7,240     $ -     $ 7,240  
Operating Costs                        
Compensation,  benefits and advisory fees     7,595       28,806       36,401  
Professional and consulting fees     54       775       829  
                         
Other expenses     1,544       1,348       2,892  
Loss from operations     (1,953 )     (30,929 )     (32,882 )
                         
Other (expenses) income                        
Interest income     -       21       21  
Gain on marketable securities     -       (168 )     (168 )
Unrealized loss on note receivable     -       221       221  
Change in carrying value of investments     -       320       320  
Total other (expenses) income     -       394       394  
Net loss   $ (1,953 )   $ (30,535 )   $ (32,488 )
                         
Total assets   $ 19,202     $ 33,103     $ 52,335  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.26.1
Organization and Description of Business and Recent Developments (Details) - USD ($)
$ in Millions
3 Months Ended
Oct. 04, 2022
Mar. 31, 2026
Jun. 17, 2025
Sep. 09, 2022
Organization and Description of Business and Recent Developments [Line Items]        
Additional seller paid (in Dollars) $ 2.0 $ 1.4    
FPS Purchase Agreement [Member]        
Organization and Description of Business and Recent Developments [Line Items]        
Membership interests 20.00% 80.00%   100.00%
American Ventures LLC [Member]        
Organization and Description of Business and Recent Developments [Line Items]        
Membership interests     90.00%  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.26.1
Liquidity and Capital Resources (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Liquidity and Capital Resources [Abstract]    
Cash and cash equivalents $ 27,477 $ 34,005
Marketable securities 6,901 46,516
Securities owned 11,118 9,756
Receivable from clearing brokers 21,883 $ 3,995
Working capital $ 21,900  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Dec. 31, 2025
May 21, 2024
Summary of Significant Accounting Policies [Line Items]      
Unobservable percent 15.00%    
Receivable from clearing brokers $ 21,883 $ 3,995  
Liquid insured deposits 500 1,400  
Commissions receivable 3,700 2,100  
Good faith deposits 17,700 $ 500  
Contract liabilities recognized 4,700    
Contract liabilities expected to be recognized 1,100    
Recognized revenue included in contract liabilities $ 300    
Employer contribution percent 50.00%    
Vesting matching percentage 100.00%    
American Ventures IM LLC and American Ventures Manager LLC [Member]      
Summary of Significant Accounting Policies [Line Items]      
Ownership interests 90.00%    
Dominari Financial Heritage Strategies LLC [Member]      
Summary of Significant Accounting Policies [Line Items]      
Ownership interests     50.00%
Maximum [Member]      
Summary of Significant Accounting Policies [Line Items]      
Employee’s eligible compensation percent 3.00%    
Vesting term 5 years    
Minimum [Member]      
Summary of Significant Accounting Policies [Line Items]      
Employee’s eligible compensation percent 2.00%    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.26.1
Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Schedule of Gains and (Losses) on Marketable Securities [Abstract]    
Realized gain / (loss) $ (6,949) $ (732)
Unrealized gain / (loss) (115) 468
Interest and dividend income 50 96
Total $ (7,014) $ (168)
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.26.1
Long-Term Equity Investments (Details) - USD ($)
$ in Thousands
3 Months Ended
Apr. 06, 2026
Jan. 13, 2026
Jul. 25, 2024
Mar. 31, 2026
Mar. 31, 2025
Long-Term Equity Investments [Line Items]          
Changes in carrying values       $ 300
Changes in carrying values       $ (320)
Subsequent Event [Member]          
Long-Term Equity Investments [Line Items]          
Payment received $ 58        
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.) [Member]          
Long-Term Equity Investments [Line Items]          
Agreed to purchase units (in Shares)     25,000    
Units purchased amount     $ 25    
Changes in carrying values        
Investment in TracX. [Member]          
Long-Term Equity Investments [Line Items]          
Units purchased amount   $ 102      
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.26.1
Long-Term Equity Investments - Schedule of Long-Term Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis $ 10,601 $ 10,499
Long-term investments, Carrying Value 11,846 11,744
Investment in Kerna Health [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 2,140 2,140
Long-term investments, Carrying Value 4,940 4,940
Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 1,000 1,000
Long-term investments, Carrying Value [1] 1,000 1,000
Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 170 170
Long-term investments, Carrying Value [1] 170 170
Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [2] 597 597
Long-term investments, Carrying Value [2] 364 364
Investment in Aeon Partners Fund Series EG (Epic Games, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 3,500 3,500
Long-term investments, Carrying Value [1] 2,248 2,248
Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [2] 1,240 1,240
Long-term investments, Carrying Value [2] 1,240 1,240
Investment in Discord Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476 476
Long-term investments, Carrying Value 476 476
Investment in Automation Anywhere, Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 476 476
Long-term investments, Carrying Value 397 397
Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 100 100
Long-term investments, Carrying Value [1] 109 109
Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 25 25
Long-term investments, Carrying Value [1] 25 25
Investment in Dominari Master SPV LLC Series XII (Groq, Inc.) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis [1] 25 25
Long-term investments, Carrying Value [1] 25 25
Investment in AdvEn Inc. [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 750 750
Long-term investments, Carrying Value 750 $ 750
Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..) [Member]    
Schedule of Long-Term Investments [Line Items]    
Long-term investments, Cost Basis 102  
Long-term investments, Carrying Value $ 102  
[1] Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.
[2] Investment made in these companies are through both an SPV and direct investments.
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.26.1
Notes Receivable (Details) - USD ($)
$ in Thousands
12 Months Ended
Mar. 24, 2025
Dec. 31, 2025
Mar. 31, 2026
Notes Receivable [Line Items]      
Notes receivable  
Total proceeds $ 1,100    
American Innovative Robotics, LLC [Member]      
Notes Receivable [Line Items]      
Interest income   20,000  
Realized gain (loss)   $ 221,000  
Ending value $ 0    
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Sep. 30, 2026
Mar. 31, 2026
Mar. 31, 2025
Fair Value of Financial Assets and Liabilities [Line Items]      
Fair value of warrant   $ (320)
Forecast [Member]      
Fair Value of Financial Assets and Liabilities [Line Items]      
Fair value of warrant $ 4,300    
Level 3 [Member]      
Fair Value of Financial Assets and Liabilities [Line Items]      
Fair value amount   $ 1,700  
Stock price (in Dollars per share)   $ 10.01  
Stock price, percentage   15.00%  
Level 2 [Member]      
Fair Value of Financial Assets and Liabilities [Line Items]      
Additional fair value   $ 1,100  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Assets    
Securities owned $ 11,118 $ 9,756
Marketable securities 6,901 46,516
Quoted Prices In Active Markets (Level 1) [Member]    
Assets    
Securities owned
Marketable securities 5,494 45,049
Significant other observable inputs (Level 2) [Member]    
Assets    
Securities owned 9,467 8,014
Marketable securities 1,407 1,467
Significant unobservable inputs (Level 3) [Member]    
Assets    
Securities owned 1,651 1,742
Marketable securities
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.26.1
Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - Level 3 [Member]
$ in Thousands
3 Months Ended
Mar. 31, 2026
USD ($)
Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]  
Securities owned at fair value as of December 31, 2025 $ 1,741
Unrealized loss included in principal transactions (90)
Securities owned at fair value as of March 31, 2026 $ 1,651
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.26.1
Prepaid Expenses and Other Assets - Schedule of Other Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Schedule of Other Assets [Abstract]    
Prepaid expenses $ 480 $ 805
Security deposits 483 483
Property and equipment, net 108 135
Other 769 980
Total $ 1,840 $ 2,403
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.26.1
Leases (Details) - USD ($)
$ in Thousands
3 Months Ended
Oct. 01, 2025
Jan. 11, 2023
Sep. 23, 2022
Mar. 31, 2026
Mar. 31, 2025
Jul. 11, 2022
Leases [Abstract]            
Lease term 2 years   23 years     7 years
Lease rent expenses $ 10,000 $ 12,874 $ 49,368 $ 200 $ 200  
Increase rent amount   $ 13,502 $ 51,868 $ 10,300    
Future minimum payments lease term       5 years    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.26.1
Leases - Schedule of Lease Assets and Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Assets:      
Operating lease right-of-use-assets $ 2,586   $ 2,721
Current      
Operating 568    
Long-term      
Operating 2,176    
Total liabilities $ 2,744   $ 2,841
Weighted-average remaining lease term - operating leases (in years) 4 years    
Weighted-average discount rate - operating leases 10.00%    
Operating lease cost $ 205 $ 178  
Short-term lease rent expense 3 22  
Net rent expense $ 208 $ 200  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.26.1
Leases - Schedule of Future Minimum Payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Schedule of Future Minimum Payments [Abstract]    
Remaining period Ended December 31, 2026 $ 638  
Year Ended December 31, 2027 801  
Year Ended December 31, 2028 766  
Year Ended December 31, 2029 784  
Year Ended December 31, 2030 377  
Thereafter  
Total 3,366  
Less present value discount (622)  
Operating lease liabilities $ 2,744 $ 2,841
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.26.1
Net Loss Per Share - Schedule of Potentially Dilute Loss Per Share (Details) - shares
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Schedule of Potentially Dilute Loss Per Share [Line Items]    
Total diluted loss per share 16,831,124 8,571,876
Convertible preferred stock [Member]    
Schedule of Potentially Dilute Loss Per Share [Line Items]    
Total diluted loss per share 34 34
Warrants to purchase common stock [Member]    
Schedule of Potentially Dilute Loss Per Share [Line Items]    
Total diluted loss per share 6,362,098 8,175,188
Restricted stock awards [Member]    
Schedule of Potentially Dilute Loss Per Share [Line Items]    
Total diluted loss per share 396,346 50,000
Options to purchase common stock [Member]    
Schedule of Potentially Dilute Loss Per Share [Line Items]    
Total diluted loss per share 10,072,646 346,654
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders’ Equity and Convertible Preferred Stock (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 04, 2026
Jan. 26, 2026
Jan. 09, 2026
Dec. 11, 2025
Dec. 10, 2025
Dec. 01, 2025
Sep. 26, 2025
Mar. 11, 2025
Mar. 03, 2025
Feb. 18, 2025
Feb. 12, 2025
Feb. 10, 2025
Jun. 11, 2024
Mar. 31, 2026
Dec. 31, 2025
Sep. 30, 2025
Mar. 31, 2025
Jun. 30, 2025
Dec. 31, 2025
Dec. 11, 2026
Sep. 30, 2026
Dec. 31, 2024
Oct. 07, 2022
Sep. 30, 2013
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Common stock, shares issued                           22,613,781 16,067,435       16,067,435          
Common stock, shares outstanding                           22,613,781 16,067,435       16,067,435          
Price per share (in Dollars per share)                       $ 3.47                        
Net proceeds (in Dollars)                               $ 13,517,000              
Fair value of issued shares (in Dollars)                                 13,517,000              
Additional paid-in capital (in Dollars)                           $ 300,000                    
Preferred stock, par value (in Dollars per share)                           $ 0.0001 $ 0.0001       $ 0.0001          
Preferred stock, shares authorized                           50,000,000 50,000,000       50,000,000          
Cash dividend per share payable (in Dollars per share)   $ 0.432         $ 0.22   $ 0.32                              
Cash dividends paid (in Dollars)                           $ 9,900,000 $ 10,300,000 $ 4,900,000 7,000,000   $ 22,200,000          
Dividend payable (in Dollars)                           400,000                    
Fair value (in Dollars)                         $ 320,000                      
Unrecognized stock-based compensation expense (in Dollars)                           1,100,000                    
Option granted (in Dollars)                           19,243,000                    
Expense (in Dollars)                           36,000       $ 26,100,000            
Nonqualified stock options issued           50,000                                    
Estimated future stock-based compensation expense (in Dollars)                           24,000                    
Non-controlling interests (in Dollars)                           (32,000)                
Distribution of non-controlling interests (in Dollars)                           $ 31,577,000 69,371,000   $ 42,428,000   69,371,000     $ 39,853,000    
Forecast [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Common stock, shares issued                                       80,000 316,346      
Series A Warrants [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Exercise price (in Dollars per share)                       $ 3.72                        
Term of warrants                       5 years                        
Series B Warrants [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Exercise price (in Dollars per share)                       $ 4.22                        
Term of warrants                       5 years                        
Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Common stock, shares issued       80,000 316,346             50,000                        
Vested fair value (in Dollars)       $ 381,000                                        
Common Stock [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Shares of common stock                                 3,876,054              
Net proceeds (in Dollars)                       $ 13,500,000                        
Fair value of issued shares (in Dollars)                                              
Additional common stock issuance                           75,000                    
Aggregate shares                                 2,550,000              
Option granted (in Dollars)                           $ 2,000                    
Distribution of non-controlling interests (in Dollars)                           2,000            
Restricted Stock Awards [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Option issued                                             1,100,000  
Restricted Stock Awards and Stock Options [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Fair value (in Dollars) $ 18,400,000                                              
Nonvested restricted stock                             396,346       396,346          
Restricted Stock Awards and Stock Options [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Vested fair value (in Dollars)         $ 1,300,000             $ 308,000                        
Stock Options [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Vested fair value (in Dollars)                           146,000                    
Stock-based compensation expense (in Dollars)                           $ 36,000     38,000              
Messr. Christopher Devall [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Common stock, shares issued                       351,851                        
Messr. Christopher Devall [Member] | Restricted Stock Awards and Stock Options [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Vested fair value (in Dollars)                       $ 2,100,000                        
Messr. Anthony Hayes [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Granted shares                     500,000                          
Messr. Anthony Hayes [Member] | Restricted Stock Awards and Stock Options [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Vested fair value (in Dollars)                     $ 3,400,000                          
Anthony Hayes and Kyle Wool [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Option granted (in Dollars)                       $ 5,000,000                        
Securities Purchase Agreements [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Shares of common stock                       1,439,467                        
Price per share (in Dollars per share)                       $ 3.47                        
Advisory Agreements [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Shares of common stock                       850,000                        
Fair value of issued shares (in Dollars)                       $ 20,900,000                        
AV Manager [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Non-controlling interests                           90.00%                    
Non-controlling interests (in Dollars)                           $ 23,000                    
AV Investment Manager [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Non-controlling interests                           10.00%                    
Non-controlling interests (in Dollars)                           $ 21,000                    
Distribution of non-controlling interests (in Dollars)                           55,000                    
Common Stock [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Shares of common stock                       2,436,587                        
Stock-based compensation expense (in Dollars)                           $ 19,200,000     $ 7,600,000              
Common Stock [Member] | Restricted Stock Awards [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Aggregate shares     75,000                                          
Common Stock [Member] | Restricted Stock Awards and Stock Options [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Common stock received 3,000,000                                              
Common Stock [Member] | Anthony Hayes and Kyle Wool [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Granted shares               154,559                                
Common Stock [Member] | Anthony Hayes and Kyle Wool [Member] | Restricted Stock Awards and Stock Options [Member] | Equity Incentive Plan [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Vested fair value (in Dollars)               $ 1,700,000                                
Common Stock [Member] | Advisory Agreements [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Shares of common stock                   2,550,000                            
Series D Convertible Preferred Stock [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Preferred stock, shares issued                           3,825 3,825       3,825          
Conversion of preferred stock                                               10
Number of common stock issued upon conversion                                               1,373
Preferred stock, shares authorized                           5,000,000 5,000,000       5,000,000          
Preferred stock, shares outstanding                           3,825 3,825       3,825          
Series D Convertible Preferred Stock [Member] | Stockholders [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Preferred stock, shares issued                                               1,379,685
Preferred stock, par value (in Dollars per share)                                               $ 0.0001
Series D-1 Convertible Preferred Stock [Member]                                                
Stockholders’ Equity and Convertible Preferred Stock [Line Items]                                                
Preferred stock, shares issued                           834 834       834          
Preferred stock, par value (in Dollars per share)                           $ 0.0001                    
Conversion of preferred stock                           10                    
Number of common stock issued upon conversion                           1,373                    
Preferred stock, shares authorized                           5,000,000 5,000,000       5,000,000          
Preferred stock, shares outstanding                           834 834       834          
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Schedule of Warrant Activity [Line Items]    
Number of shares, ending balance 6,690,768 6,362,098
Weighted Average per share, ending balance $ 5.38 $ 4.25
Outstanding ending balance, Total Intrinsic Value $ 6,186
Outstanding ending balance, Weighted Average Remaining Contractual Life 3 years 10 months 24 days 3 years 9 months 18 days
Granted, Warrants  
Granted, Weighted Average Exercise Price  
Granted, Total Intrinsic Value  
Granted, Weighted Average Remaining Contractual Life  
Expired, Warrants   (253,670)
Expired, Weighted Average Exercise Price   $ 34
Expired, Total Intrinsic Value  
Expired, Weighted Average Remaining Contractual Life (in years)  
Exercised, Warrants   (75,000)
Exercised, Weighted Average Exercise Price   $ 4.22
Exercised, Total Intrinsic Value  
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) - Restricted Stock [Member]
3 Months Ended
Mar. 31, 2026
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Restricted Stock Awards, Balance | shares 396,346
Weighted Average Grant Day Fair Value, Balance | $ / shares $ 4.29
Number of Restricted Stock Awards, Granted | shares 6,075,000
Weighted Average Grant Day Fair Value, Granted | $ / shares $ 3.08
Number of Restricted Stock Awards, Vested | shares (6,075,000)
Weighted Average Grant Day Fair Value, Vested | $ / shares $ 3.08
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Day Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Balance | shares 396,346
Weighted Average Grant Day Fair Value, Balance | $ / shares $ 4.29
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.26.1
Stockholders’ Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company’s Stock Option Plan (Details) - Stock Option [Member] - USD ($)
3 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Schedule of Option Activity Under the Company’s Stock Option Plan [Line Items]    
Outstanding ending balance, Number of Shares 10,072,646 10,072,646
Outstanding ending balance, Weighted Average Exercise Price $ 6.16 $ 6.16
Outstanding ending balance, Total Intrinsic Value $ 26,000  
Outstanding ending balance, Weighted Average Remaining Contractual Life (in years) 9 years 1 month 6 days 8 years 9 months 18 days
Employee options granted, Number of Shares  
Employee options granted, Weighted Average Exercise Price  
Employee options exercised, Number of Shares  
Employee options exercised, Weighted Average Exercise Price  
Employee options forfeited  
Employee options forfeited  
Options vested and exercisable, Number of Shares   10,064,313
Options vested and exercisable, Weighted Average Exercise Price   $ 6.17
Options vested and exercisable, Weighted Average Remaining Contractual Life (in years)   8 years 9 months 18 days
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Underwriting Services [Member] | Transferred at Point in Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers $ 32,900  
Carried Interest [Member] | Transferred at Point in Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 1,100 $ 5,600
Commissions [Member] | Transferred at Point in Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 2,500 2,200
Principal Transaction Losses [Member] | Transferred at Point in Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 1,500 900
Realized Gains [Member] | Transferred at Point in Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 600 300
Unrealized Losses [Member] | Transferred at Point in Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 2,100 1,200
Other Revenue [Member] | Transferred over Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 230 233
Management Fees [Member] | Transferred over Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 265 66
Interest Income From Customers [Member] | Transferred over Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers 72 $ 53
Interest Income Non Customers [Member] | Transferred over Time [Member]    
Revenue [Line Items]    
Total revenue from contracts with customers $ 235  
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers $ 37,102 $ 8,150
Total revenue 35,805 7,240
Underwriting services [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers 32,949 5,606
Carried interest [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers 1,096
Commissions [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers 2,490 2,190
Interest income – customers [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers 72 39
Other revenue [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers 230 249
Management fees [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue from contracts with customers 265 66
Principal transactions [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue (1,532) (910)
Interest income – noncustomer [Member]    
Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]    
Total revenue $ 235
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes (Details) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Taxes [Line Items]    
Recognized book loss $ 6,900,000  
Taxable gain 32,500,000  
Taxable ordinary income 32,500,000  
Current income tax $ 12,868,000  
Effective tax rate 9.00%  
Valuation allowance $ 49,400,000 $ 38,300,000
Change in valuation allowances 11,100,000  
Federal net operating loss carryforwards 76,700,000  
State net operating loss carryforwards 74,500,000  
Foreign net operating loss 0  
Minimum [Member]    
Income Taxes [Line Items]    
Federal net operating loss carryforwards 29,800,000  
State net operating loss carryforwards 74,500,000  
Maximum [Member]    
Income Taxes [Line Items]    
Federal net operating loss carryforwards 47,000,000  
ABTC Stock [Member]    
Income Taxes [Line Items]    
Current income tax 9,500,000  
Section 382 Limitation [Member]    
Income Taxes [Line Items]    
Acquired intangible assets $ 76,000,000  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.26.1
Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Schedule of Income Tax Expense (Benefit)    
U.S. Federal $ 8,537  
State 4,331  
Foreign  
Current income tax expense (benefit) 12,868  
U.S. Federal  
State  
Foreign  
Deferred income tax expense (benefit)  
Total income tax expense (benefit) $ 12,868
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.26.1
Regulatory (Details)
$ in Millions
Mar. 31, 2026
USD ($)
Regulatory [Line Items]  
Excess Net capital requirement $ 0.7
Dominari Securities [Member]  
Regulatory [Line Items]  
Net capital $ 23.4
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.26.1
Related Party Transactions (Details) - USD ($)
3 Months Ended 12 Months Ended
Jun. 30, 2023
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2025
Related Party Transactions [Line Items]          
Revere’s outstanding equity percentage 30.00%        
Earned amount     $ 368,000    
Employee loans       $ 2,400,000  
Average annual interest rate       3.20%  
Interest received   $ 17,000 21,000    
Other current liabilities   1,700,000 2,000,000    
Related party long-term equity investments   11,846,000     $ 11,744,000
Fair value   2,300,000     2,300,000
Amount of non-controlling interest   (32,000)    
Management fee revenues   300,000 $ 100,000    
Employee loans   4,700,000     4,500,000
Underwriting revenue   400,000      
Carried interest revenue   1,100,000      
Commission revenue   1,000,000      
Related Party [Member]          
Related Party Transactions [Line Items]          
Related party long-term equity investments   $ 261,000     $ 150,000
Minimum [Member]          
Related Party Transactions [Line Items]          
Terms of loan agreements       3 years  
Maximum [Member]          
Related Party Transactions [Line Items]          
Terms of loan agreements       7 years  
AV Manager [Member]          
Related Party Transactions [Line Items]          
Non-controlling interests   90.00%      
Amount of non-controlling interest   $ 23,000      
AV Investment Manager [Member]          
Related Party Transactions [Line Items]          
Non-controlling interests   10.00%      
Amount of non-controlling interest   $ 21,000      
Non-Controlling Interests [Member]          
Related Party Transactions [Line Items]          
Non-controlling interests   10.00%      
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting (Details)
3 Months Ended
Mar. 31, 2026
Segments
Segment Reporting [Abstract]  
CODM description Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Chief Executive Officer
Reportable segments 2
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting - Schedule of CODM Views the Expenses (Details) - CODM [Member] - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Schedule of CODM Views the Expenses [Line Items]    
Revenue $ 35,805 $ 7,240
Operating Costs    
Compensation and benefits 68,159 36,401
Professional and consulting fees 876 829
Other operating expenses 4,392 2,892
Income / (loss) from operations (37,622) (32,882)
Other (expenses) income    
Other income 108  
Interest income 61 21
Gain (Loss) on marketable securities (7,014) (168)
Unrealized loss on note receivable   221
Change in carrying value of investments   320
Total other income (expenses) (6,845) 394
Net income (/loss) before income taxes (44,467)  
Provision for income taxes 12,868  
Net income (loss) (57,335) (32,488)
Non-controlling interests 23  
Net loss attributable to stockholders (57,358)  
Total assets 85,320 52,335
Dominari Financial [Member]    
Schedule of CODM Views the Expenses [Line Items]    
Revenue 35,805 7,240
Operating Costs    
Compensation and benefits 23,891 7,595
Professional and consulting fees 291 54
Other operating expenses 3,063 1,544
Income / (loss) from operations 8,560 (1,953)
Other (expenses) income    
Other income  
Interest income
Gain (Loss) on marketable securities
Unrealized loss on note receivable  
Change in carrying value of investments  
Total other income (expenses)
Net income (/loss) before income taxes 8,560  
Provision for income taxes  
Net income (loss) 8,560 (1,953)
Non-controlling interests  
Net loss attributable to stockholders 8,560  
Total assets 25,104 19,202
Legacy Holding Co. [Member]    
Schedule of CODM Views the Expenses [Line Items]    
Revenue
Operating Costs    
Compensation and benefits 44,268 28,806
Professional and consulting fees 585 775
Other operating expenses 1,329 1,348
Income / (loss) from operations (46,182) (30,929)
Other (expenses) income    
Other income 108  
Interest income 61 21
Gain (Loss) on marketable securities (7,014) (168)
Unrealized loss on note receivable   221
Change in carrying value of investments   320
Total other income (expenses) (6,845) 394
Net income (/loss) before income taxes (53,027)  
Provision for income taxes 12,868  
Net income (loss) (65,895) (30,535)
Non-controlling interests 23  
Net loss attributable to stockholders (65,918)  
Total assets $ 60,216 $ 33,103
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.26.1
Subsequent Events (Details) - ABTC [Member] - Subsequent Event [Member]
$ / shares in Units, $ in Millions
May 04, 2026
USD ($)
$ / shares
Subsequent Events [Line Items]  
Cash dividend | $ $ 9.0
Common Stock [Member]  
Subsequent Events [Line Items]  
Cash dividend per share payable | $ / shares $ 0.31
XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 227 347 1 true 83 0 false 5 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Sheet http://www.aikidopharma.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Stockholders??? Equity (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.aikidopharma.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - Organization and Description of Business and Recent Developments Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments Organization and Description of Business and Recent Developments Notes 7 false false R8.htm 995307 - Disclosure - Liquidity and Capital Resources Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResources Liquidity and Capital Resources Notes 8 false false R9.htm 995308 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 995309 - Disclosure - Marketable Securities Sheet http://www.aikidopharma.com/role/MarketableSecurities Marketable Securities Notes 10 false false R11.htm 995310 - Disclosure - Long-Term Equity Investments Sheet http://www.aikidopharma.com/role/LongTermEquityInvestments Long-Term Equity Investments Notes 11 false false R12.htm 995311 - Disclosure - Notes Receivable Notes http://www.aikidopharma.com/role/NotesReceivable Notes Receivable Notes 12 false false R13.htm 995312 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities Fair Value of Financial Assets and Liabilities Notes 13 false false R14.htm 995313 - Disclosure - Prepaid Expenses and Other Assets Sheet http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssets Prepaid Expenses and Other Assets Notes 14 false false R15.htm 995314 - Disclosure - Leases Sheet http://www.aikidopharma.com/role/Leases Leases Notes 15 false false R16.htm 995315 - Disclosure - Net Loss Per Share Sheet http://www.aikidopharma.com/role/NetLossPerShare Net Loss Per Share Notes 16 false false R17.htm 995316 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock Stockholders??? Equity and Convertible Preferred Stock Notes 17 false false R18.htm 995317 - Disclosure - Revenue Sheet http://www.aikidopharma.com/role/Revenue Revenue Notes 18 false false R19.htm 995318 - Disclosure - Commitments and Contingencies Sheet http://www.aikidopharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 995319 - Disclosure - Income Taxes Sheet http://www.aikidopharma.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 995320 - Disclosure - Regulatory Sheet http://www.aikidopharma.com/role/Regulatory Regulatory Notes 21 false false R22.htm 995321 - Disclosure - Related Party Transactions Sheet http://www.aikidopharma.com/role/RelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 995322 - Disclosure - Segment Reporting Sheet http://www.aikidopharma.com/role/SegmentReporting Segment Reporting Notes 23 false false R24.htm 995323 - Disclosure - Subsequent Events Sheet http://www.aikidopharma.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 25 false false R26.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 26 false false R27.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.aikidopharma.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 996001 - Disclosure - Marketable Securities (Tables) Sheet http://www.aikidopharma.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.aikidopharma.com/role/MarketableSecurities 28 false false R29.htm 996002 - Disclosure - Long-Term Equity Investments (Tables) Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables Long-Term Equity Investments (Tables) Tables http://www.aikidopharma.com/role/LongTermEquityInvestments 29 false false R30.htm 996003 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities 30 false false R31.htm 996004 - Disclosure - Prepaid Expenses and Other Assets (Tables) Sheet http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssetsTables Prepaid Expenses and Other Assets (Tables) Tables http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssets 31 false false R32.htm 996005 - Disclosure - Leases (Tables) Sheet http://www.aikidopharma.com/role/LeasesTables Leases (Tables) Tables http://www.aikidopharma.com/role/Leases 32 false false R33.htm 996006 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.aikidopharma.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.aikidopharma.com/role/NetLossPerShare 33 false false R34.htm 996007 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Tables) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables Stockholders??? Equity and Convertible Preferred Stock (Tables) Tables http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock 34 false false R35.htm 996008 - Disclosure - Revenue (Tables) Sheet http://www.aikidopharma.com/role/RevenueTables Revenue (Tables) Tables http://www.aikidopharma.com/role/Revenue 35 false false R36.htm 996009 - Disclosure - Income Taxes (Tables) Sheet http://www.aikidopharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.aikidopharma.com/role/IncomeTaxes 36 false false R37.htm 996010 - Disclosure - Segment Reporting (Tables) Sheet http://www.aikidopharma.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.aikidopharma.com/role/SegmentReporting 37 false false R38.htm 996011 - Disclosure - Organization and Description of Business and Recent Developments (Details) Sheet http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails Organization and Description of Business and Recent Developments (Details) Details http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments 38 false false R39.htm 996012 - Disclosure - Liquidity and Capital Resources (Details) Sheet http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails Liquidity and Capital Resources (Details) Details http://www.aikidopharma.com/role/LiquidityandCapitalResources 39 false false R40.htm 996013 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 40 false false R41.htm 996014 - Disclosure - Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) Sheet http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details) Details 41 false false R42.htm 996015 - Disclosure - Long-Term Equity Investments (Details) Sheet http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails Long-Term Equity Investments (Details) Details http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables 42 false false R43.htm 996016 - Disclosure - Long-Term Equity Investments - Schedule of Long-Term Investments (Details) Sheet http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable Long-Term Equity Investments - Schedule of Long-Term Investments (Details) Details 43 false false R44.htm 996017 - Disclosure - Notes Receivable (Details) Notes http://www.aikidopharma.com/role/NotesReceivableDetails Notes Receivable (Details) Details http://www.aikidopharma.com/role/NotesReceivable 44 false false R45.htm 996018 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) Sheet http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails Fair Value of Financial Assets and Liabilities (Details) Details http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables 45 false false R46.htm 996019 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) Sheet http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) Details 46 false false R47.htm 996020 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) Details 47 false false R48.htm 996021 - Disclosure - Prepaid Expenses and Other Assets - Schedule of Other Assets (Details) Sheet http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable Prepaid Expenses and Other Assets - Schedule of Other Assets (Details) Details 48 false false R49.htm 996022 - Disclosure - Leases (Details) Sheet http://www.aikidopharma.com/role/LeasesDetails Leases (Details) Details http://www.aikidopharma.com/role/LeasesTables 49 false false R50.htm 996023 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details) Sheet http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable Leases - Schedule of Lease Assets and Liabilities (Details) Details 50 false false R51.htm 996024 - Disclosure - Leases - Schedule of Future Minimum Payments (Details) Sheet http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable Leases - Schedule of Future Minimum Payments (Details) Details 51 false false R52.htm 996025 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilute Loss Per Share (Details) Sheet http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable Net Loss Per Share - Schedule of Potentially Dilute Loss Per Share (Details) Details 52 false false R53.htm 996026 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock (Details) Sheet http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails Stockholders??? Equity and Convertible Preferred Stock (Details) Details http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables 53 false false R54.htm 996027 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) Sheet http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details) Details 54 false false R55.htm 996028 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) Sheet http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) Details 55 false false R56.htm 996029 - Disclosure - Stockholders??? Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company???s Stock Option Plan (Details) Sheet http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable Stockholders??? Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company???s Stock Option Plan (Details) Details 56 false false R57.htm 996030 - Disclosure - Revenue (Details) Sheet http://www.aikidopharma.com/role/RevenueDetails Revenue (Details) Details http://www.aikidopharma.com/role/RevenueTables 57 false false R58.htm 996031 - Disclosure - Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) Sheet http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details) Details 58 false false R59.htm 996032 - Disclosure - Income Taxes (Details) Sheet http://www.aikidopharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.aikidopharma.com/role/IncomeTaxesTables 59 false false R60.htm 996033 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) Sheet http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable Income Taxes - Schedule of Income Tax Expense (Benefit) (Details) Details 60 false false R61.htm 996034 - Disclosure - Regulatory (Details) Sheet http://www.aikidopharma.com/role/RegulatoryDetails Regulatory (Details) Details http://www.aikidopharma.com/role/Regulatory 61 false false R62.htm 996035 - Disclosure - Related Party Transactions (Details) Sheet http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.aikidopharma.com/role/RelatedPartyTransactions 62 false false R63.htm 996036 - Disclosure - Segment Reporting (Details) Sheet http://www.aikidopharma.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.aikidopharma.com/role/SegmentReportingTables 63 false false R64.htm 996037 - Disclosure - Segment Reporting - Schedule of CODM Views the Expenses (Details) Sheet http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable Segment Reporting - Schedule of CODM Views the Expenses (Details) Details 64 false false R65.htm 996038 - Disclosure - Subsequent Events (Details) Sheet http://www.aikidopharma.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.aikidopharma.com/role/SubsequentEvents 65 false false All Reports Book All Reports domh-20260331.xsd domh-20260331_cal.xml domh-20260331_def.xml domh-20260331_lab.xml domh-20260331_pre.xml ea0289782-10q_dominari.htm http://fasb.org/us-gaap/2026 http://xbrl.sec.gov/dei/2026 http://xbrl.sec.gov/ecd/2026 true true JSON 82 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0289782-10q_dominari.htm": { "nsprefix": "domh", "nsuri": "http://www.aikidopharma.com/20260331", "dts": { "schema": { "local": [ "domh-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026_def.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026_lab.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026_pre.xsd", "https://xbrl.sec.gov/dei/2026/dei-sub-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd", "https://xbrl.sec.gov/sic/2026/sic-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] }, "calculationLink": { "local": [ "domh-20260331_cal.xml" ] }, "definitionLink": { "local": [ "domh-20260331_def.xml" ] }, "labelLink": { "local": [ "domh-20260331_lab.xml" ] }, "presentationLink": { "local": [ "domh-20260331_pre.xml" ] }, "inline": { "local": [ "ea0289782-10q_dominari.htm" ] } }, "keyStandard": 304, "keyCustom": 43, "axisStandard": 22, "axisCustom": 0, "memberStandard": 23, "memberCustom": 56, "hidden": { "total": 131, "http://fasb.org/us-gaap/2026": 109, "http://www.aikidopharma.com/20260331": 18, "http://xbrl.sec.gov/dei/2026": 4 }, "contextCount": 227, "entityCount": 1, "segmentCount": 83, "elementCount": 787, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2026": 798, "http://xbrl.sec.gov/dei/2026": 30, "http://xbrl.sec.gov/ecd/2026": 4 }, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R3": { "role": "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R4": { "role": "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:UnderwritingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:UnderwritingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders\u2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c29", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c29", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R7": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments", "longName": "995306 - Disclosure - Organization and Description of Business and Recent Developments", "shortName": "Organization and Description of Business and Recent Developments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResources", "longName": "995307 - Disclosure - Liquidity and Capital Resources", "shortName": "Liquidity and Capital Resources", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LiquidationBasisOfAccountingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "995308 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.aikidopharma.com/role/MarketableSecurities", "longName": "995309 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestments", "longName": "995310 - Disclosure - Long-Term Equity Investments", "shortName": "Long-Term Equity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.aikidopharma.com/role/NotesReceivable", "longName": "995311 - Disclosure - Notes Receivable", "shortName": "Notes Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities", "longName": "995312 - Disclosure - Fair Value of Financial Assets and Liabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssets", "longName": "995313 - Disclosure - Prepaid Expenses and Other Assets", "shortName": "Prepaid Expenses and Other Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.aikidopharma.com/role/Leases", "longName": "995314 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.aikidopharma.com/role/NetLossPerShare", "longName": "995315 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock", "longName": "995316 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.aikidopharma.com/role/Revenue", "longName": "995317 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.aikidopharma.com/role/CommitmentsandContingencies", "longName": "995318 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.aikidopharma.com/role/IncomeTaxes", "longName": "995319 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.aikidopharma.com/role/Regulatory", "longName": "995320 - Disclosure - Regulatory", "shortName": "Regulatory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransactions", "longName": "995321 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.aikidopharma.com/role/SegmentReporting", "longName": "995322 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.aikidopharma.com/role/SubsequentEvents", "longName": "995323 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:Rule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:NonRule10b51ArrTrmntdFlag", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.aikidopharma.com/role/MarketableSecuritiesTables", "longName": "996001 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables", "longName": "996002 - Disclosure - Long-Term Equity Investments (Tables)", "shortName": "Long-Term Equity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables", "longName": "996003 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssetsTables", "longName": "996004 - Disclosure - Prepaid Expenses and Other Assets (Tables)", "shortName": "Prepaid Expenses and Other Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.aikidopharma.com/role/LeasesTables", "longName": "996005 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.aikidopharma.com/role/NetLossPerShareTables", "longName": "996006 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables", "longName": "996007 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.aikidopharma.com/role/RevenueTables", "longName": "996008 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.aikidopharma.com/role/IncomeTaxesTables", "longName": "996009 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.aikidopharma.com/role/SegmentReportingTables", "longName": "996010 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "longName": "996011 - Disclosure - Organization and Description of Business and Recent Developments (Details)", "shortName": "Organization and Description of Business and Recent Developments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c45", "name": "us-gaap:InvestmentCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c45", "name": "us-gaap:InvestmentCompanyFeePaidIndirectly", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails", "longName": "996012 - Disclosure - Liquidity and Capital Resources (Details)", "shortName": "Liquidity and Capital Resources (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "domh:WorkingCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LiquidationBasisOfAccountingTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R40": { "role": "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996013 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c2", "name": "domh:UnobservableInputsPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "domh:UnobservableInputsPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable", "longName": "996014 - Disclosure - Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details)", "shortName": "Marketable Securities - Schedule of Gains and (Losses) on Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "domh:RealizedGainloss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "domh:RealizedGainloss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "longName": "996015 - Disclosure - Long-Term Equity Investments (Details)", "shortName": "Long-Term Equity Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:PaymentsToAcquireLongtermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c8", "name": "us-gaap:PaymentsToAcquireLongtermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable", "longName": "996016 - Disclosure - Long-Term Equity Investments - Schedule of Long-Term Investments (Details)", "shortName": "Long-Term Equity Investments - Schedule of Long-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:InvestmentOwnedAtCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.aikidopharma.com/role/NotesReceivableDetails", "longName": "996017 - Disclosure - Notes Receivable (Details)", "shortName": "Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c83", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c83", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "longName": "996018 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)", "shortName": "Fair Value of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c87", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R46": { "role": "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "longName": "996019 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details)", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable", "longName": "996020 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c93", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c93", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable", "longName": "996021 - Disclosure - Prepaid Expenses and Other Assets - Schedule of Other Assets (Details)", "shortName": "Prepaid Expenses and Other Assets - Schedule of Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.aikidopharma.com/role/LeasesDetails", "longName": "996022 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c98", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c98", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable", "longName": "996023 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details)", "shortName": "Leases - Schedule of Lease Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R51": { "role": "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "longName": "996024 - Disclosure - Leases - Schedule of Future Minimum Payments (Details)", "shortName": "Leases - Schedule of Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable", "longName": "996025 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilute Loss Per Share (Details)", "shortName": "Net Loss Per Share - Schedule of Potentially Dilute Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "longName": "996026 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true }, "uniqueAnchor": { "contextRef": "c113", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "unique": true } }, "R54": { "role": "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "longName": "996027 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c156", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c156", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "longName": "996028 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c160", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c160", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "longName": "996029 - Disclosure - Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company\u2019s Stock Option Plan (Details)", "shortName": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company\u2019s Stock Option Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c163", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c163", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.aikidopharma.com/role/RevenueDetails", "longName": "996030 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c167", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c167", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable", "longName": "996031 - Disclosure - Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details)", "shortName": "Revenue - Schedule of Total Revenue Disaggregated by Revenue Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.aikidopharma.com/role/IncomeTaxesDetails", "longName": "996032 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable", "longName": "996033 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)", "shortName": "Income Taxes - Schedule of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.aikidopharma.com/role/RegulatoryDetails", "longName": "996034 - Disclosure - Regulatory (Details)", "shortName": "Regulatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:ExcessCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ExcessCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "longName": "996035 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c206", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c206", "name": "us-gaap:RelatedPartyTransactionRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.aikidopharma.com/role/SegmentReportingDetails", "longName": "996036 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "longName": "996037 - Disclosure - Segment Reporting - Schedule of CODM Views the Expenses (Details)", "shortName": "Segment Reporting - Schedule of CODM Views the Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c215", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c215", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.aikidopharma.com/role/SubsequentEventsDetails", "longName": "996038 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c225", "name": "us-gaap:DividendsCash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c225", "name": "us-gaap:DividendsCash", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0289782-10q_dominari.htm", "first": true, "unique": true } } }, "tag": { "domh_ABTCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ABTCMember", "presentation": [ "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ABTC [Member]", "label": "ABTCMember" } } }, "auth_ref": [] }, "domh_ABTCStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ABTCStockMember", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ABTC Stock [Member]", "label": "ABTCStock Member" } } }, "auth_ref": [] }, "domh_AVInvestmentManagerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AVInvestmentManagerMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AV Investment Manager [Member]", "label": "AVInvestment Manager Member" } } }, "auth_ref": [] }, "domh_AVManagerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AVManagerMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AV Manager [Member]", "verboseLabel": "AVManager [Member]", "label": "AVManager Member" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r207", "r1074", "r1167", "r1168" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r551", "r552", "r557" ] }, "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedSalesCommissionCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and commissions", "label": "Accrued Sales Commission", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions." } } }, "auth_ref": [ "r1068" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r978" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r102", "r295", "r551", "r552", "r563", "r900", "r1358" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r578", "r653", "r1143", "r1144", "r1145", "r1146", "r1263", "r1365" ] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r1034" ] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r1034" ] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r1032" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r991" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r991" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r991" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r991" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation- advisors", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [ "r1191", "r1204" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]" } } }, "auth_ref": [] }, "domh_AdvisoryAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AdvisoryAgreementsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory Agreements [Member]", "label": "Advisory Agreements Member" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1025" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r941", "r952", "r968", "r1003" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r944", "r955", "r971", "r1006" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1026" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r991" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r998" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r945", "r956", "r972", "r998", "r1007", "r1011", "r1019" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1017" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r391", "r395", "r404" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated future stock-based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [ "r1232" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "domh_AmericanInnovativeRoboticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AmericanInnovativeRoboticsLLCMember", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Innovative Robotics, LLC [Member]", "label": "American Innovative Robotics LLCMember" } } }, "auth_ref": [] }, "domh_AmericanVenturesIMLLCAndAmericanVenturesManagerLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AmericanVenturesIMLLCAndAmericanVenturesManagerLLCMember", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Ventures IM LLC and American Ventures Manager LLC [Member]", "label": "American Ventures IMLLCAnd American Ventures Manager LLCMember" } } }, "auth_ref": [] }, "domh_AmericanVenturesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AmericanVenturesLLCMember", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "American Ventures LLC [Member]", "label": "American Ventures LLCMember" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AnnualInformationForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r948" ] }, "domh_AnthonyHayesAndKyleWoolMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AnthonyHayesAndKyleWoolMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anthony Hayes and Kyle Wool [Member]", "label": "Anthony Hayes And Kyle Wool Member" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total diluted loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r159" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r159" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Potentially Dilute Loss Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r159" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r159" ] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r438" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r63", "r64", "r82", "r126", "r127", "r128", "r164", "r177", "r195", "r199", "r215", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r298", "r440", "r444", "r493", "r551", "r552", "r554", "r571", "r572", "r595", "r696", "r854", "r855", "r866", "r900", "r905", "r906", "r920", "r1185", "r1186", "r1285" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "verboseLabel": "Assets:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsFairValueAdjustment", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional fair value", "label": "Assets, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [ "r1264" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value amount", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r467", "r468", "r891" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r948" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditorFirmId", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r933", "r936", "r948" ] }, "dei_AuditorLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditorLocation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r933", "r936", "r948" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditorName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r933", "r936", "r948" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r1030" ] }, "dei_AuditorTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AuditorTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation" ], "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } }, "auth_ref": [] }, "domh_AverageAnnualInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "AverageAnnualInterestRate", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average annual interest rate", "documentation": "Average annual interest rate.", "label": "Average Annual Interest Rate" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1014" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1015" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1010" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1010" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1010" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1010" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1010" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1010" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AwardTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r387", "r388", "r389", "r390" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1013" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1012" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1011" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1011" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1133" ] }, "us-gaap_BrokerageCommissionsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BrokerageCommissionsRevenue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions", "label": "Brokerage Commissions Revenue", "documentation": "Amount of commission revenue from buying and selling securities on behalf of customers." } } }, "auth_ref": [ "r41", "r42" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r936", "r948" ] }, "domh_CarriedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "CarriedInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Carried interest", "documentation": "The amount of carried interest.", "label": "Carried Interest" } } }, "auth_ref": [] }, "domh_CarriedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "CarriedInterestMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Carried interest [Member]", "verboseLabel": "Carried Interest [Member]", "label": "Carried Interest Member" } } }, "auth_ref": [] }, "domh_CarriedInterestRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "CarriedInterestRevenue", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carried interest revenue", "documentation": "The amount of carried interest revenue.", "label": "Carried Interest Revenue" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Capital Resources [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalent", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r79", "r122", "r123", "r836", "r1287" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r27", "r122", "r123" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation", "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r27" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liquid insured deposits", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingEstimateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ChangeInAccountingEstimateLineItems", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r143", "r571", "r573" ] }, "domh_ChangeInCarryingValueOfLongtermEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ChangeInCarryingValueOfLongtermEquityInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in carrying value of long-term investment", "verboseLabel": "Changes in carrying values", "documentation": "The amount of change in carrying value of long-term equity investments.", "label": "Change In Carrying Value Of Longterm Equity Investments" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r989" ] }, "domh_ChiefOperatingDecisionMakerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ChiefOperatingDecisionMakerMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "CODM [Member]", "label": "Chief Operating Decision Maker Member" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r986" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r984" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfStockDomain", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r53", "r72", "r73", "r95", "r96", "r97", "r98", "r99", "r100", "r126", "r128", "r153", "r154", "r156", "r158", "r166", "r167", "r215", "r231", "r233", "r234", "r235", "r238", "r239", "r258", "r259", "r261", "r262", "r264", "r267", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r283", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r297", "r298", "r299", "r493", "r551", "r552", "r560", "r561", "r562", "r578", "r641", "r642", "r643", "r644", "r653", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r681", "r704", "r729", "r814", "r815", "r816", "r817", "r818", "r1043", "r1136", "r1138", "r1147", "r1199", "r1202" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r72", "r73", "r95", "r99", "r100", "r166", "r261", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r283", "r287", "r288", "r290", "r291", "r293", "r294", "r297", "r299", "r446", "r551", "r552", "r561", "r562", "r641", "r642", "r643", "r644", "r1043", "r1134", "r1136", "r1199" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1192" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [ "r1192" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r126", "r130", "r288" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Activity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1192" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r1192" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r990" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r990" ] }, "domh_CommissionRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "CommissionRevenue", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commission revenue", "documentation": "The amount of commission revenue.", "label": "Commission Revenue" } } }, "auth_ref": [] }, "us-gaap_CommissionsAndFloorBrokerageReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommissionsAndFloorBrokerageReceivables", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions receivable", "label": "Commissions and Floor Brokerage Receivables", "documentation": "Amount receivable from broker-dealers from commissions for executing orders on the floor of an exchange." } } }, "auth_ref": [ "r1061", "r1073", "r1288" ] }, "domh_CommissionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "CommissionsMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Commissions [Member]", "label": "Commissions Member" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r225", "r226", "r829", "r1176", "r1181", "r1182" ] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividend per share payable (in Dollars per share)", "verboseLabel": "Cash dividend per share payable", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r1198", "r1200" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r100", "r294", "r551", "r552", "r562", "r908", "r909", "r910", "r912", "r913", "r914", "r915", "r1143", "r1144", "r1146", "r1263", "r1350", "r1365" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r1072", "r1197", "r1293", "r1294", "r1299" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in Shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r294", "r551", "r552", "r562", "r681" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in Shares)", "verboseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r100", "r294", "r551", "r552", "r562" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in Shares)", "verboseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r100", "r294", "r551", "r552", "r562", "r681", "r702", "r1191", "r1365", "r1366" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 100,000,000 shares authorized; 22,613,781 and 16,067,435 shares issued as of March 31, 2026, and December 31, 2025, respectively; 22,613,781 and 16,067,435 shares outstanding as of March 31, 2026 and December 31, 2025, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r259", "r266", "r294", "r551", "r552", "r562", "r599", "r900" ] }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStocksIncludingAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital (in Dollars)", "label": "Common Stocks, Including Additional Paid in Capital", "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued." } } }, "auth_ref": [ "r100", "r294", "r551", "r552", "r562", "r563", "r1042", "r1045", "r1195", "r1201" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r995" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r994" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r996" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r993" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r32", "r37" ] }, "us-gaap_ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComplianceWithRegulatoryCapitalRequirementsForMortgageCompaniesLineItems", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Regulatory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r821", "r822", "r823", "r824" ] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContactPersonnelFaxNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth_ref": [ "r936" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContainedFileInformationFileDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContainedFileInformationFileName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContainedFileInformationFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth_ref": [] }, "dei_ContainedFileInformationFileType": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ContainedFileInformationFileType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)." } } }, "auth_ref": [] }, "domh_ContractLiabilitiesExpectedToBeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ContractLiabilitiesExpectedToBeRecognized", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities expected to be recognized", "documentation": "Represents the amount of contract liabilities expected to be recognized.", "label": "Contract Liabilities Expected To Be Recognized" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r315", "r316", "r318", "r337" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r338" ] }, "domh_ConvertiblePreferredOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ConvertiblePreferredOptionMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred stock [Member]", "label": "Convertible Preferred Option Member" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of preferred stock", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r45", "r286", "r288" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CountryRegion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1051", "r1134", "r1140", "r1242" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1051", "r1134", "r1140" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "totalLabel": "Current income tax expense (benefit)", "terseLabel": "Current income tax", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r422", "r1134", "r1140" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1051", "r1134", "r1140", "r1242" ] }, "us-gaap_CustodyFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CustodyFees", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory fees", "label": "Custody Fees", "documentation": "Those fees charged for services related to holding, advising, and managing customer investment assets. These account fees usually charged annually or semi-annually, on a per security basis, for the costs of services." } } }, "auth_ref": [ "r19", "r1361", "r1363" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r77", "r78", "r84", "r86", "r87", "r88", "r89", "r90", "r92", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r288", "r551", "r552", "r559", "r861", "r862", "r863", "r864", "r865", "r898", "r1134", "r1135", "r1137", "r1142", "r1177", "r1178", "r1179", "r1275", "r1276", "r1301" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r77", "r78", "r84", "r86", "r87", "r88", "r89", "r90", "r92", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r288", "r551", "r552", "r559", "r861", "r862", "r863", "r864", "r865", "r898", "r1134", "r1135", "r1137", "r1142", "r1177", "r1178", "r1179", "r1275", "r1276", "r1301" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terms of loan agreements", "label": "Debt Instrument, Term", "documentation": "Period between issuance and maturity of debt instrument, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtSecuritiesRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain (loss)", "label": "Debt Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r613", "r1082", "r1083" ] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ending value", "label": "Debt Securities, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r614", "r1082", "r1083" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1134", "r1140", "r1241", "r1242" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1134", "r1140", "r1241" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax expense (benefit)", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r3", "r50", "r1134", "r1140" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1134", "r1140", "r1241", "r1242" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1236" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r1239" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign net operating loss", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r1239" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r1239" ] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution percent", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting matching percentage", "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee\u2019s eligible compensation percent", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r960", "r961", "r975" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r117", "r224", "r839", "r840", "r842", "r844" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Total Revenue Disaggregated by Revenue Type [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r335", "r336", "r870", "r871", "r872", "r873", "r874", "r875", "r876" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r335", "r336", "r870", "r871", "r872", "r873", "r874", "r875", "r876" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenue Disaggregated by Revenue Type", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1203" ] }, "domh_DistributionToNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "DistributionToNonControllingInterest", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions to non-controlling interest", "documentation": "The amount of distribution to Non Controlling Interest.", "label": "Distribution To Non Controlling Interest" } } }, "auth_ref": [] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r960", "r961", "r975" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends issued", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r1198", "r1200" ] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DividendsCash", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash dividends paid (in Dollars)", "verboseLabel": "Cash dividend", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r1198", "r1200" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DividendsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend payable (in Dollars)", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1066" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued dividends payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r916", "r1068", "r1293", "r1294", "r1296", "r1307" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r936" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentAnnualReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r933", "r936", "r948" ] }, "dei_DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentCopyrightInformation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth_ref": [] }, "dei_DocumentCreationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentCreationDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth_ref": [] }, "dei_DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth_ref": [] }, "dei_DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth_ref": [] }, "dei_DocumentEffectiveDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentEffectiveDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth_ref": [] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r933", "r936", "r948", "r999" ] }, "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)." } } }, "auth_ref": [ "r933", "r936", "r948", "r999" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationDocumentAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodStartDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentQuarterlyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r934" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r922" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r936" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentShellCompanyReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r936" ] }, "dei_DocumentSubtitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentSubtitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth_ref": [] }, "dei_DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentSynopsis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'" } } }, "auth_ref": [] }, "dei_DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTransitionReport", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r976" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentVersion", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r925" ] }, "domh_DominariFinancialHeritageStrategiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "DominariFinancialHeritageStrategiesLLCMember", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Financial Heritage Strategies LLC [Member]", "label": "Dominari Financial Heritage Strategies LLCMember" } } }, "auth_ref": [] }, "domh_DominariFinancialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "DominariFinancialMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Financial [Member]", "label": "Dominari Financial Member" } } }, "auth_ref": [] }, "domh_DominariSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "DominariSecuritiesMember", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Securities [Member]", "label": "Dominari Securities Member" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r988" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "label": "Net Loss Per Share [Abstract]", "terseLabel": "Net loss per share, basic and diluted" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r56", "r115", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r151", "r153", "r156", "r157", "r158", "r163", "r222", "r257", "r342", "r394", "r434", "r437", "r463", "r464", "r570", "r610", "r846" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r56", "r115", "r136", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r153", "r156", "r157", "r158", "r163", "r222", "r257", "r342", "r394", "r434", "r437", "r463", "r464", "r570", "r610", "r846" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r150", "r159", "r160", "r161", "r162", "r303" ] }, "domh_EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "EffectOfNewAccountingPronouncementsToBeAdoptedInFuturePeriodsPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of new accounting pronouncements to be adopted in future periods", "documentation": "Effect of new accounting pronouncements to be adopted in future periods.", "label": "Effect Of New Accounting Pronouncements To Be Adopted In Future Periods Policy Text Block" } } }, "auth_ref": [] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r1038" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r411", "r884", "r1134", "r1141", "r1234" ] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r1038" ] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r1039" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r1038" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r1039" ] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r1037" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r1039" ] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r1041" ] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [ "r1079" ] }, "domh_EmployeeLoansOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "EmployeeLoansOutstanding", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee loans", "documentation": "The amount of outstanding employee loans.", "label": "Employee Loans Outstanding" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r392" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Options to purchase common stock [Member]", "netLabel": "Stock Options [Member]", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231" ] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitiesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAccountingStandard", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Accounting Standard", "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element." } } }, "auth_ref": [] }, "dei_EntityAddressAddressDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Description", "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCountry", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressesLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressesTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r924" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r928" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r924" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityContactPersonnelLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityContactPersonnelLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Contact Personnel [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r924" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1040" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r924" ] }, "dei_EntityHomeCountryISOCode": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityHomeCountryISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Home Country ISO Code", "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element." } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInformationLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1029" ] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r1028" ] }, "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityLegalForm", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } }, "auth_ref": [] }, "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingForeign", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } }, "auth_ref": [] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingParValuePerShare", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingPrimary", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } }, "auth_ref": [] }, "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingSecurityTradingCurrency", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingsLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingsTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity" } } }, "auth_ref": [] }, "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityNumberOfEmployees", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity" } } }, "auth_ref": [] }, "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPrimarySicNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r948" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r924" ] }, "dei_EntityReportingCurrencyISOCode": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityReportingCurrencyISOCode", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityShellCompany", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r924" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r924" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r924" ] }, "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTextBlock", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityVoluntaryFilers", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1031" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r982" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1024" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1024" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1024" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityComponentDomain", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r55", "r56", "r72", "r99", "r100", "r111", "r112", "r113", "r133", "r134", "r135", "r137", "r144", "r146", "r148", "r165", "r216", "r217", "r221", "r222", "r223", "r256", "r287", "r292", "r293", "r294", "r297", "r299", "r302", "r340", "r341", "r343", "r344", "r394", "r423", "r424", "r431", "r432", "r433", "r435", "r436", "r437", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r496", "r497", "r498", "r499", "r500", "r501", "r505", "r517", "r544", "r551", "r552", "r561", "r562", "r578", "r609", "r627", "r628", "r629", "r653", "r729", "r1202" ] }, "domh_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "EquityIncentivePlanMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Equity Incentive Plan [Member]", "verboseLabel": "Equity Incentive Plan [Member]", "label": "Equity Incentive Plan Member" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r212", "r213", "r214", "r430", "r493", "r1046", "r1047", "r1048", "r1243", "r1244", "r1245", "r1246" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interests", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r212", "r493" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term equity investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r164", "r187", "r199", "r211", "r1063", "r1172" ] }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Securities owned", "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r1171", "r1303", "r1304", "r1305" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r992" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r941", "r952", "r968", "r1003" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r938", "r949", "r965", "r1000" ] }, "us-gaap_ExcessCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ExcessCapital", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess Net capital requirement", "label": "Banking Regulation, Total Risk-Based Capital, Excess, Actual", "documentation": "Amount of total risk-based capital exceeding minimum required for capital adequacy as defined by regulatory framework." } } }, "auth_ref": [ "r582" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ExchangeDomain", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r998" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r1036" ] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r1036" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Extension", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "domh_FPSPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "FPSPurchaseAgreementMember", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "FPS Purchase Agreement [Member]", "label": "FPSPurchase Agreement Member" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in carrying value of investments", "negatedTerseLabel": "Change in carrying value of investments", "terseLabel": "Fair value of warrant", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r3" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets and Liabilities that are Measured at Fair Value [Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r465", "r467", "r468", "r481", "r891" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r248", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r465", "r466", "r468", "r469", "r470", "r471", "r480", "r481", "r483", "r490", "r530", "r531", "r532", "r537", "r862", "r863", "r877", "r878", "r879", "r880", "r881", "r891", "r892", "r896", "r897" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Assets and Liabilities", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r469", "r476", "r478", "r479", "r480", "r483", "r484", "r485", "r486", "r487", "r549", "r891", "r893" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices In Active Markets (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r248", "r346", "r351", "r353", "r468", "r481", "r490", "r530", "r877", "r878", "r879", "r880", "r881", "r891", "r896", "r897" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Significant other observable inputs (Level 2) [Member]", "verboseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r248", "r346", "r351", "r353", "r355", "r468", "r469", "r481", "r490", "r531", "r862", "r863", "r877", "r878", "r879", "r880", "r881", "r891", "r896", "r897" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable", "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Significant unobservable inputs (Level 3) [Member]", "verboseLabel": "Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r248", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r468", "r469", "r470", "r471", "r481", "r490", "r532", "r862", "r863", "r877", "r878", "r879", "r880", "r881", "r891", "r892", "r896", "r897" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r472", "r473", "r474", "r475", "r476", "r477" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r248", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r465", "r466", "r468", "r469", "r470", "r471", "r480", "r481", "r483", "r490", "r530", "r531", "r532", "r537", "r862", "r863", "r877", "r878", "r879", "r880", "r881", "r891", "r892", "r896", "r897" ] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetAssetLiability", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Securities owned at fair value as of December 31, 2025", "periodEndLabel": "Securities owned at fair value as of March 31, 2026", "label": "Fair Value, Net Asset (Liability)", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": [ "r1265", "r1266" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r472", "r473", "r474", "r475", "r476", "r477", "r482" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r472", "r477", "r482" ] }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueOptionChangesInFairValueGainLoss1", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFinancialAssetsthatareMeasuredatFairValueonaRecurringBasisTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss included in principal transactions", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings." } } }, "auth_ref": [ "r494", "r495", "r896", "r897" ] }, "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueOptionQuantitativeDisclosuresLineItems", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r491", "r492", "r494", "r495", "r896", "r897" ] }, "domh_FairValueofFinancialAssetsandLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "FairValueofFinancialAssetsandLiabilitiesDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "domh_FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "FairValueofFinancialAssetsandLiabilitiesScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities - Schedule of Assets and Liabilities that are Measured at Fair Value (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_FeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FeeIncome", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management fee revenues", "label": "Fee Income", "documentation": "Amount of fee income including, but not limited to, managerial assistance, servicing of investment, and origination and commitment fees." } } }, "auth_ref": [ "r1362" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired intangible assets", "label": "Intangible Asset, Finite-Lived, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r219", "r220", "r548", "r834", "r1174" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r945", "r956", "r972", "r1007" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r945", "r956", "r972", "r1007" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r945", "r956", "r972", "r1007" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r945", "r956", "r972", "r1007" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r945", "r956", "r972", "r1007" ] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "FormerAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r935", "r959" ] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "FormerFiscalYearEndDate", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r987" ] }, "us-gaap_GainLossOnSaleOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GainLossOnSaleOfNotesReceivable", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Realized and unrealized gain loss on notes receivable, net", "negatedLabel": "Realized and unrealized (gain) loss on note receivable", "label": "Gain (Loss) on Sale of Financing Receivable", "documentation": "Amount of gain (loss) from sale of financing receivable, including, but not limited to, lease receivable." } } }, "auth_ref": [ "r542" ] }, "us-gaap_GoodFaithAndMarginDepositsWithBrokerDealers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodFaithAndMarginDepositsWithBrokerDealers", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Good faith deposits", "label": "Good Faith and Margin Deposit with Broker-Dealer", "documentation": "Amount of right to receive cash and securities on deposit with broker-dealers to demonstrate an intention to complete a purchase (good faith deposit) and collateral deposited by counterparty to cover the credit risk assumed (margin deposit)." } } }, "auth_ref": [ "r1062", "r1064" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r933", "r936", "r948" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before income tax expense", "terseLabel": "Net income (/loss) before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r17", "r43", "r571", "r573", "r605", "r835", "r841", "r843", "r845", "r849", "r854", "r1149", "r1152", "r1158", "r1161", "r1162" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r126", "r129", "r406", "r410", "r413", "r414", "r415", "r417", "r420", "r425", "r427", "r428", "r429", "r593", "r633", "r647", "r884" ] }, "us-gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxExaminationLineItems", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r416" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 4.0 }, "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "http://www.aikidopharma.com/role/ScheduleofIncomeTaxExpenseBenefitTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total income tax expense (benefit)", "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r47", "r51", "r126", "r147", "r148", "r164", "r185", "r199", "r409", "r410", "r426", "r617", "r835", "r841", "r843", "r845", "r884" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r110", "r407", "r408", "r417", "r418", "r419", "r421", "r640" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in valuation allowances", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r412", "r884", "r1234" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized book loss", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r410", "r884" ] }, "domh_IncomeTaxesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "IncomeTaxesDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest and taxes", "label": "Income Tax Paid, before Refund Received", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r29", "r1132", "r1237", "r1238" ] }, "domh_IncreaseDecreaseInAccruedCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "IncreaseDecreaseInAccruedCommissions", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and commissions", "documentation": "Increase decrease in accrued commissions.", "label": "Increase Decrease In Accrued Commissions" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInBrokerageReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInBrokerageReceivables", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivable from clearing brokers", "label": "Increase (Decrease) in Receivable from Broker-Dealer and Clearing Organization", "documentation": "The increase (decrease) during the reporting period in the total amount due to the entity related to activities and operations with other broker dealers, and clearing organizations, including deposits." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r546", "r1130" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset and liability, net", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1050", "r1130" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r1130" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInPrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidRent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase rent amount", "label": "Increase (Decrease) in Prepaid Rent", "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods." } } }, "auth_ref": [ "r2" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r945", "r956", "r972", "r998", "r1007", "r1011", "r1019" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1017" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r937", "r1023" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r937", "r1023" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r937", "r1023" ] }, "domh_InterestIncomeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InterestIncomeCustomersMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income \u2013 customers [Member]", "label": "Interest Income Customers Member" } } }, "auth_ref": [] }, "domh_InterestIncomeFromCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InterestIncomeFromCustomersMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income From Customers [Member]", "label": "Interest Income From Customers Member" } } }, "auth_ref": [] }, "domh_InterestIncomeNonCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InterestIncomeNonCustomersMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Income Non Customers [Member]", "label": "Interest Income Non Customers Member" } } }, "auth_ref": [] }, "domh_InterestIncomeNoncustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InterestIncomeNoncustomerMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income \u2013 noncustomer [Member]", "label": "Interest Income Noncustomer Member" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r180", "r574", "r575", "r705", "r800", "r802", "r854", "r917", "r918", "r1077", "r1367" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [ "r843" ] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r961", "r962", "r963", "r964" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r977" ] }, "us-gaap_InvestmentCompanyFeePaidIndirectly": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentCompanyFeePaidIndirectly", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional seller paid (in Dollars)", "label": "Investment Company, Fee Paid Indirectly", "documentation": "Amount that would have been incurred for brokerage service had service been paid for directly in arm's-length transaction." } } }, "auth_ref": [ "r645", "r708", "r709", "r710", "r711", "r714" ] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r977" ] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r977" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Investments", "label": "Investment Holdings, Schedule of Investments [Table Text Block]", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r1351", "r1352", "r1353", "r1354", "r1355", "r1356" ] }, "domh_InvestmentInAdvEnIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInAdvEnIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in AdvEn Inc. [Member]", "label": "Investment In Adv En Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Aeon Partners Fund Series EG (Epic Games, Inc.) [Member]", "label": "Investment In Aeon Partners Fund Series EGEpic Games Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInAmericanVenturesLLCSeriesXXTracXLogisPteLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInAmericanVenturesLLCSeriesXXTracXLogisPteLtdMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..) [Member]", "label": "Investment In American Ventures LLCSeries XXTrac XLogis Pte Ltd Member" } } }, "auth_ref": [] }, "domh_InvestmentInAutomationAnywhereIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInAutomationAnywhereIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Automation Anywhere, Inc. [Member]", "label": "Investment In Automation Anywhere Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInDiscordIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInDiscordIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Discord Inc. [Member]", "label": "Investment In Discord Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI) [Member]", "label": "Investment In Dominari Master SPVLLCSeries VIXAICorp Dba XAIMember" } } }, "auth_ref": [] }, "domh_InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.) [Member]", "label": "Investment In Dominari Master SPVLLCSeries XICerebras Systems Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Dominari Master SPV LLC Series XII (Groq, Inc.) [Member]", "label": "Investment In Dominari Master SPVLLCSeries XIIGroq Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInKernaHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInKernaHealthIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Kerna Health [Member]", "label": "Investment In Kerna Health Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a. Masterclass) [Member]", "label": "Investment In MWLSVMaster Class LLCYanka Industries Inc Dba Masterclass Member" } } }, "auth_ref": [] }, "domh_InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a. Kraken) [Member]", "label": "Investment In Payward Inc And MWSIVCKraken IILLCPayward Inc Dba Kraken Member" } } }, "auth_ref": [] }, "domh_InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd) [Member]", "label": "Investment In Revere Master SPVSeries1 Qxpress Pte Ltd Member" } } }, "auth_ref": [] }, "domh_InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.) [Member]", "label": "Investment In Tesspay Inc And Revere Master SPVSeries VITess Pay Inc Member" } } }, "auth_ref": [] }, "domh_InvestmentInTracXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "InvestmentInTracXMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in TracX. [Member]", "label": "Investment In Trac XMember" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r164", "r180", "r199", "r854", "r1081" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and dividend income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r22", "r23" ] }, "us-gaap_InvestmentOwnedAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentOwnedAtCost", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, Cost Basis", "label": "Investment Owned, Cost", "documentation": "Cost of the investment." } } }, "auth_ref": [ "r636", "r669", "r670", "r750", "r760", "r776", "r805", "r910", "r920", "r1354" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Equity Investments and marketable securities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r612", "r636", "r637", "r638", "r639", "r757", "r759" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Equity Investments", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r1053", "r1054", "r1169" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r666", "r667", "r668", "r669", "r671", "r737", "r746", "r762", "r770", "r783", "r787", "r806", "r810", "r811", "r812", "r813", "r910" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r666", "r667", "r668", "r669", "r671", "r737", "r746", "r762", "r770", "r783", "r787", "r806", "r810", "r811", "r812", "r813", "r910" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investment in Debt and Equity Securities and Other Trading Assets [Text Block]", "documentation": "The entire disclosure for investment in debt and equity securities and other assets at fair value and held for trading." } } }, "auth_ref": [ "r54", "r208", "r210", "r488", "r489", "r1290", "r1302" ] }, "domh_JointVenturesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "JointVenturesPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Ventures", "documentation": "Disclosure of accounting policy for joint ventures.", "label": "Joint Ventures Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Labor and Related Expense", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r569", "r843", "r1080" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Net rent expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r509", "r899" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Lease Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Assets and Liabilities", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1280" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "domh_LegacyHoldingCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "LegacyHoldingCoMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy Holding Co. [Member]", "label": "Legacy Holding Co Member" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LegalEntityAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LegalEntityIdentifier", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } }, "auth_ref": [ "r921" ] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LegalFees", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r1052", "r1360", "r1364" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r508" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1281" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r514", "r1135", "r1142", "r1301" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r514", "r1135", "r1142", "r1301" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r514", "r1135", "r1142", "r1301" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2030", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r514", "r1135", "r1142", "r1301" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r514", "r1135", "r1142", "r1301" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Year Ended December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r514", "r1135", "r1142", "r1301" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining period Ended December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1281" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r514" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum payments lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r516", "r1278" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r504" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r63", "r64", "r126", "r127", "r128", "r215", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r298", "r441", "r444", "r445", "r493", "r680", "r848", "r866", "r920", "r1075", "r1185", "r1285", "r1286" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r106", "r551", "r552", "r565", "r602", "r900", "r905", "r906", "r1134", "r1139", "r1173", "r1274" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiquidationBasisOfAccountingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiquidationBasisOfAccountingTextBlock", "presentation": [ "http://www.aikidopharma.com/role/LiquidityandCapitalResources" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Capital Resources", "label": "Liquidation Basis of Accounting [Text Block]", "documentation": "The entire disclosure for the liquidation basis of accounting." } } }, "auth_ref": [ "r67", "r68", "r69", "r70", "r71" ] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Receivable", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r503", "r1164" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r896", "r897", "r1265", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272", "r1273" ] }, "domh_LongTermEquityInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "LongTermEquityInvestmentsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermInvestments", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments, Carrying Value", "verboseLabel": "Related party long-term equity investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r75", "r80" ] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Equity Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MajorityShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MajorityShareholderMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders [Member]", "label": "Majority Shareholder [Member]", "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership." } } }, "auth_ref": [] }, "domh_ManagementFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ManagementFeesMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Management fees [Member]", "verboseLabel": "Management Fees [Member]", "label": "Management Fees Member" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails", "http://www.aikidopharma.com/role/ScheduleofAssetsandLiabilitiesthatareMeasuredatFairValueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r1058", "r1065" ] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecuritiesGainLossAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Gains and (Losses) on Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Gain (loss) on marketable securities, net", "verboseLabel": "Gain (Loss) on marketable securities", "label": "Marketable Security, Gain (Loss)", "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized loss on marketable securities", "label": "Marketable Security, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains and (Losses) on Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized (gain) loss on marketable securities", "terseLabel": "Unrealized gain / (loss)", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r24" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MaximumMember", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r65", "r66", "r171", "r227", "r228", "r229", "r230", "r357", "r387", "r388", "r389", "r405", "r471", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r545", "r625", "r626", "r632", "r672", "r673", "r740", "r761", "r766", "r767", "r796", "r825", "r826", "r827", "r828", "r830", "r831", "r860", "r882", "r885", "r886", "r887", "r892", "r893", "r894", "r895", "r902", "r1187", "r1189" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r990" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r990" ] }, "domh_MessrAnthonyHayesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "MessrAnthonyHayesMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Messr. Anthony Hayes [Member]", "label": "Messr Anthony Hayes Member" } } }, "auth_ref": [] }, "domh_MessrChristopherDevallMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "MessrChristopherDevallMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Messr. Christopher Devall [Member]", "label": "Messr Christopher Devall Member" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MinimumMember", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r65", "r66", "r171", "r227", "r228", "r229", "r230", "r357", "r387", "r388", "r389", "r405", "r471", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r545", "r625", "r626", "r632", "r672", "r673", "r740", "r761", "r766", "r767", "r796", "r825", "r826", "r827", "r828", "r830", "r831", "r860", "r882", "r885", "r886", "r887", "r892", "r893", "r894", "r902", "r1187", "r1189" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "verboseLabel": "Non-controlling interests (in Dollars)", "netLabel": "Amount of non-controlling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r105", "r126", "r127", "r128", "r215", "r231", "r233", "r234", "r235", "r238", "r239", "r298", "r551", "r552", "r564", "r601", "r683", "r1274" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Membership interests", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1010" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1018" ] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NameChangeEventDateAxis", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth_ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NameChangeEventLineItems", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth_ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NameChangeEventTable", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r991" ] }, "domh_NetCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "NetCapitalAmount", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net capital", "documentation": "The amount of net capital.", "label": "Net Capital Amount" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r120" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r120" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by operating activities", "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r27", "r28", "r30" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders of Dominari Holdings Inc.", "verboseLabel": "Net loss attributable to stockholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r18", "r30", "r44", "r56", "r63", "r64", "r108", "r109", "r113", "r126", "r127", "r128", "r132", "r136", "r140", "r141", "r142", "r143", "r144", "r147", "r148", "r155", "r215", "r222", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r257", "r260", "r263", "r268", "r298", "r342", "r394", "r434", "r437", "r464", "r493", "r608", "r703", "r727", "r728", "r841", "r843", "r845", "r918", "r1185" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net income attributable to non-controlling interests", "verboseLabel": "Non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r16", "r40", "r63", "r64", "r108", "r109", "r144", "r147", "r148", "r215", "r607", "r1076" ] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r961", "r962", "r963", "r964" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r1035" ] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r1035" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r990" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r945", "r956", "r972", "r998", "r1007" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r981" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r980" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r998" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1018" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1018" ] }, "domh_NoncashCommissionsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "NoncashCommissionsExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash commission expense", "documentation": "The amount of non-cash commissions expense.", "label": "Noncash Commissions Expense" } } }, "auth_ref": [] }, "domh_NoncashUnderwritingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "NoncashUnderwritingRevenue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash underwriting revenues", "documentation": "The amount of non-cash underwriting revenue.", "label": "Noncash Underwriting Revenue" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Non- Controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r13", "r297", "r299", "r1143", "r1144", "r1145", "r1146", "r1365" ] }, "domh_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Controlling Interests [Member]", "label": "Noncontrolling Interests Member" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expenses)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r25", "r1056", "r1057", "r1173" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "domh_NonqualifiedStockOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "NonqualifiedStockOptions", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonqualified stock options issued", "documentation": "Number of shares issued nonqualified stock options.", "label": "Nonqualified Stock Options" } } }, "auth_ref": [] }, "domh_NotesReceivableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "NotesReceivableDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Receivable (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r218", "r690", "r1166", "r1287", "r1293", "r1294", "r1300", "r1309" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r850", "r858", "r1151" ] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating costs and expenses", "verboseLabel": "Operating Costs", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r845", "r1056", "r1057", "r1173" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "terseLabel": "Income / (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r841", "r845", "r849", "r1056", "r1057", "r1149", "r1152", "r1158", "r1161", "r1162", "r1173" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r510", "r899" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease rent expenses", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1277" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Payments [Abstract]", "terseLabel": "Long-term" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 }, "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofFutureMinimumPaymentsTable", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Lease liability", "verboseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r507", "r838" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "verboseLabel": "Operating lease right-of-use-assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r506" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1131" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r513", "r899" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term - operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r512", "r899" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopments" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business and Recent Developments", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r39", "r57", "r58", "r60", "r634", "r635" ] }, "domh_OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "OrganizationandDescriptionofBusinessandRecentDevelopmentsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_OriginationOfLoansToEmployeeStockOwnershipPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OriginationOfLoansToEmployeeStockOwnershipPlans", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee loans", "label": "Origination of Loans to Employee Stock Ownership Plans", "documentation": "The cash outflow to finance the entity's defined contribution plan to acquire shares of the entity. The plan initially holds the shares in a suspense account, which is collateral for the loan. As the plan makes payment on the debt, the shares are released from the suspense account and become available to be allocated to participant accounts." } } }, "auth_ref": [ "r9" ] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "OtherAddressMember", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } } }, "auth_ref": [] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "verboseLabel": "Total assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r76", "r81", "r551", "r552", "r553", "r594", "r855", "r905", "r906", "r920" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 }, "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other expenses", "verboseLabel": "Other operating expenses", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r19", "r616", "r854" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other assets", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expense (in Dollars)", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r20", "r21", "r905", "r906" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "verboseLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r615", "r706", "r801", "r802", "r803", "r905", "r906" ] }, "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherIncomeDisclosureNonoperatingAbstract", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expenses) income", "label": "Other Income, Nonoperating [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r77", "r83", "r94", "r551", "r552", "r555", "r556", "r558", "r596", "r676", "r677", "r866", "r905", "r906", "r920", "r1067", "r1308", "r1357" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r77", "r83", "r85", "r900" ] }, "domh_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "OtherMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue [Member]", "label": "Other Member" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r116" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r990" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Loans to employees", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r74", "r101", "r689", "r855", "r905", "r906", "r1309" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/NotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total proceeds", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r837" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r936" ] }, "domh_OtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "OtherRevenueMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Revenue [Member]", "label": "Other Revenue Member" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r943", "r954", "r970", "r1005" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r946", "r957", "r973", "r1008" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r946", "r957", "r973", "r1008" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "OwnershipAxis", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [ "r297", "r299" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "OwnershipDomain", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [ "r297", "r299" ] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "ParentEntityLegalName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ParentMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Dominari Holding Stockholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r979" ] }, "us-gaap_PaymentsForProceedsFromLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsForProceedsFromLongtermInvestments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment received", "label": "Payments for (Proceeds from) Long-Term Investments", "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of long-term investments which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash paid for dividends", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of securities owned", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r8", "r118", "r209" ] }, "us-gaap_PaymentsToAcquireLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquireLongtermInvestments", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in carrying values", "label": "Payments to Acquire Long-Term Investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term." } } }, "auth_ref": [ "r1127" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of marketable securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r1170" ] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions to non-controlling interest", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r9" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r989" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r989" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r981" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r998" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r991" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r980" ] }, "domh_PercentageValueOfStockPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "PercentageValueOfStockPrice", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price, percentage", "documentation": "The percentage value of stock price.", "label": "Percentage Value Of Stock Price" } } }, "auth_ref": [] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PhoneFaxNumberDescription", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r982" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1027" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r981" ] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r922" ] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r922" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r929" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreCommencementTenderOffer", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r931" ] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r922" ] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r922" ] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of common stock issued upon conversion", "label": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r275" ] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference (in Dollars per share)", "label": "Preferred Stock, Liquidation Preference Per Share", "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share." } } }, "auth_ref": [ "r867", "r1134", "r1136", "r1190", "r1199", "r1293", "r1294", "r1298" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r72", "r99", "r292", "r293", "r302", "r551", "r552", "r561", "r908", "r909", "r912", "r913", "r914", "r915", "r1350", "r1365" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r273", "r1059", "r1071", "r1196", "r1293", "r1294", "r1298" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in Shares)", "verboseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r72", "r99", "r293", "r551", "r552", "r561", "r681" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in Shares)", "verboseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r72", "r99", "r273", "r293", "r551", "r552", "r561" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in Shares)", "verboseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r72", "r99", "r293", "r551", "r552", "r561", "r681", "r702", "r1191", "r1365", "r1366" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, value", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r72", "r99", "r259", "r265", "r293", "r551", "r552", "r561", "r598", "r900" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 }, "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }, "auth_ref": [ "r107", "r695", "r1293", "r1294", "r1295", "r1306" ] }, "domh_PrincipalTransactionLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "PrincipalTransactionLossesMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Transaction Losses [Member]", "label": "Principal Transaction Losses Member" } } }, "auth_ref": [] }, "us-gaap_PrincipalTransactionsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrincipalTransactionsRevenue", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Principal transactions", "label": "Principal Transactions Revenue, Net", "documentation": "Amount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships." } } }, "auth_ref": [ "r1292" ] }, "domh_PrincipalTransactionsRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "PrincipalTransactionsRevenueMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Principal transactions [Member]", "label": "Principal Transactions Revenue Member" } } }, "auth_ref": [] }, "us-gaap_PrincipleTransactionRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrincipleTransactionRevenueLineItems", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "label": "Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1292" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of prior year amounts", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1055" ] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of principal on note receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r1129" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash from issuance common stock, net of offering cost", "verboseLabel": "Net proceeds (in Dollars)", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of securities owned", "label": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r46", "r119" ] }, "us-gaap_ProceedsFromSaleOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromSaleOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of long-term investments", "label": "Proceeds from Sale of Other Investments", "documentation": "Amount of cash inflow from the sale of investments classified as other." } } }, "auth_ref": [ "r1126" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash from issuance common stock for exercised warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r1128" ] }, "domh_ProceedsfromCollectionofLoansToEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ProceedsfromCollectionofLoansToEmployees", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Collection of loans to employees", "documentation": "Represent the amount of cash inflow of collection of loans to employees.", "label": "Proceedsfrom Collectionof Loans To Employees" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r202", "r547", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r833", "r840", "r843", "r845", "r868", "r870", "r901", "r902", "r903", "r904", "r907", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1183", "r1184", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r202", "r547", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r833", "r840", "r843", "r845", "r868", "r870", "r901", "r902", "r903", "r904", "r907", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1183", "r1184", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349" ] }, "us-gaap_ProfessionalAndContractServicesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfessionalAndContractServicesExpense", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Professional and Contracted Services Expense", "documentation": "Amount of expense for professional and contracted services." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r843", "r854", "r918", "r1360", "r1364" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow", "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r56", "r63", "r64", "r108", "r109", "r121", "r126", "r127", "r128", "r132", "r136", "r144", "r147", "r148", "r215", "r222", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r257", "r298", "r342", "r394", "r434", "r437", "r439", "r442", "r443", "r464", "r493", "r571", "r573", "r606", "r652", "r703", "r727", "r728", "r835", "r888", "r889", "r919", "r1076", "r1185" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization", "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r515", "r551", "r552", "r568", "r576", "r577", "r604", "r900", "r1175" ] }, "domh_PurchaseOfShorttermAndLongtermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "PurchaseOfShorttermAndLongtermInvestments", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of long-term investments", "documentation": "Purchase of short-term and long-term investments.", "label": "Purchase Of Shortterm And Longterm Investments" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r979" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r979" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeAxis", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r65", "r66", "r171", "r227", "r228", "r229", "r230", "r345", "r357", "r387", "r388", "r389", "r393", "r405", "r471", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r543", "r545", "r625", "r626", "r632", "r672", "r673", "r740", "r761", "r766", "r767", "r796", "r825", "r826", "r827", "r828", "r830", "r831", "r860", "r882", "r885", "r886", "r887", "r892", "r893", "r894", "r895", "r902", "r910", "r1180", "r1187", "r1189", "r1268" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeMember", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r65", "r66", "r171", "r227", "r228", "r229", "r230", "r345", "r357", "r387", "r388", "r389", "r393", "r405", "r471", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r543", "r545", "r625", "r626", "r632", "r672", "r673", "r740", "r761", "r766", "r767", "r796", "r825", "r826", "r827", "r828", "r830", "r831", "r860", "r882", "r885", "r886", "r887", "r892", "r893", "r894", "r895", "r902", "r910", "r1180", "r1187", "r1189", "r1268" ] }, "domh_RealizedGainloss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RealizedGainloss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable": { "parentTag": "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofGainsandLossesonMarketableSecuritiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain / (loss)", "documentation": "Realized gain / (loss).", "label": "Realized Gainloss" } } }, "auth_ref": [] }, "domh_RealizedGainsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RealizedGainsMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized Gains [Member]", "label": "Realized Gains Member" } } }, "auth_ref": [] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized (gain) loss on securities owned", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r611" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Notes Receivable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReceivablesFromBrokersDealersAndClearingOrganizations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ReceivablesFromBrokersDealersAndClearingOrganizations", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails", "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from clearing brokers", "label": "Receivable from Broker-Dealer and Clearing Organization", "documentation": "Amount receivable from broker-dealers and clearing organizations, including, but not limited to, securities failed-to-deliver, certain deposits for securities borrowed, open transactions, good faith and margin deposits, commissions and floor brokerage receivables." } } }, "auth_ref": [ "r1289" ] }, "domh_ReceivablesFromClearingBrokersPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ReceivablesFromClearingBrokersPolicyPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable from Clearing Brokers", "documentation": "Disclosure of accounting policy for receivables from clearing brokers.", "label": "Receivables From Clearing Brokers Policy Policy Text Block" } } }, "auth_ref": [] }, "domh_RecognizedRevenueIncludedInContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RecognizedRevenueIncludedInContractLiabilities", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized revenue included in contract liabilities", "documentation": "Represents the amount of recognized revenue included in contract liabilities.", "label": "Recognized Revenue Included In Contract Liabilities" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r938", "r949", "r965", "r1000" ] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "RegistrationStatementAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Registration Statement Amendment Number", "documentation": "Amendment number to registration statement under the Investment Company Act of 1940." } } }, "auth_ref": [ "r922" ] }, "srt_RegulatoryCapitalRequirementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RegulatoryCapitalRequirementsAbstract", "lang": { "en-us": { "role": { "label": "Regulatory [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RegulatoryCapitalRequirementsUnderBankingRegulationsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Regulatory" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory", "label": "Regulatory Capital Requirements under Banking Regulations [Text Block]", "documentation": "The entire disclosure for regulatory capital requirement for depository and lending institutions. Institutions include, but not are not limited to, finance company, insured depository institution, bank holding company, savings and loan association holding company, bank and savings institution not federally insured, mortgage company, foreign financial institution and credit union." } } }, "auth_ref": [ "r579", "r580", "r581", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592" ] }, "domh_RegulatoryDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RegulatoryDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Regulatory (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyDomain", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r77", "r78", "r83", "r91", "r93", "r126", "r131", "r132", "r206", "r352", "r356", "r521", "r522", "r551", "r552", "r555", "r556", "r559", "r566", "r597", "r603", "r675", "r676", "r677", "r678", "r679", "r701", "r736", "r837", "r1359", "r1368" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyMember", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r77", "r78", "r83", "r91", "r93", "r126", "r131", "r132", "r521", "r522", "r523", "r524", "r551", "r552", "r559", "r597", "r603", "r675", "r676", "r677", "r678", "r679", "r701", "r736" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earned amount", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r521" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r126", "r131", "r132", "r206", "r521", "r522", "r524", "r551", "r552", "r555", "r556", "r559", "r566", "r709", "r710", "r714", "r1368" ] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revere\u2019s outstanding equity percentage", "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [ "r1282" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r77", "r78", "r83", "r91", "r93", "r126", "r131", "r132", "r206", "r352", "r356", "r521", "r522", "r551", "r552", "r555", "r556", "r559", "r566", "r597", "r603", "r675", "r676", "r677", "r678", "r679", "r701", "r736", "r837", "r1284", "r1359", "r1368" ] }, "domh_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r518", "r519", "r520", "r522", "r525", "r551", "r552", "r567", "r648", "r649", "r650", "r712", "r713", "r714", "r733", "r735" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r939", "r950", "r966", "r1001" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r940", "r951", "r967", "r1002" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r947", "r958", "r974", "r1009" ] }, "domh_RestrictedStockAwardsAndStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RestrictedStockAwardsAndStockOptionsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards and Stock Options [Member]", "label": "Restricted Stock Awards And Stock Options Member" } } }, "auth_ref": [] }, "domh_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RestrictedStockAwardsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards [Member]", "label": "Restricted Stock Awards Member" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedStockMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards [Member]", "verboseLabel": "Restricted Stock [Member]", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r1148", "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r103", "r104", "r295", "r551", "r552", "r563", "r600", "r630", "r631", "r646", "r682", "r900" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r55", "r56", "r133", "r134", "r135", "r137", "r144", "r146", "r148", "r216", "r217", "r221", "r222", "r223", "r256", "r292", "r302", "r340", "r341", "r343", "r344", "r394", "r423", "r424", "r431", "r432", "r433", "r435", "r436", "r437", "r447", "r448", "r449", "r450", "r452", "r453", "r455", "r462", "r505", "r544", "r578", "r627", "r629", "r653", "r1198", "r1200", "r1365" ] }, "domh_RevenueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "RevenueDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "label": "Revenue (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue from contracts with customers", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r164", "r178", "r179", "r193", "r199", "r202", "r204", "r205", "r334", "r335", "r336", "r547" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r52", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r832" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.aikidopharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r52", "r317", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r336", "r339" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement", "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue", "terseLabel": "Total revenue", "verboseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r114", "r126", "r127", "r128", "r164", "r178", "r179", "r193", "r199", "r202", "r204", "r205", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r298", "r493", "r571", "r573", "r854", "r890", "r905", "r906", "r1056", "r1057", "r1173", "r1185" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenuesAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "label": "Revenue [Abstract]", "terseLabel": "Revenues" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1018" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1018" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScenarioForecastMember", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": [ "r358" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r59", "r61", "r149", "r358", "r1044" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r159" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.aikidopharma.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potentially Dilute Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r1148" ] }, "domh_ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfAssetsAndLiabilitiesThatAreMeasuredAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities That Are Measured At Fair Value Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCapitalizationLongtermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfCapitalizationLongtermDebtLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "domh_ScheduleOfCodmViewsTheExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfCodmViewsTheExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Codm Views The Expenses Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1240" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r212", "r213", "r214", "r430", "r493", "r1046", "r1047", "r1048", "r1243", "r1244", "r1245", "r1246" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities that are Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1265", "r1266" ] }, "domh_ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets That Are Measured At Fair Value On ARecurring Basis Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfInvestmentsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLongTermInvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": [ "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r758", "r760", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r804", "r805", "r806", "r807", "r808", "r809" ] }, "domh_ScheduleOfLongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfLongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Investments Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfOptionActivityUnderTheCompanySStockOptionPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfOptionActivityUnderTheCompanySStockOptionPlanAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Option Activity Under The Company SStock Option Plan Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfOtherAssetsTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/PrepaidExpensesandOtherAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Assets", "label": "Schedule of Other Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "domh_ScheduleOfPotentiallyDiluteLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfPotentiallyDiluteLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Potentially Dilute Loss Per Share Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfRestrictedStockAwardsActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfRestrictedStockAwardsActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Awards Activity Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table]", "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r173", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r199", "r200", "r201" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of CODM Views the Expenses", "label": "Segment Reporting [Table Text Block]", "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r1150", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1159", "r1160", "r1163" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Activity Under the Company\u2019s Stock Option Plan", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r5", "r6", "r33" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Awards Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r1216" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r1192" ] }, "domh_ScheduleOfTotalRevenueDisaggregatedByRevenueTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfTotalRevenueDisaggregatedByRevenueTypeAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Total Revenue Disaggregated By Revenue Type Abstract" } } }, "auth_ref": [] }, "domh_ScheduleOfWarrantActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ScheduleOfWarrantActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Activity Abstract" } } }, "auth_ref": [] }, "domh_Section382LimitationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "Section382LimitationMember", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Section 382 Limitation [Member]", "label": "Section382 Limitation Member" } } }, "auth_ref": [] }, "us-gaap_SecuritiesOwnedNotReadilyMarketablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SecuritiesOwnedNotReadilyMarketablePolicy", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Securities owned", "label": "Securities Owned Not Readily Marketable, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for not readily marketable securities, valuation methods and significant assumptions used to determine fair value, restrictions on the investment and reasons investments are not readily marketable, including securities that are not registered, investments in nonpublic entities." } } }, "auth_ref": [ "r550" ] }, "domh_SecuritiesPurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SecuritiesPurchaseAgreementsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreements [Member]", "label": "Securities Purchase Agreements Member" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12bTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r923" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12gTitle", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r927" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOtherAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposits", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r1062", "r1064" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityExchangeName", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r926" ] }, "us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityOwned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityOwned", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities owned", "label": "Security Owned and Sold, Not yet Purchased Fair Value, Security Owned", "documentation": "Fair value of financial instruments held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes determined by management based upon quoted prices of a financial instrument with similar characteristics or on a valuation technique or model." } } }, "auth_ref": [ "r1291" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityReportingObligation", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r932" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r176", "r853", "r859" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting [Text Block]", "documentation": "The entire disclosure for segment reporting." } } }, "auth_ref": [ "r164", "r172", "r173", "r174", "r175", "r177", "r189", "r191", "r192", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r205", "r850", "r851", "r852", "r854", "r856", "r857", "r858" ] }, "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingExpenseInformationUsedByCodmDescription", "presentation": [ "http://www.aikidopharma.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CODM description", "label": "Segment Reporting, Expense Information Used by CODM, Description", "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed." } } }, "auth_ref": [ "r164", "r192", "r199" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of CODM Views the Expenses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r173", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r199", "r200", "r201" ] }, "domh_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SeriesAWarrantsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Warrants [Member]", "label": "Series AWarrants Member" } } }, "auth_ref": [] }, "domh_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SeriesBWarrantsMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Warrants [Member]", "label": "Series BWarrants Member" } } }, "auth_ref": [] }, "domh_SeriesD1ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SeriesD1ConvertiblePreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Convertible Preferred Stock [Member]", "documentation": "Series D1 Convertible Preferred Stock Member.", "label": "Series D1 Convertible Preferred Stock Member" } } }, "auth_ref": [] }, "domh_SeriesD1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SeriesD1PreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Series D-1 Convertible Preferred Stock", "label": "Series D1 Preferred Stock Member" } } }, "auth_ref": [] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D Convertible Preferred Stock", "verboseLabel": "Series D Convertible Preferred Stock [Member]", "netLabel": "Series D Preferred Stock [Member]", "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r1059", "r1060", "r1069", "r1070", "r1071", "r1188", "r1191", "r1192", "r1193", "r1194", "r1196", "r1293", "r1294", "r1297", "r1298" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation \u2013 employees", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r883" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Granted", "documentation": "Number of equity instruments other than non options outstanding, granted.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Non Option Grants In Period Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Forfeited", "documentation": "Number of equity instruments other than non options outstanding, forfeited.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Non Options Forfeitures Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant Day Fair Value, Balance", "periodEndLabel": "Weighted Average Grant Day Fair Value, Balance", "documentation": "Number of equity instruments other than non options outstanding, including non-vested instruments.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Non Options Nonvested Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanNonOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Day Fair Value, Vested", "documentation": "Number of equity instruments other than non options outstanding, vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Non Options Vested In Period Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWarrants", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised, Warrants", "documentation": "Exercised, warrants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Warrants" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Exercise Price", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards expired during the period on other than stock (or unit) option plans.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expiration Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWarrants", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired, Warrants", "documentation": "Expired, warrants.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Warrants" } } }, "auth_ref": [] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualLifeinYears": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualLifeinYears", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Remaining Contractual Life (in years)", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expired, weighted average remaining contractual life.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Lifein Years" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Warrants", "verboseLabel": "Common stock received", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r377" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r377" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Remaining Contractual Life", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants weighted average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants Weighted Average Remaining Contractual Terms" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of shares, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r374", "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average per share, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r374", "r375" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingExercisedWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, Weighted Average Exercise Price", "documentation": "Exercised, weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Exercised Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Remaining Contractual Term", "documentation": "Weighted-average contractual term remaining for equity-based award excluding option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested fair value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Schedule of Option Activity Under the Company\u2019s Stock Option Plan [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r393" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Restricted Stock Awards, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Restricted Stock Awards, Balance", "periodEndLabel": "Number of Restricted Stock Awards, Balance", "terseLabel": "Nonvested restricted stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r34", "r35" ] }, "domh_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Restricted Stock Awards, Vested", "documentation": "Number of equity instruments other than options outstanding restricted stock awards, vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee options forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r372", "r1059", "r1071", "r1072", "r1196", "r1197" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation - employees (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1059", "r1071", "r1072", "r1196", "r1197", "r1212" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Number of Shares", "verboseLabel": "Granted shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r370", "r1059", "r1071", "r1072", "r1196", "r1197" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r366", "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r366", "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r362", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r386", "r387", "r388", "r389", "r390" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options exercised, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employee options granted, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r370" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r359", "r365", "r384", "r385", "r386", "r387", "r390", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharePrice", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExercised", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, Total Intrinsic Value", "documentation": "Exercised, total intrinsic value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Option Aggregate Intrinsic Value Exercised" } } }, "auth_ref": [] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionAggregateIntrinsicValueExpiration", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Total Intrinsic Value", "documentation": "Intrinsic value of expired award under share-based payment arrangement. Excludes share and unit options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Option Aggregate Intrinsic Value Expiration" } } }, "auth_ref": [] }, "domh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGrants", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Total Intrinsic Value", "documentation": "Amount of aggregate intrinsic value grants under other than options.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Grants" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Outstanding ending balance, Total Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1233" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding ending balance, Weighted Average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term", "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r38" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable, Weighted Average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term", "documentation": "Weighted-average contractual term remaining for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested option for which requisite service period has not been rendered but that is expected to vest based on achievement of performance condition, if forfeiture is recognized when it occurs." } } }, "auth_ref": [ "r383" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r381" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [ "r1191", "r1198", "r1200" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofLeaseAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease rent expense", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r511", "r899" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r124", "r125" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SolicitingMaterial", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r930" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r53", "r72", "r73", "r95", "r96", "r97", "r98", "r99", "r100", "r126", "r128", "r153", "r154", "r156", "r158", "r166", "r167", "r215", "r231", "r233", "r234", "r235", "r238", "r239", "r258", "r259", "r261", "r262", "r264", "r267", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r283", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r297", "r298", "r299", "r493", "r551", "r552", "r560", "r561", "r562", "r578", "r641", "r642", "r643", "r644", "r653", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r681", "r704", "r729", "r814", "r815", "r816", "r817", "r818", "r1043", "r1136", "r1138", "r1147", "r1199", "r1202" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r55", "r56", "r72", "r99", "r100", "r111", "r112", "r113", "r133", "r134", "r135", "r137", "r144", "r146", "r148", "r165", "r216", "r217", "r221", "r222", "r223", "r256", "r287", "r292", "r293", "r294", "r297", "r299", "r302", "r340", "r341", "r343", "r344", "r394", "r423", "r424", "r431", "r432", "r433", "r435", "r436", "r437", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r496", "r497", "r498", "r499", "r500", "r501", "r505", "r517", "r544", "r551", "r552", "r561", "r562", "r578", "r609", "r627", "r628", "r629", "r653", "r729", "r1202" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementLineItems", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r72", "r73", "r77", "r78", "r83", "r91", "r93", "r95", "r98", "r99", "r100", "r104", "r133", "r134", "r135", "r165", "r258", "r259", "r261", "r264", "r270", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r301", "r302", "r314", "r505", "r547", "r551", "r552", "r560", "r561", "r562", "r636", "r654", "r665", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r684", "r685", "r686", "r687", "r688", "r691", "r692", "r693", "r694", "r697", "r698", "r699", "r700", "r701", "r707", "r708", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r729", "r837", "r843", "r845", "r911", "r1359" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StatementScenarioAxis", "presentation": [ "http://www.aikidopharma.com/role/FairValueofFinancialAssetsandLiabilitiesDetails", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r59", "r61", "r149", "r358", "r1044", "r1049" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementTable", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r62", "r72", "r73", "r77", "r78", "r83", "r91", "r93", "r95", "r98", "r99", "r100", "r104", "r133", "r134", "r135", "r165", "r206", "r258", "r259", "r261", "r264", "r270", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r301", "r302", "r314", "r505", "r547", "r551", "r552", "r560", "r561", "r562", "r578", "r636", "r654", "r665", "r674", "r675", "r676", "r677", "r678", "r679", "r681", "r684", "r685", "r686", "r687", "r688", "r691", "r692", "r693", "r694", "r697", "r698", "r699", "r700", "r701", "r707", "r708", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r729", "r837", "r843", "r845", "r911", "r1359" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r942", "r953", "r969", "r1004" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1205", "r1206", "r1207", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231" ] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation - employees", "verboseLabel": "Option granted (in Dollars)", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r10", "r1059", "r1071", "r1072", "r1196", "r1197", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in Shares)", "verboseLabel": "Shares of common stock", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r641", "r729", "r815", "r1059", "r1071", "r1072", "r1191", "r1196", "r1197", "r1198", "r1200", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory shares issued (in Shares)", "verboseLabel": "Aggregate shares", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [ "r1059", "r1071", "r1072", "r1196", "r1197" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r1059", "r1071", "r1072", "r1191", "r1196", "r1197", "r1198", "r1200", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock from warrants exercised (in Shares)", "negatedLabel": "Employee options exercised, Number of Shares", "verboseLabel": "Additional common stock issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r371", "r1059", "r1071", "r1072", "r1191", "r1196", "r1197", "r1198", "r1200", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "verboseLabel": "Fair value of issued shares (in Dollars)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r653", "r729", "r815", "r919", "r1059", "r1071", "r1072", "r1191", "r1196", "r1197", "r1198", "r1200", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockIssuedDuringPeriodValueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueOther", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Advisory shares issued", "label": "Stock Issued During Period, Value, Other", "documentation": "Value of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [ "r1059", "r1071", "r1072", "r1196", "r1197" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r12", "r1059", "r1071", "r1072", "r1191", "r1196", "r1197", "r1198", "r1200", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock from warrants exercised", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r1059", "r1071", "r1072", "r1191", "r1196", "r1197", "r1198", "r1200", "r1293", "r1294", "r1298", "r1299" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockOptionMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r910", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262" ] }, "domh_StockbasedCompensationAdvisors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "StockbasedCompensationAdvisors", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation \u2013 advisors", "documentation": "The amount of stock-based compensation advisors.", "label": "Stockbased Compensation Advisors" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Dominari stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r31", "r683", "r702", "r730", "r731", "r900", "r920", "r1075", "r1134", "r1138", "r1139", "r1173", "r1274", "r1365" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet", "http://www.aikidopharma.com/role/ShareholdersEquityType2or3", "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "terseLabel": "Distribution of non-controlling interests (in Dollars)", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r13", "r14", "r15", "r55", "r56", "r100", "r112", "r133", "r134", "r135", "r137", "r144", "r146", "r216", "r217", "r221", "r222", "r223", "r256", "r287", "r293", "r294", "r297", "r299", "r340", "r341", "r343", "r344", "r394", "r423", "r424", "r431", "r432", "r433", "r435", "r436", "r437", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r462", "r496", "r497", "r501", "r517", "r544", "r551", "r552", "r561", "r562", "r628", "r629", "r651", "r683", "r702", "r730", "r731", "r819", "r905", "r906", "r919", "r1059", "r1071", "r1134", "r1138", "r1139", "r1173", "r1274", "r1365" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStock" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity and Convertible Preferred Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r72", "r99", "r100", "r105", "r269", "r272", "r274", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r293", "r294", "r297", "r299", "r300", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r446", "r460", "r461", "r529", "r732", "r734", "r820" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units purchased amount", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [ "r1191" ] }, "us-gaap_StockholdersEquityOtherShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityOtherShares", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreed to purchase units (in Shares)", "label": "Stockholders' Equity, Other Shares", "documentation": "Number of increase (decrease) in shares of stock classified as other." } } }, "auth_ref": [ "r1191" ] }, "domh_StockholdersEquityandConvertiblePreferredStockDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "StockholdersEquityandConvertiblePreferredStockDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock (Details) [Table]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockScheduleofOptionActivityUndertheCompanysStockOptionPlanDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "StockholdersEquityandConvertiblePreferredStockScheduleofOptionActivityUndertheCompanysStockOptionPlanDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofOptionActivityUndertheCompanysStockOptionPlanTable" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Option Activity Under the Company\u2019s Stock Option Plan (Details) [Table]" } } }, "auth_ref": [] }, "domh_StockholdersEquityandConvertiblePreferredStockScheduleofRestrictedStockAwardsActivityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "StockholdersEquityandConvertiblePreferredStockScheduleofRestrictedStockAwardsActivityDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofRestrictedStockAwardsActivityTable" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity and Convertible Preferred Stock - Schedule of Restricted Stock Awards Activity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsegmentsAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsegmentsDomain", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r502", "r527" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventMember", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r502", "r527" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails", "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r502", "r527" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.aikidopharma.com/role/LongTermEquityInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r502", "r527" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "domh_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.aikidopharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r526", "r528" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": [ "http://www.aikidopharma.com/role/OrganizationandDescriptionofBusinessandRecentDevelopmentsDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business and Recent Developments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails", "http://www.aikidopharma.com/role/RegulatoryDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "domh_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r997" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TaxPeriodAxis", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1235" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TaxPeriodDomain", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r1235" ] }, "domh_TaxableGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "TaxableGain", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable gain", "documentation": "The amount of taxable gain.", "label": "Taxable Gain" } } }, "auth_ref": [] }, "domh_TaxableOrdinaryIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "TaxableOrdinaryIncome", "crdr": "debit", "presentation": [ "http://www.aikidopharma.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxable ordinary income", "documentation": "Taxable ordinary income.", "label": "Taxable Ordinary Income" } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TaxesPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Taxes Payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes." } } }, "auth_ref": [ "r1068", "r1307" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r336", "r868", "r875" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r1165", "r1283" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r989" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r996" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1017" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1019" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "TradingSymbol", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognized at a Point in Time [Member]", "verboseLabel": "Transferred at Point in Time [Member]", "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r868", "r869", "r875" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TransferredOverTimeMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transferred over Time [Member]", "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r868", "r869", "r875" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1020" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1021" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1021" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1019" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1019" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1022" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1020" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r551", "r552", "r562", "r1202" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.aikidopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r311", "r312", "r1293", "r1294", "r1299" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r438" ] }, "us-gaap_UnderwritingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnderwritingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting services", "label": "Underwriting Income (Loss)", "documentation": "The difference between the price paid by the public and the contract price less the related expenses. A broker-dealer may underwrite a security offering by contracting to buy the issue either at a fixed price or a price based on selling the offering on a best-effort basis." } } }, "auth_ref": [] }, "domh_UnderwritingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "UnderwritingRevenue", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting revenue", "documentation": "The amount of underwriting revenue.", "label": "Underwriting Revenue" } } }, "auth_ref": [] }, "domh_UnderwritingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "UnderwritingServicesMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails", "http://www.aikidopharma.com/role/ScheduleofTotalRevenueDisaggregatedbyRevenueTypeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Underwriting services [Member]", "verboseLabel": "Underwriting Services [Member]", "label": "Underwriting Services Member" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1016" ] }, "domh_UnobservableInputsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "UnobservableInputsPercentage", "presentation": [ "http://www.aikidopharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unobservable percent", "documentation": "Unobservable inputs percentage.", "label": "Unobservable Inputs Percentage" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.aikidopharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized loss on securities owned", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r3" ] }, "domh_UnrealizedLossOnNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "UnrealizedLossOnNoteReceivable", "crdr": "debit", "calculation": { "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aikidopharma.com/role/ScheduleofCODMViewstheExpensesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized loss on note receivable", "documentation": "Amount of (loss) on sale of unrealized financing receivable.", "label": "Unrealized Loss On Note Receivable" } } }, "auth_ref": [] }, "domh_UnrealizedLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "UnrealizedLossesMember", "presentation": [ "http://www.aikidopharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses [Member]", "label": "Unrealized Losses Member" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UseOfEstimates", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r48", "r49", "r168", "r169", "r170", "r171", "r571", "r573", "r847" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r985" ] }, "domh_WarrantInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "WarrantInvestmentsPolicyTextBlock", "presentation": [ "http://www.aikidopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Investments", "documentation": "Warrant investments policy.", "label": "Warrant Investments Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantMember", "presentation": [ "http://www.aikidopharma.com/role/ScheduleofPotentiallyDiluteLossPerShareTable", "http://www.aikidopharma.com/role/ScheduleofWarrantActivityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r908", "r909", "r912", "r913", "r914", "r915" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.aikidopharma.com/role/StockholdersEquityandConvertiblePreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of warrants", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1267", "r1268", "r1269" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r152", "r158" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding, basic and diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.aikidopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r151", "r158" ] }, "domh_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aikidopharma.com/20260331", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://www.aikidopharma.com/role/LiquidityandCapitalResourcesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital", "documentation": "Represents the amount of working capital.", "label": "Working Capital" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "WrittenCommunications", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r1033" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r983" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.4-03(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-30/tableOfContent" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-2" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-2" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479910/205-30-50-2" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-4" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 5.Q.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 1.D.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "45", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 1.B.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479255/942-310-S50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.H.2.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478116/942-310-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1D" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1F" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1H", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1H" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1H", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1H" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1H", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1H" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1H", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1H" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1H", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477270/942-505-50-1H" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481019/946-20-45-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-3" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-5" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-5" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481586/948-10-50-5" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "Global LEI Foundation" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1003": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1004": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1005": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1006": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1007": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1008": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1009": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1010": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1012": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1013": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1014": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1015": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1016": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1017": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1018": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1020": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1021": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1022": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1023": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1026": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1027": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1028": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r1029": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1030": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r1031": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1032": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r1033": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r1040": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1041": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" }, "r1042": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1044": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1045": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r1046": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1047": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1048": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1049": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-1" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.4-07)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-2" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-1C" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481913/940-20-25-2" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481833/940-20-45-3" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-2" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479048/940-320-50-1" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "810", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1" } } } ZIP 83 0001213900-26-055369-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-26-055369-xbrl.zip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end XML 84 ea0289782-10q_dominari_htm.xml IDEA: XBRL DOCUMENT 0000012239 2026-01-01 2026-03-31 0000012239 2026-05-12 0000012239 2026-03-31 0000012239 2025-12-31 0000012239 us-gaap:SeriesDPreferredStockMember 2026-03-31 0000012239 us-gaap:SeriesDPreferredStockMember 2025-12-31 0000012239 domh:SeriesD1PreferredStockMember 2026-03-31 0000012239 domh:SeriesD1PreferredStockMember 2025-12-31 0000012239 2025-01-01 2025-03-31 0000012239 us-gaap:PreferredStockMember 2025-12-31 0000012239 us-gaap:CommonStockMember 2025-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000012239 us-gaap:RetainedEarningsMember 2025-12-31 0000012239 us-gaap:ParentMember 2025-12-31 0000012239 us-gaap:NoncontrollingInterestMember 2025-12-31 0000012239 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000012239 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000012239 us-gaap:ParentMember 2026-01-01 2026-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0000012239 us-gaap:PreferredStockMember 2026-03-31 0000012239 us-gaap:CommonStockMember 2026-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000012239 us-gaap:RetainedEarningsMember 2026-03-31 0000012239 us-gaap:ParentMember 2026-03-31 0000012239 us-gaap:NoncontrollingInterestMember 2026-03-31 0000012239 us-gaap:PreferredStockMember 2024-12-31 0000012239 us-gaap:CommonStockMember 2024-12-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000012239 us-gaap:TreasuryStockCommonMember 2024-12-31 0000012239 us-gaap:RetainedEarningsMember 2024-12-31 0000012239 2024-12-31 0000012239 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000012239 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000012239 us-gaap:PreferredStockMember 2025-03-31 0000012239 us-gaap:CommonStockMember 2025-03-31 0000012239 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000012239 us-gaap:TreasuryStockCommonMember 2025-03-31 0000012239 us-gaap:RetainedEarningsMember 2025-03-31 0000012239 2025-03-31 0000012239 domh:FPSPurchaseAgreementMember 2022-09-09 0000012239 2022-10-04 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2022-10-04 0000012239 domh:FPSPurchaseAgreementMember 2026-03-31 0000012239 domh:AmericanVenturesLLCMember 2025-06-17 0000012239 domh:AmericanVenturesIMLLCAndAmericanVenturesManagerLLCMember 2026-03-31 0000012239 domh:DominariFinancialHeritageStrategiesLLCMember 2024-05-21 0000012239 srt:MaximumMember 2026-01-01 2026-03-31 0000012239 srt:MinimumMember 2026-01-01 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2024-07-25 2024-07-25 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2026-01-01 2026-03-31 0000012239 us-gaap:SubsequentEventMember 2026-04-06 2026-04-06 0000012239 domh:InvestmentInTracXMember 2026-01-13 2026-01-13 0000012239 domh:InvestmentInKernaHealthIncMember 2026-03-31 0000012239 domh:InvestmentInKernaHealthIncMember 2025-12-31 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2026-03-31 0000012239 domh:InvestmentInRevereMasterSPVSeries1QxpressPteLtdMember 2025-12-31 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2026-03-31 0000012239 domh:InvestmentInMWLSVMasterClassLLCYankaIndustriesIncDbaMasterclassMember 2025-12-31 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2026-03-31 0000012239 domh:InvestmentInPaywardIncAndMWSIVCKrakenIILLCPaywardIncDbaKrakenMember 2025-12-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2026-03-31 0000012239 domh:InvestmentInAeonPartnersFundSeriesEGEpicGamesIncMember 2025-12-31 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2026-03-31 0000012239 domh:InvestmentInTesspayIncAndRevereMasterSPVSeriesVITessPayIncMember 2025-12-31 0000012239 domh:InvestmentInDiscordIncMember 2026-03-31 0000012239 domh:InvestmentInDiscordIncMember 2025-12-31 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2026-03-31 0000012239 domh:InvestmentInAutomationAnywhereIncMember 2025-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesVIXAICorpDbaXAIMember 2025-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXICerebrasSystemsIncMember 2025-12-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2026-03-31 0000012239 domh:InvestmentInDominariMasterSPVLLCSeriesXIIGroqIncMember 2025-12-31 0000012239 domh:InvestmentInAdvEnIncMember 2026-03-31 0000012239 domh:InvestmentInAdvEnIncMember 2025-12-31 0000012239 domh:InvestmentInAmericanVenturesLLCSeriesXXTracXLogisPteLtdMember 2026-03-31 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-01-01 2025-12-31 0000012239 2025-03-24 0000012239 domh:AmericanInnovativeRoboticsLLCMember 2025-03-24 2025-03-24 0000012239 us-gaap:FairValueInputsLevel3Member 2026-03-31 0000012239 us-gaap:FairValueInputsLevel2Member 2026-01-01 2026-03-31 0000012239 srt:ScenarioForecastMember 2026-09-30 2026-09-30 0000012239 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0000012239 us-gaap:FairValueInputsLevel1Member 2026-03-31 0000012239 us-gaap:FairValueInputsLevel2Member 2026-03-31 0000012239 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000012239 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000012239 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000012239 2022-07-11 0000012239 2023-01-11 2023-01-11 0000012239 2022-09-23 0000012239 2022-09-23 2022-09-23 0000012239 2025-10-01 0000012239 2025-10-01 2025-10-01 0000012239 domh:ConvertiblePreferredOptionMember 2026-01-01 2026-03-31 0000012239 domh:ConvertiblePreferredOptionMember 2025-01-01 2025-03-31 0000012239 us-gaap:WarrantMember 2026-01-01 2026-03-31 0000012239 us-gaap:WarrantMember 2025-01-01 2025-03-31 0000012239 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0000012239 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000012239 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000012239 srt:ScenarioForecastMember 2026-09-30 0000012239 srt:ScenarioForecastMember 2026-12-11 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 2025-02-10 0000012239 domh:SecuritiesPurchaseAgreementsMember 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-02-10 2025-02-10 0000012239 2025-02-10 0000012239 domh:SeriesAWarrantsMember 2025-02-10 0000012239 domh:SeriesBWarrantsMember 2025-02-10 0000012239 us-gaap:CommonStockMember 2025-02-10 2025-02-10 0000012239 us-gaap:CommonStockMember domh:AdvisoryAgreementsMember 2025-02-18 2025-02-18 0000012239 domh:AdvisoryAgreementsMember 2025-02-10 2025-02-10 0000012239 us-gaap:MajorityShareholderMember us-gaap:SeriesDPreferredStockMember 2013-09-30 0000012239 us-gaap:SeriesDPreferredStockMember 2013-09-30 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2026-03-31 0000012239 domh:SeriesD1ConvertiblePreferredStockMember 2025-12-31 0000012239 2025-03-03 2025-03-03 0000012239 2025-09-26 2025-09-26 0000012239 2026-01-26 2026-01-26 0000012239 2025-01-01 2025-12-31 0000012239 2025-07-01 2025-09-30 0000012239 2025-10-01 2025-12-31 0000012239 domh:RestrictedStockAwardsMember domh:EquityIncentivePlanMember 2022-10-07 0000012239 domh:EquityIncentivePlanMember 2025-02-10 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember 2025-02-10 2025-02-10 0000012239 domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember domh:MessrChristopherDevallMember 2025-02-10 2025-02-10 0000012239 domh:MessrAnthonyHayesMember 2025-02-12 2025-02-12 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:MessrAnthonyHayesMember 2025-02-12 2025-02-12 0000012239 domh:EquityIncentivePlanMember domh:AnthonyHayesAndKyleWoolMember us-gaap:CommonStockMember 2025-03-11 2025-03-11 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember domh:AnthonyHayesAndKyleWoolMember us-gaap:CommonStockMember 2025-03-11 2025-03-11 0000012239 domh:EquityIncentivePlanMember 2025-12-10 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember domh:EquityIncentivePlanMember 2025-12-10 2025-12-10 0000012239 domh:EquityIncentivePlanMember 2025-12-11 0000012239 domh:EquityIncentivePlanMember 2025-12-11 2025-12-11 0000012239 domh:RestrictedStockAwardsMember domh:EquityIncentivePlanMember us-gaap:CommonStockMember 2026-01-09 2026-01-09 0000012239 2024-06-11 2024-06-11 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember us-gaap:CommonStockMember 2026-03-04 2026-03-04 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember 2026-03-04 2026-03-04 0000012239 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000012239 domh:RestrictedStockAwardsAndStockOptionsMember 2025-12-31 0000012239 domh:AnthonyHayesAndKyleWoolMember 2025-02-10 2025-02-10 0000012239 2025-01-01 2025-06-30 0000012239 2025-12-01 2025-12-01 0000012239 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0000012239 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0000012239 domh:AVManagerMember 2026-03-31 0000012239 domh:AVInvestmentManagerMember 2026-03-31 0000012239 us-gaap:WarrantMember 2025-12-31 0000012239 us-gaap:WarrantMember 2025-12-31 2025-12-31 0000012239 us-gaap:WarrantMember 2026-01-01 2026-03-31 0000012239 us-gaap:WarrantMember 2026-03-31 0000012239 us-gaap:RestrictedStockMember 2025-12-31 0000012239 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0000012239 us-gaap:RestrictedStockMember 2026-03-31 0000012239 us-gaap:StockOptionMember 2025-12-31 0000012239 us-gaap:StockOptionMember 2025-12-31 2025-12-31 0000012239 us-gaap:StockOptionMember 2026-01-01 2026-03-31 0000012239 us-gaap:StockOptionMember 2026-03-31 0000012239 domh:UnderwritingServicesMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:CarriedInterestMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:CommissionsMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:PrincipalTransactionLossesMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:RealizedGainsMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:UnrealizedLossesMember us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-03-31 0000012239 domh:CarriedInterestMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:CommissionsMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:PrincipalTransactionLossesMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:RealizedGainsMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:UnrealizedLossesMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-03-31 0000012239 domh:OtherRevenueMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:ManagementFeesMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeFromCustomersMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeNonCustomersMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-03-31 0000012239 domh:OtherRevenueMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000012239 domh:ManagementFeesMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000012239 domh:InterestIncomeFromCustomersMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-31 0000012239 domh:UnderwritingServicesMember 2026-01-01 2026-03-31 0000012239 domh:UnderwritingServicesMember 2025-01-01 2025-03-31 0000012239 domh:CarriedInterestMember 2026-01-01 2026-03-31 0000012239 domh:CarriedInterestMember 2025-01-01 2025-03-31 0000012239 domh:CommissionsMember 2026-01-01 2026-03-31 0000012239 domh:CommissionsMember 2025-01-01 2025-03-31 0000012239 domh:InterestIncomeCustomersMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeCustomersMember 2025-01-01 2025-03-31 0000012239 domh:OtherMember 2026-01-01 2026-03-31 0000012239 domh:OtherMember 2025-01-01 2025-03-31 0000012239 domh:ManagementFeesMember 2026-01-01 2026-03-31 0000012239 domh:ManagementFeesMember 2025-01-01 2025-03-31 0000012239 domh:PrincipalTransactionsRevenueMember 2026-01-01 2026-03-31 0000012239 domh:PrincipalTransactionsRevenueMember 2025-01-01 2025-03-31 0000012239 domh:InterestIncomeNoncustomerMember 2026-01-01 2026-03-31 0000012239 domh:InterestIncomeNoncustomerMember 2025-01-01 2025-03-31 0000012239 domh:ABTCStockMember 2026-01-01 2026-03-31 0000012239 srt:MinimumMember 2026-03-31 0000012239 srt:MaximumMember 2026-03-31 0000012239 domh:Section382LimitationMember 2026-03-31 0000012239 domh:DominariSecuritiesMember 2026-03-31 0000012239 2023-06-30 2023-06-30 0000012239 2024-01-01 2024-12-31 0000012239 srt:MinimumMember 2024-01-01 2024-12-31 0000012239 srt:MaximumMember 2024-01-01 2024-12-31 0000012239 us-gaap:RelatedPartyMember 2026-03-31 0000012239 us-gaap:RelatedPartyMember 2025-12-31 0000012239 domh:NoncontrollingInterestsMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2026-01-01 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2026-01-01 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2026-01-01 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2026-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-01-01 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2025-01-01 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-01-01 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:DominariFinancialMember 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember domh:LegacyHoldingCoMember 2025-03-31 0000012239 domh:ChiefOperatingDecisionMakerMember 2025-03-31 0000012239 domh:ABTCMember us-gaap:SubsequentEventMember 2026-05-04 2026-05-04 0000012239 domh:ABTCMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-05-04 2026-05-04 shares iso4217:USD iso4217:USD shares pure domh:Segments 10-Q true 2026-03-31 2026 false 001-41845 DOMINARI HOLDINGS INC. DE 52-0849320 725 5th Avenue 23rd Floor New York NY 10022 (212) 393-4540 Common Stock ($0.0001 par value per share) DOMH NASDAQ Yes Yes Non-accelerated Filer true false false 22613781 27477000 34005000 6901000 46516000 11118000 9756000 21883000 3995000 11846000 11744000 1669000 1767000 2586000 2721000 1840000 2403000 85320000 112907000 777000 611000 25005000 17754000 364000 10335000 4679000 4504000 2744000 2841000 20174000 7318000 173000 53743000 43536000 0.0001 0.0001 50000000 50000000 5000000 5000000 3825 3825 3825 3825 0.0001 0.0001 5000000 5000000 834 834 834 834 0.0001 0.0001 0.0001 0.0001 100000000 100000000 22613781 16067435 22613781 16067435 2000 357099000 337505000 -325492000 -268134000 31609000 69371000 -32000 31577000 69371000 85320000 112907000 32949000 5606000 1096000 2490000 2190000 308000 39000 -1532000 -910000 494000 315000 35805000 7240000 68159000 15457000 36000 20944000 1485000 704000 876000 829000 2871000 2188000 73427000 40122000 -37622000 -32882000 108000 61000 21000 -7014000 -168000 221000 -320000 -6845000 394000 -44467000 -32488000 12868000 -57335000 -32488000 23000 -57358000 -32488000 -3.17 -3.17 -3.02 -3.02 18068269 18068269 10775219 10775219 4659 16067435 337505000 -268134000 69371000 69371000 6471346 2000 19241000 19243000 19243000 75000 317000 317000 317000 36000 36000 36000 -55000 -55000 -57358000 -57358000 23000 -57335000 4659 22613781 2000 357099000 -325492000 31609000 -32000 31577000 4659 7037022 263820000 60148 -501000 -223466000 39853000 1240969 7682000 7682000 3876054 13517000 13517000 2550000 20944000 20944000 7080000 7080000 -32488000 -32488000 4659 14704045 305963000 60148 -501000 -263034000 42428000 -57335000 -32488000 135000 52000 26000 26000 -320000 10080000 697000 7610000 19243000 28626000 36000 590000 -714000 -2122000 -259000 -6949000 -670000 -115000 468000 221000 -537000 2401000 17888000 -4848000 165000 520000 7251000 1210000 -97000 -122000 175000 632000 12856000 -173000 395000 -28942000 1235000 9185000 9035000 41736000 1776000 1666000 1242000 -102000 538000 1143000 98000 142000 32123000 -5436000 9971000 7080000 55000 13517000 317000 -9709000 6437000 -6528000 2236000 34005000 4079000 27477000 6315000 17000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1. Organization and Description of Business and Recent Developments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Organization and Description of Business</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Holdings Inc. (the “Company”), formerly Aikido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. The Company is in the process of winding down its historical pipeline of biotechnology assets held by Dominari Labs, LLC (formerly Aikido Labs, LLC). In an effort to enhance shareholder value, in June of 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker- dealer, a member of the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities is also licensed to provide investment advisory services and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank &amp; Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer, a member of FINRA and an investment adviser registered with the SEC. Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). The registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financials’ acquisition of FPS’ Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari Financial paid to the Seller $2.0 million in consideration for a transfer by the Seller to Dominari Financial 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional $1.4 million in consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the Membership Interests. As a result of the ownership change, FPS was renamed Dominari Securities LLC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 13, 2023, the Company entered into two separate Limited Liability Agreements with Dominari Manager LLC (“Manager”) and Dominari IM LLC (“Investment Manager”), which are both wholly owned subsidiaries and whose operations are included within the unaudited condensed consolidated financial statements of Dominari Holdings Inc. Manager was named as the manager of Dominari Master SPV LLC (the “Master SPV”), a limited liability company formed by the Company in 2022, and is responsible for the day-to-day operations of the Master SPV. Investment Manager was named the investment manager of Master SPV and is responsible for providing investment advice and decisions on behalf of the Master SPV. Beginning in March 2024, the Manager established various series of funds (the “Series”) of the Master SPV for the purpose of making investments in companies identified by the Investment Manager with proceeds generated by the sale of non-voting interests in such Series by the Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2025, the Company entered into two Limited Liability Agreements with American Ventures Management LLC (“AV Manager”) and American Ventures IM LLC (“AV Investment Manager”). The Company holds a ninety percent (90%) Membership Interest in each, and their operations are included within the condensed consolidated financial statements of Dominari Holdings Inc. AV Manager was named as the manager of American Ventures LLC (the “AV Master SPV”), a series limited liability company formed by AV Manager and owned by the investors of each fund series, and is responsible for the day-to-day operations of the AV Master SPV. AV Investment Manager was named the investment manager of the AV Master SPV and is responsible for providing investment advice and decisions on behalf of the AV Master SPV. AV Manager and AV Investment Manager are the managing members of AV Master SPV and may not be removed without their respective consent. The other members of AV Master SPV are the passive investing members of each series of funds (the “AV Series”) established under the AV Master SPV. The AV Manager established various AV Series of the AV Master SPV for the purpose of making investments in companies identified by the AV Investment Manager with proceeds generated by the sale of non-voting interests in such AV Series by the AV Master SPV to investors, in which the Company may, from time to time as it deems appropriate, also invest in such series alongside third-party investors.</p> 1 2000000 0.20 1400000 0.80 0.90 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2. Liquidity and Capital Resources</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company monitors its liquidity position on a regular basis The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to fund its activities through managing current cash on hand from the Company’s past equity offerings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, the Company has approximately $27.5 million of cash and cash equivalents and $6.9 million of marketable securities as well as $11.1 million of securities owned. Additionally, the Company had approximately $21.9 million in receivable from clearing brokers. Additionally, the Company’s working capital balance at March 31, 2026, totaled $21.9 million. Unless otherwise noted, all such funds are available to fund the Company’s operations. Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities, together with the anticipated cash flow to fund its operations for at least the next twelve months from the date of the issuance of these unaudited condensed consolidated financial statements.</p> 27500000 6900000 11100000 21900000 21900000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3. Summary of Significant Accounting Policies</b></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the 2025 Annual Report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Basis of Presentation and Principles of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheets as of March 31, 2026, condensed consolidated statements of operations for the three months ended March 31, 2026 and 2025, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2026 and 2025, and the condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026 or for any future interim period. The condensed consolidated balance sheets as of December 31, 2025 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial Inc., Dominari IM LLC, Dominari Manager LLC and Dominari Securities along with American Ventures IM LLC and American Ventures Manager LLC, both of which are owned 90% by the Company. All significant intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Joint Ventures</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its unaudited condensed consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of March 31, 2026, there has been no material activity in DFHS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, marketable securities, securities owned, the valuation of long-term equity investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Securities owned</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities owned consist of equity securities including, common stock and warrants of publicly traded companies which are held by Dominari Securities. Securities owned and securities sold, but not yet purchased are recorded in the balance sheet at fair value, with the change in fair value and any realized gains or losses upon purchase or sale recorded within the statement of operations as principal transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities may receive securities, including common or preferred stock and stock purchase warrants, from companies as part of its compensation for underwriting services. These instruments are stated at fair value in accordance with GAAP, and recorded within the balance sheet as securities owned. Such securities that the Company receives may be subject to contractual or instrument specific restrictions which prevent Dominari Securities from reselling the securities within the open market. Under ASC 820 only those restrictions which are an attribute of the instrument, and do not arise from any contractual agreement, are considered when determining fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company’s equity securities, which are held by Dominari Securities, are subject to restrictions as disclosed in Note 7. Equities that have periods of contractual trading restrictions, discounts were considered in determining fair value The Company’s significant unobservable inputs, included the implied probability of 15% of certain marketplace transactions and events occurring, which would permit the sale of equities held. These equities are included in securities owned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrant Investments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant fair values are primarily determined using a Black Scholes option pricing model, which includes the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value. Warrants held by Dominari Securities are included in securities owned and other warrants are included in marketable securities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following inputs are considered for determining the fair values of warrants:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The expected remaining term is equal to the time to expiration of the warrant investment.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Marketability discounts are applied for warrants that have sales restrictions (or lock-up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Receivable from Clearing Brokers</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receivable from Dominari Securities’ clearing brokers totaling $21.9 million consisted of approximately $0.5 million of liquid insured deposits $3.7 million of commission receivable and $17.7 million of liquid deposits maintained by the Company with its clearing brokers as of March 31, 2026. Receivable from Dominari Securities’ clearing brokers consisted of approximately $1.4 million of liquid insured deposits, $2.1 million of commissions receivable and $0.5 million of liquid deposits maintained by the Company with its clearing brokers as of December 31, 2025. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of March 31, 2026 and December 31, 2025 an allowance for credit losses was deemed not necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Long-term Equity Investments and marketable securities</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company holds certain strategic investments that are not part of its broker-dealer trading activities. The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying unaudited condensed consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are accounted for under ASC 321 using the measurement alternative. Equity method investments and other long-term investments that are not part of our broker-dealer trading activities are included in “long term equity investment” on the unaudited condensed consolidated balance sheet. These investments are generally strategic in nature and are not actively traded. Unrealized gains and losses on these investments are recognized in earnings when impairment is identified or when observable price changes occur and are classified in other income (loss) in the unaudited condensed consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Leases</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its leases under ASC 842, <i>Leases</i> (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 9 - <i>Leases</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Revenue</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue under ASC 606 - <i>Revenue from Contracts with Customers</i> (“ASC 606”)<i>.</i> Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized. The Company records such Non-Cash Consideration on the date at which its performance obligation is fulfilled using the date of contract inception as the fair value measurement date, as required by FASB ASC 606-10-32-21 and recorded as underwriting revenues. Any changes resulting from the form of the consideration after contract inception (e.g. fair value) are not included in the transaction price and, therefore, are included in principal transactions. To the extent changes in the noncash consideration occur for reasons other than the form of the consideration (e.g., notional quantity of instruments provided is based upon the Company’s performance), the Company applies relevant guidance on variable consideration, constraining such amounts until the associated uncertainty is resolved. Similarly, any commissions or compensation expense from providing non-cash consideration provided to employees and is recognized at fair value in accordance with ASC 820 on the same date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying unaudited condensed consolidated balance sheet.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Carried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high-water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Carried Interest Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to claw back or reversal.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">o</td><td style="text-align: justify">The Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">o</td><td style="text-align: justify">Management fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Principal transactions are recorded on a trade-date basis (as if they had settled). Realized and unrealized gains and losses arising from all securities transactions entered into for the account and risk of the Company are recorded in principal transactions in the accompanying statement of operations. These gains and losses are not in scope for ASC 606 as they are not generated from contracts with customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management As of March 31, 2026, the Company recognized $4.7 million of contract liabilities of which $1.1 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2031. During the three months ended March 31, 2026, the Company recognized revenue of $0.3 million that was included in contract liabilities as of March 31, 2026.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b-1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation and benefits</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation and benefits includes fixed salaries, commissions (paid in either cash or in securities), related benefits and stock-based compensation incurred on an accrual basis. The Company has a defined contribution 401(k) plan that covers all employees and allows an employer contribution of up to 50% of the first 3% of each participating employee’s eligible compensation contributed to the plan and 50% of the next two percent of each participating employee’s eligible compensation. Participants are 100% vested in these matching contributions when they are made. Eligible employees may elect to defer pre-tax contributions regulated under Section 401(k) of the Internal Revenue Code. The Company’s matching contributions are included in compensation and benefits in the unaudited condensed consolidated statements of operations. Please see “Stock based compensation” section below for additional information on stock-based compensation accounting policies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock-based Compensation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on either the simplified method, if applicable, which is the half-life from vesting to the end of its contractual term or when applicable, probability estimates of expected exercises of such options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for forfeitures as they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Income Taxes </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense for interim periods is calculated in accordance with ASC 740, Income Taxes, and ASC 740 270, Interim Reporting. Interim periods are treated as integral parts of the annual reporting period, and income tax expense is recognized using estimates that reflect management’s best assessment of the expected annual tax position, including discrete items recognized in the period incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Effect of new accounting pronouncements to be adopted in future periods</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity discloses more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassification of prior year amounts</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or stockholders’ equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Basis of Presentation and Principles of Consolidation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”), and in conformity with the rules and regulations of the SEC. In the opinion of management, these financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The condensed consolidated balance sheets as of March 31, 2026, condensed consolidated statements of operations for the three months ended March 31, 2026 and 2025, condensed consolidated statements of stockholders’ equity for the three months ended March 31, 2026 and 2025, and the condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2026 are not necessarily indicative of results to be expected for the year ending December 31, 2026 or for any future interim period. The condensed consolidated balance sheets as of December 31, 2025 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s policy is to consolidate all entities that it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Dominari Labs LLC (formerly, Aikido Labs LLC), Dominari Financial Inc., Dominari IM LLC, Dominari Manager LLC and Dominari Securities along with American Ventures IM LLC and American Ventures Manager LLC, both of which are owned 90% by the Company. All significant intercompany balances and transactions have been eliminated in consolidation.</p> 0.90 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Joint Ventures</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 21, 2024, the Company entered into a limited liability company operating agreement to form Dominari Financial Heritage Strategies LLC (“DFHS”). The Company has a 50% interest in DFHS. The purpose of DFHS is to sell various insurance products and services, including life insurance, private placement insurance, group medical plans, qualified plans, business insurance, and family office and estate planning services. The Company has determined it is not the primary beneficiary of DFH and thus will not consolidate the activities in its unaudited condensed consolidated financial statements. The Company will account for its interest in DFHS under the equity method accounting in accordance with ASC 323. As of March 31, 2026, there has been no material activity in DFHS.</p> 0.50 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, marketable securities, securities owned, the valuation of long-term equity investments, the valuation of notes receivable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Securities owned</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities owned consist of equity securities including, common stock and warrants of publicly traded companies which are held by Dominari Securities. Securities owned and securities sold, but not yet purchased are recorded in the balance sheet at fair value, with the change in fair value and any realized gains or losses upon purchase or sale recorded within the statement of operations as principal transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities may receive securities, including common or preferred stock and stock purchase warrants, from companies as part of its compensation for underwriting services. These instruments are stated at fair value in accordance with GAAP, and recorded within the balance sheet as securities owned. Such securities that the Company receives may be subject to contractual or instrument specific restrictions which prevent Dominari Securities from reselling the securities within the open market. Under ASC 820 only those restrictions which are an attribute of the instrument, and do not arise from any contractual agreement, are considered when determining fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company’s equity securities, which are held by Dominari Securities, are subject to restrictions as disclosed in Note 7. Equities that have periods of contractual trading restrictions, discounts were considered in determining fair value The Company’s significant unobservable inputs, included the implied probability of 15% of certain marketplace transactions and events occurring, which would permit the sale of equities held. These equities are included in securities owned.</p> 0.15 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Warrant Investments</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrant fair values are primarily determined using a Black Scholes option pricing model, which includes the underlying stock price, warrant strike price, expected remaining term, volatility, and risk-free rate as the primary inputs to the model. Increases or decreases in any of these inputs could result in a material change in fair value. Additionally, for warrants that have periods of contractual trading restrictions, marketability discounts were considered in determining fair value. Warrants held by Dominari Securities are included in securities owned and other warrants are included in marketable securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following inputs are considered for determining the fair values of warrants:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The underlying stock price is equal to the closing price of the underlying stock as of the measurement date.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The expected remaining term is equal to the time to expiration of the warrant investment.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant investment price.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining term of the warrant investment.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Marketability discounts are applied for warrants that have sales restrictions (or lock-up periods). These discounts are calculated using a combination of the Finnerty Model and the Asian Put Model using a term equal to the period of such restriction.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Receivable from Clearing Brokers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receivable from Dominari Securities’ clearing brokers totaling $21.9 million consisted of approximately $0.5 million of liquid insured deposits $3.7 million of commission receivable and $17.7 million of liquid deposits maintained by the Company with its clearing brokers as of March 31, 2026. Receivable from Dominari Securities’ clearing brokers consisted of approximately $1.4 million of liquid insured deposits, $2.1 million of commissions receivable and $0.5 million of liquid deposits maintained by the Company with its clearing brokers as of December 31, 2025. Such amount is stated at the amount the Company expects to collect. The Company maintains allowances for credit losses for estimated losses resulting from the inability of its clearing brokers to make required payments. Management considers the following factors when determining the collectability of specific accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. As of March 31, 2026 and December 31, 2025 an allowance for credit losses was deemed not necessary.</p> 21900000 500000 3700000 17700000 1400000 2100000 500000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Long-term Equity Investments and marketable securities</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company holds certain strategic investments that are not part of its broker-dealer trading activities. The Company accounts for long-term equity investments under Accounting Standards Codification (“ASC”) 321 “Investments-Equity Securities” (“ASC 321”). In accordance with ASC 321, equity securities with readily determinable fair values are accounted for at fair value based on quoted market prices. Any equity securities with a readily determinable fair value are included within marketable securities on the accompanying unaudited condensed consolidated balance sheet. Equity securities without readily determinable fair values are accounted for either at net asset value or using the measurement alternative. Under the measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. These investments are accounted for under ASC 321 using the measurement alternative. Equity method investments and other long-term investments that are not part of our broker-dealer trading activities are included in “long term equity investment” on the unaudited condensed consolidated balance sheet. These investments are generally strategic in nature and are not actively traded. Unrealized gains and losses on these investments are recognized in earnings when impairment is identified or when observable price changes occur and are classified in other income (loss) in the unaudited condensed consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Leases</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its leases under ASC 842, <i>Leases</i> (“ASC 842”). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the condensed consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred (see Note 9 - <i>Leases</i>).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Revenue</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue under ASC 606 - <i>Revenue from Contracts with Customers</i> (“ASC 606”)<i>.</i> Revenue is recognized when control of the promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following provides detailed information on the recognition of the Company’s revenue from contracts with customers:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Underwriting services include underwriting and private placement agent services in both the public and private equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenue are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. The Company expenses any costs associated with underwriting transactions and they are recorded on a gross basis within the general and administrative line item in the condensed consolidated statements of operations as the Company is acting as a principal in the arrangement. The Company applies the practical expedient under ASC 606, as any such costs would by amortized in one year or less. The Company also provides investment banking services. Investment banking services typically include fees earned for acting as a financial advisor for mergers and acquisitions or similar transactions. These services provided by the Company are not distinct from the potential transaction that may occur. Due to this, the Company believes the performance obligation for providing investment banking services is satisfied when the earliest occurs (i) termination of the engagement letter, (ii) expiration of engagement letter or (iii) successful transaction has occurred.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any non-cash consideration earned by the Company in providing the aforementioned services is recorded at fair value in accordance with ASC 820, on the date that revenue is recognized. The Company records such Non-Cash Consideration on the date at which its performance obligation is fulfilled using the date of contract inception as the fair value measurement date, as required by FASB ASC 606-10-32-21 and recorded as underwriting revenues. Any changes resulting from the form of the consideration after contract inception (e.g. fair value) are not included in the transaction price and, therefore, are included in principal transactions. To the extent changes in the noncash consideration occur for reasons other than the form of the consideration (e.g., notional quantity of instruments provided is based upon the Company’s performance), the Company applies relevant guidance on variable consideration, constraining such amounts until the associated uncertainty is resolved. Similarly, any commissions or compensation expense from providing non-cash consideration provided to employees and is recognized at fair value in accordance with ASC 820 on the same date.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Commissions are earned by executing transactions for clients primarily in equity, equity-related, and debt products. Commission revenue associated with trade execution are recognized at a point in time on trade-date. Commissions revenue are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date and are included in receivable from clearing brokers on the accompanying unaudited condensed consolidated balance sheet.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Carried interest fees are earned based on performance of the vehicle during the period, subject to the achievement of minimum return levels, or high-water marks, in accordance with the respective terms set out in each vehicle’s governing agreements. Carried interest is a form of variable consideration in the Company’s contracts with investment management customers and is fully constrained at contract inception. Carried interest fees are not recognized as revenue until (a) it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, or (b) the uncertainty associated with the variable consideration is subsequently resolved. Carried Interest Fees are typically recognized as revenue when realized at the end of the measurement period. Once realized, such fees are not subject to claw back or reversal.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Account advisory and management fees are two revenue streams which are both recognized over time. Please see further description below:</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">o</td><td style="text-align: justify">The Company earns revenue for performing account advisory and investment advisory services for customers based on contractually fixed rates applied, as a percentage, to the market value of assets in a customer’s account. The performance obligation for investment advisory services is considered a series of distinct services that are substantially the same and are satisfied each day of the contract and are recognized as revenue over time. Investment advisory fees are payable in arrears on a quarterly basis.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">o</td><td style="text-align: justify">Management fees represent asset-based fees received in exchange for providing management services to certain related party pooled investment vehicles (funds). These fees are charged based upon contractually fixed rates applied, as a percentage, to the total assets of those pooled investment vehicles managed by the Company at the date upon which an investor subscribes into the fund, subsequently deferred. The Company recognizes these revenues over time as the Company has determined that the customer simultaneously receives and consumes the benefits of the management services as they are provided. Revenues are typically recognized over a period of five years, which the Company has estimated to be a reasonable estimate of the period during which the Company shall provide management services.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Principal transactions are recorded on a trade-date basis (as if they had settled). Realized and unrealized gains and losses arising from all securities transactions entered into for the account and risk of the Company are recorded in principal transactions in the accompanying statement of operations. These gains and losses are not in scope for ASC 606 as they are not generated from contracts with customers.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Contract liabilities relate to payments received in advance of performance under the contract and are the result of remaining performance obligations for management services. Contract liabilities are recognized as revenues when the Company provides ongoing investment management As of March 31, 2026, the Company recognized $4.7 million of contract liabilities of which $1.1 million is expected to be recognized within a year. The remaining balance is expected to be recognized through 2031. During the three months ended March 31, 2026, the Company recognized revenue of $0.3 million that was included in contract liabilities as of March 31, 2026.</td> </tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Other revenue includes amounts recognized over time and at a point in time. Amounts recognized over time are recognized ratably over the period that such services are provided which are distinct from the services provided in other periods. Types of other revenue include trailing fees for mutual funds 12b-1, variable annuity, fixed annuities, and insurance products. These trailing fees are paid by product partners for ongoing services and/or advice provided to underlying investor accounts. Trailing fees are recognized as income when earned, usually monthly or quarterly as net asset value is determined. As the value of the eligible assets in an advisory account is susceptible to changes due to customer activity, this revenue includes variable consideration and is constrained until the date that the fees are determinable.</td> </tr></table> 4700000 1100000 300000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Compensation and benefits</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation and benefits includes fixed salaries, commissions (paid in either cash or in securities), related benefits and stock-based compensation incurred on an accrual basis. The Company has a defined contribution 401(k) plan that covers all employees and allows an employer contribution of up to 50% of the first 3% of each participating employee’s eligible compensation contributed to the plan and 50% of the next two percent of each participating employee’s eligible compensation. Participants are 100% vested in these matching contributions when they are made. Eligible employees may elect to defer pre-tax contributions regulated under Section 401(k) of the Internal Revenue Code. The Company’s matching contributions are included in compensation and benefits in the unaudited condensed consolidated statements of operations. Please see “Stock based compensation” section below for additional information on stock-based compensation accounting policies.</p> 0.50 0.03 0.50 0.02 1 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock-based Compensation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on either the simplified method, if applicable, which is the half-life from vesting to the end of its contractual term or when applicable, probability estimates of expected exercises of such options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for forfeitures as they occur.</p> P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Income Taxes </i></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense for interim periods is calculated in accordance with ASC 740, Income Taxes, and ASC 740 270, Interim Reporting. Interim periods are treated as integral parts of the annual reporting period, and income tax expense is recognized using estimates that reflect management’s best assessment of the expected annual tax position, including discrete items recognized in the period incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Effect of new accounting pronouncements to be adopted in future periods</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU No. 2024-03, “Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures.” This ASU requires that each interim and annual reporting period, an entity discloses more information about the components of certain expense captions that is currently disclosed in the financial statements. This update is effective for annual reporting periods beginning after December 15, 2026. Early adoption is permitted. Management is currently evaluating the effects this guidance will have on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on these unaudited condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassification of prior year amounts</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to the prior years’ financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or stockholders’ equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4. Marketable Securities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2026 and 2025, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Realized gain / (loss)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,949</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(732</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unrealized gain / (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(115</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">468</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Interest and dividend income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,014</td><td style="vertical-align: middle; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(168</td><td style="vertical-align: middle; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three months ended March 31, 2026 and 2025, which are recorded as a component of gains and (losses) on marketable securities on the unaudited condensed consolidated statements of operations, are as follows ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Realized gain / (loss)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,949</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(732</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Unrealized gain / (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(115</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">468</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Interest and dividend income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,014</td><td style="vertical-align: middle; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(168</td><td style="vertical-align: middle; text-align: left">)</td></tr> </table> -6949000 -732000 -115000 468000 50000 96000 -7014000 -168000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5. Long-Term Equity Investments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company holds interests in several privately held companies as long-term investments. The following table presents the Company’s long-term investments as of March 31, 2026, and December 31, 2025 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Kerna Health</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in">Masterclass)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a.Kraken)* *</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,248</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.)**</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Discord Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Automation Anywhere, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">397</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in AdvEn Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">102</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">102</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,601</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,846</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,499</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,744</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">Investment made in these companies are through both an SPV and direct investments.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had <span style="-sec-ix-hidden: hidden-fact-81">no</span> changes to the carrying values for the three months ended March 31, 2026, and recorded an increase in the carrying values of approximately $0.3 million for the three months ended March 31, 2025. Please see below details of the changes in carrying value by investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investment in Dominari Master SPV LLC Series XII (Groq, Inc.) </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 25, 2024, the Company entered into an agreement (the “Groq Agreement”) with Dominari Master SPV LLC whereby the Company agreed to purchase 25,000 Series XII Groq Units for $25 thousand. As of March 31, 2026, there was <span style="-sec-ix-hidden: hidden-fact-82">no</span> change to the carrying value. On April 6, 2026, the Company received a payment of $58 thousand as a payment related to the Company’s investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investment in TracX. </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 13, 2026, the Company entered into an agreement (the “TracX Agreement”) with American Ventures LLC whereby the Company agreed to purchase Series XX TracX Logis units for $102 thousand.</p> The following table presents the Company’s long-term investments as of March 31, 2026, and December 31, 2025 ($ in thousands):<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Carrying</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Cost Basis</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Kerna Health</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Revere Master SPV Series 1 (Qxpress Pte Ltd)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in MW LSV MasterClass, LLC (Yanka Industries, Inc. d.b.a.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in">Masterclass)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Payward, Inc. and MWSI VC Kraken-II, LLC (Payward, Inc. d.b.a.Kraken)* *</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">364</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Aeon Partners Fund Series EG (Epic Games, Inc.)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,248</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Tesspay, Inc. and Revere Master SPV Series VI (TessPay, Inc.)**</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,240</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Discord Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Automation Anywhere, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">476</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">397</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Dominari Master SPV LLC Series VI (X.AI Corp. d.b.a. xAI)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Dominari Master SPV LLC Series XI (Cerebras Systems Inc.)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in Dominari Master SPV LLC Series XII (Groq, Inc.)*</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investment in AdvEn Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Investment in American Ventures LLC Series XX (TracX Logis Pte Ltd..)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">102</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">102</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,601</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,846</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,499</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,744</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">Investment made in these companies are through both an SPV and direct investments.</td> </tr></table> 2140000 4940000 2140000 4940000 1000000 1000000 1000000 1000000 170000 170000 170000 170000 597000 364000 597000 364000 3500000 2248000 3500000 2248000 1240000 1240000 1240000 1240000 476000 476000 476000 476000 476000 397000 476000 397000 100000 109000 100000 109000 25000 25000 25000 25000 25000 25000 25000 25000 750000 750000 750000 750000 102000 102000 10601000 11846000 10499000 11744000 300000 25000 25000 58000 102000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6. Notes Receivable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, and December 31, 2025, the Company had <span style="-sec-ix-hidden: hidden-fact-83"><span style="-sec-ix-hidden: hidden-fact-84">no</span></span> notes receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>American Innovative Robotics, LLC</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded interest income of approximately $20,000, and a realized gain on the note of approximately $221,000 on the American Innovative Robotics Promissory Note in the 31, 2025. The note was fully paid off as of March 24, 2025, with proceeds totaling $1.1 million, resulting in an ending value of $0.</p> 20000000 221000000 1100000 0 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7. Fair Value of Financial Assets and Liabilities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, including cash and cash equivalents, accounts payable and accrued expenses and accrued compensation and commissions are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company uses three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Level 1 - quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2026 and December 31, 2025 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measured as of March 31, 2026</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Quoted</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Significant</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Total at</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">prices in<br/> Active</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">other<br/> observable </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Significant<br/> unobservable</b></td><td style="white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">March 31,</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Markets</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">inputs</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">inputs</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2026</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">(Level 1)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">(Level 2)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">(Level 3)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 52%; text-align: left">Securities owned</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,467</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,651</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,494</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">—</div></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measured as of December 31, 2025</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Quoted</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Significant</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Total at</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">prices in active</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">other observable</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Significant unobservable</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> markets</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">inputs</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">inputs</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 52%; text-align: left">Securities owned</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,756</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,014</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">46,516</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">45,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">—</div></td><td style="text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of level 3 securities owned totaling $1.7 million shown above at March 31, 2026 are subject to an initial lock-up period until approximately June 30, 2026, and further restrictions to which the Company cannot liquidate its investment until such restrictions are met. Additionally, approximately $1.1 million of fair value of level 2 securities owned shown above at March 31, 2026 represents warrants that are subject to lock-up periods that will end by June 30, 2026 and another $4.3 million of fair value of warrant securities with lock-up periods that will end by September 30, 2026 as well.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Level 3 Measurement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Securities owned at fair value as of December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized loss included in principal transactions</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Securities owned at fair value as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,651</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company’s Level 3 fair value measurements at March 31, 2026 were determined by the following quantitative inputs:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The underlying stock price of $10.01 per share as of the measurement date.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Implied success rates of similar type instruments from other comparable entities’ recent historical results of 15% of the underlying value of the stock price.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents the Company’s assets and liabilities that are measured at fair value as of March 31, 2026 and December 31, 2025 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measured as of March 31, 2026</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Quoted</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Significant</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Total at</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">prices in<br/> Active</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">other<br/> observable </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><b>Significant<br/> unobservable</b></td><td style="white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">March 31,</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Markets</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">inputs</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">inputs</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">2026</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">(Level 1)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">(Level 2)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">(Level 3)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 52%; text-align: left">Securities owned</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,118</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,467</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,651</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,494</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,407</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">—</div></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measured as of December 31, 2025</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Quoted</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold">Significant</td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold"> </td><td style="white-space: nowrap; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Total at</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">prices in active</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">other observable</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">Significant unobservable</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold"> markets</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">inputs</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">inputs</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 1)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 2)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 52%; text-align: left">Securities owned</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,756</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">—</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,014</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Marketable securities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">46,516</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">45,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,467</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">—</div></td><td style="text-align: left"> </td></tr> </table> 11118000 9467000 1651000 6901000 5494000 1407000 9756000 8014000 1742000 46516000 45049000 1467000 1700000 1100000 4300000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Securities owned at fair value as of December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized loss included in principal transactions</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Securities owned at fair value as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,651</td><td style="text-align: left"> </td></tr> </table> 1741000 -90000 1651000 10.01 0.15 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8. Prepaid expenses and other assets </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other assets consist of the following as of March 31, 2026, and December 31, 2025 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">480</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">805</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Security deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">483</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">483</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">769</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">980</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,840</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,403</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other assets consist of the following as of March 31, 2026, and December 31, 2025 ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">480</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">805</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Security deposits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">483</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">483</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">769</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">980</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,840</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,403</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 480000 805000 483000 483000 108000 135000 769000 980000 1840000 2403000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9. Leases</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2021, the Company entered into a Lease Agreement (the “Company’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under the Company’s Lease, the Company rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the “22<sup>nd</sup> Floor Premises”). The Company currently uses the 22<sup>nd</sup> Floor Premises to run its day-to-day operations. The initial term of the Company’s Lease is seven (7) years commencing on July 11, 2022 (“Commencement Date). Under the Company’s Lease, the Company is required to pay monthly rent, commencing on January 11, 2023, equal to $12,874. Effective for the sixth and seventh years of the Company’s Lease, the rent shall increase to $13,502. The Company took possession of the 22<sup>nd</sup> Floor Premises on the Commencement Date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2022, Dominari Financial entered into a Lease Agreement (“Dominari Financial’s Lease”) with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari Financial’s Lease, Dominari Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the “23<sup>rd</sup> Floor Premises”). Dominari Financial currently uses the 23rd Floor Premises to run its day-to-day operations. The initial term of Dominari Financial’s Lease is seven (7) years commencing on the date that possession of the 23rd Floor Premises is delivered to Dominari Financial. Under Dominari Financial’s Lease, Dominari Financial is required to pay monthly rent equal to $49,368. Effective for the sixth and seventh years of Dominari Financial’s Lease, the rent shall increase to $51,868 per month. The Company took possession of the 23rd Floor Premises in February 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2025, the Company entered into a Lease Agreement (the “Company’s Florida Lease”) with Blue Diamond Towers, LLC, a Delaware limited liability company. Under the Company’s Florida Lease, the Company rents a portion of the first floor designated as Suite 103 of the North Building at 3835 PGA Boulevard in Palm Beach Gardens, Florida, (the “Florida Premises”). The Company will use the Florida Premises as Executive Offices. The initial term of the Company’s Florida Lease is two (2) years commencing on October 1, 2025. Under the Company’s Florida Lease, the Company is required to pay monthly rent, commencing on October 1, 2025, equal to $10,000. Effective for the second year of the Company’s Florida Lease, the rent shall increase to $10,300. The Company took possession of Florida Premises in October 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tables below represent the Company’s lease assets and liabilities as of March 31, 2026:</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">March 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets:</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating lease right-of-use-assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,586</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Operating</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">568</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Long-term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,744</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">March 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Weighted-average remaining lease term - operating leases (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.0</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended March 31, 2026 and 2025, the Company recorded approximately $0.2 million and $0.2 million, respectively, of lease expense to current period operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating leases</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt">As of March 31, 2026, future minimum payments during the next five years and thereafter are as follows:</span></p> <p style="margin: 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Remaining period Ended December 31, 2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">638</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Year Ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">801</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Year Ended December 31, 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,366</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(622</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,744</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> P7Y 12874000 13502000 P23Y 49368000 51868000 P2Y 10000000 10300000 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tables below represent the Company’s lease assets and liabilities as of March 31, 2026:</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">March 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Assets:</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating lease right-of-use-assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,586</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Operating</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">568</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Long-term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Operating</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,744</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC 842:</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">March 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Weighted-average remaining lease term - operating leases (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.0</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.0</td><td style="text-align: left">%</td></tr> </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2026</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating leases</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net rent expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">208</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 2586000 568000 2176000 2744000 P4Y 0.10 200000 200000 205000 178000 3000 22000 208000 200000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt">As of March 31, 2026, future minimum payments during the next five years and thereafter are as follows:</span></p> <p style="margin: 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Remaining period Ended December 31, 2026</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">638</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Year Ended December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">801</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Year Ended December 31, 2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">784</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year Ended December 31, 2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,366</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Less present value discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(622</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Operating lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,744</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> P5Y 638000 801000 766000 784000 377000 3366000 622000 2744000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10. Net Loss per Share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share of common stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding for the period. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock as of the first day of the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended March 31, 2026, and 2025 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Convertible preferred stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,362,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,175,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">396,346</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,072,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">346,654</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,831,124</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,571,876</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the years ended March 31, 2026, and 2025 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Convertible preferred stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">34</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,362,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,175,188</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock awards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">396,346</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase common stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,072,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">346,654</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,831,124</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,571,876</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 34 34 6362098 8175188 396346 50000 10072646 346654 16831124 8571876 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11. Stockholders’ Equity and Convertible Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, there are 22,613,781 shares of common stock issued and outstanding This includes 316,346 unvested shares issued that are subject to forfeiture through September 30, 2026, and 80,000 unvested shares issued that are subject to forfeiture through December 11, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 10, 2025, the Company entered into securities purchase agreements with certain accredited investors for the sale by the Company of 1,439,467 registered shares of its common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants in a direct offering. In a concurrent private placement, the Company entered into securities purchase agreements with certain accredited investors for the sale of 2,436,587 unregistered shares of common stock, and the same amount of unregistered Series A warrants and unregistered Series B warrants were issued at a combined purchase price of $3.47 per share and accompanying warrants (the “February 2025 Financings”). The Series A warrants are exercisable immediately upon issuance at an exercise price of $3.72 per share and will expire five years from the date of issuance. The Series B warrants are exercisable immediately upon issuance at an exercise price of $4.22 per share and will expire five years from the date of issuance. The net proceeds to the Company from the February 2025 Financings were approximately $13.5 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 10, 2025, the Company entered into advisory agreements with various individuals who were issued shares of common stock. The agreements are for a term of two years but are cancellable by either party. As part of these agreements, 2,550,000 shares of common stock were issued on February 18, 2025. An additional 850,000 shares may be issued under the terms of the agreements when certain provisions are met, which as of the date of grant is probable. These shares are nonforfeitable and thus were fully expensed by the Company at the time of grant. The Company used a Monte Carlo simulation to calculate the grant date fair value of the common stock. The fair value of issued shares amounted to $20.9 million and is presented in advisory fees expense on the unaudited condensed consolidated statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the unregistered shares, the warrants, and the shares of common stock underlying the warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain officers, directors, employees and members of the Company’s advisory board participated in the February 2025 Financings on the same terms as the other investors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period January 1, 2026 to March 31, 2026, various individuals exercised warrants, resulting in the additional issuance of 75,000 shares of common stock and cash proceeds of $0.3 million, which were recorded in additional paid-in capital and are reflected in the unaudited condensed consolidated statements of changes in stockholders’ equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series D Convertible Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the acquisition of North South’s patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock (“Series D Preferred Stock”) to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2026, and December 31, 2025, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series D-1 Convertible Preferred Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s Series D-1 Convertible Preferred Stock (“Series D-1 Preferred Stock”) was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of $0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company’s business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an “as converted” basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company’s stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company’s outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company’s Series D-1 Preferred Stock on a one-for-one basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2026 and December 31, 2025, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividends</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2025, the board of directors approved a special cash dividend of $0.32 per share payable on March 3, 2025, to holders of common stock and certain warrant holders as of close of business on February 24, 2025. On September 9, 2025, the board of directors approved a special cash dividend of $0.22 per share payable on September 26, 2025, to holders of common stock and certain warrant holders as of close of business on September 3, 2025. On December 11, 2025, the board of directors approved a special cash dividend of $0.432 per share payable on January 26, 2026, to holders of common stock and certain warrant holders as of close of business on January 5, 2026, Cash dividends declared in 2025 totaled $22.2 million and have been charged to accumulated deficit. Dividends paid for the three months ended March 31, 2025, totaled $7.0 million, and dividends paid for the three months ended September 30, 2025, totaled $4.9 million. Dividends declared totaled $10.3 million during the three months ended December 31, 2025, of which $9.9 million were paid during the three months ended March 31, 2026, resulting in a dividend payable of $0.4 million as of March 31, 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of warrant activity for the three months ended March 31, 2026, is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total Intrinsic</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Value <span style="text-decoration:underline">($</span>000s)</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life (in years)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6,690,768</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,186</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(253,670</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">34.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">4.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,362,098</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">4.25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">              -</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Restricted Stock Awards and Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”). The 2022 Plan provided for the issuance of up to 1,100,000 shares in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards. The 2022 Plan expires on January 1, 2032, and is administered by the Dominari Holdings’ board of directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 10, 2025, the Company issued 50,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $308,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 10, 2025, the Company issued 351,851 shares of the Company’s common stock to Messrs. Christopher Devall under the Company’s 2022 Equity Incentive Plan. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value $2.1 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2025 in connection with the closing of the PIPE, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant to Messrs. Anthony Hayes. Pursuant to the Committee’s decision, he received 500,000 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $3.4 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 11, 2025, the Company executed grant agreements with each of Messrs. Anthony Hayes and Kyle Wool pursuant to their employment agreements with the Company, and in accordance with the Company’s 2022 Equity Incentive Plan. Pursuant to the grant agreements, each received 154,559 shares of the Company’s common stock. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $1.7 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 10, 2025, the Company issued 316,346 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. These shares will vest on September 30, 2026; provided that in the event of a change in control prior to any such vesting date, the shares, which have not yet vested shall vest and become nonforfeitable upon the effective date of such change in control, with a total fair value of $1.3 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2025, the Company issued 80,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan. These shares will vest on the one-year anniversary of the grant date; provided that in the event of a change in control prior to any such vesting date, the shares, which have not yet vested shall vest and become nonforfeitable upon the effective date of such change in control, with a total fair value of $381 thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2026, the Company issued 75,000 shares of the Company’s common stock under the Company’s 2022 Equity Incentive Plan to members of the board of directors. Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of $320 thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 4, 2026, the Committee determined that it is in the best interests of the Company and its stockholders to make a special equity grant of 3.0 million shares of the Company’s common stock each to Messrs. Anthony Hayes and Kyle Wool, pursuant to shareholder approval to increase the shares of common stock reserved for issuance under the Company’s 2022 Equity Incentive Plan, which was approved on March 4, 2026 at a Special Meeting of Shareholders Upon issuance, the shares were fully-vested and nonforfeitable with a total fair value of approximately $18.4 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt">See Restricted Stock roll-forward below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt">A summary of restricted stock awards activity for the three months ended March 31, 2026, is presented below:</span></p> <p style="margin: 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Restricted</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Grant Day</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Nonvested at December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">396,346</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,075,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,075,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Nonvested at March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">396,346</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation associated with restricted stock awards was approximately $19.2 million and $7.6 million for the three months ended March 31, 2026, and 2025, respectively. All stock compensation was recorded as a component of compensation and benefits expenses. The 396,346 nonvested restricted stock units that were approved in December 2025 in the table above are reflected as being issued in the unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2026, there is approximately $1.1 million unrecognized stock-based compensation expense related to restricted stock awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 10, 2025, the Company granted an additional 5.0 million fully vested nonqualified stock options (each, a “Performance Award” and collectively, the “Performance Awards”) each to Anthony Hayes and Kyle Wool conditioned upon either the Company’s shareholders approving the Performance Awards or approving an increase in the share reserve of the Company’s 2022 Equity Incentive Plan (the “Plan”) such that the full number of shares underlying the Performance Awards could be delivered under the Plan. On April 1, 2025, following a special meeting of shareholders, the Company’s shareholders voted to approve an increase in the Plan’s share reserve allowing the Performance Awards to be delivered under the Plan. The Company recorded an expense of $26.1 million for the Performance Awards during the second quarter of 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2025, the Company entered into an advisory agreement with a certain individual who was issued 50,000 nonqualified stock options (“Advisor Options”). Each party reserves the right to terminate the agreement at any time, with or without cause, upon five (5) days prior written notice to the other party. One half of the Advisor Options shall vest and become exercisable during its term on December 1, 2025, and one half of the Advisor Options shall vest and become exercisable during its term on June 1, 2026, in the manner and subject to the terms and conditions of the Plan and the Stock Option Grant Agreement (the “Option Grant Agreement”). The Company used a Black Scholes valuation to calculate the grant date fair value of the Advisor Options. The fair value of the Advisor Options amounted to $146 thousand and the Company recorded an expense of $36 thousand during the three months ended 2026 related to such options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2026, is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,072,646</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.16</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Employee options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Employee options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Employee options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,072,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.16</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,064,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.8</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation associated with stock options was approximately $36 thousand and $38 thousand for the three months ended March 31, 2026, and 2025, respectively. All stock compensation was recorded as a component of compensation and benefits expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Estimated future stock-based compensation expense relating to unvested stock options is approximately $24 thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Non-controlling Interest</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously discussed, the Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of March 31, 2026, the revenue attributable to non-controlling interest was $23 thousand of which the Company owes $21 thousand at March 31, 2026. During the three months ended March 31, 2026, the Company distributed $55 thousand to non-controlling interests.</p> 22613781 22613781 316346 80000 1439467 3.47 2436587 3.47 3.72 P5Y 4.22 P5Y 13500000 2550000 850000 20900000 75000 300000 1379685 0.0001 10 1373 5000000 5000000 3825 3825 3825 3825 0.0001 10 1373 5000000 5000000 834 834 834 834 0.32 0.22 0.432 22200000 7000000 4900000 10300000 9900000 400000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of warrant activity for the three months ended March 31, 2026, is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total Intrinsic</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrants</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-size: 10pt"><b>Value <span style="text-decoration:underline">($</span>000s)</b></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life (in years)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6,690,768</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,186</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(253,670</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">34.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">4.22</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6,362,098</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">4.25</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">              -</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 6690768 5.38 6186000 P3Y10M24D 253670 34 75000 4.22 6362098 4.25 P3Y9M18D 1100000 50000 308000 351851 2100000 500000 3400000 154559 1700000 316346 1300000 80000 381000 75000 320000 3000000 18400000 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt">A summary of restricted stock awards activity for the three months ended March 31, 2026, is presented below:</span></p> <p style="margin: 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Restricted</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Grant Day</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Nonvested at December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">396,346</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,075,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,075,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Nonvested at March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">396,346</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.29</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 396346 4.29 6075000 3.08 6075000 3.08 396346 4.29 19200000 7600000 396346 1100000 5000000 26100000 50000 146000 36000 <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of option activity under the Company’s stock option plan for the three months ended March 31, 2026, is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Outstanding as of December 31, 2025</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">10,072,646</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.16</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">9.1</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 0.125in">Employee options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Employee options exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Employee options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of March 31, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,072,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.16</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Options vested and exercisable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,064,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.8</td><td style="text-align: left"> </td></tr> </table> 10072646 6.16 26000 P9Y1M6D 10072646 6.16 P8Y9M18D 10064313 6.17 P8Y9M18D 36000 38000 24000 0.90 0.10 0.10 23000 21000 55000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 12. Revenue</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Disaggregation of Revenue</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2026, and 2025 total revenue and revenue related to contracts with customers within the scope of Topic 606 were ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Revenues</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Underwriting services</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,606</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Carried interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,190</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Interest income – customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">265</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Total revenue from contracts with customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Principal transactions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,532</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(910</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest income – noncustomer</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">35,805</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,240</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Revenue Recognized at a Point in Time</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue that is transactional in nature and such revenue is earned at a point in time. For the three months ended March 31, 2026, revenue that was recognized at a point in time includes underwriting services of $32.9. million, carried interest of $1.1 million, commissions of $2.5 million and principal transactions losses of $1.5 million consisting of $0.6 million of realized gains and $2.1 million of unrealized losses. For the three months ended March 31, 2025, revenue that is recognized at a point in time includes underwriting services of $5.6 million, commissions of $2.2 million, and principal transactions losses of $0.9 million consisting of $0.3 million of realized gains and $1.2 million of unrealized losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Revenue Recognized Over Time</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue over a period of time, generally monthly on a straight-line basis, as services are performed, and performance obligations are satisfied. For the three months ended March 31, 2026, revenue that is recognized over time includes other revenue of $230 thousand, management fees of $265 thousand, interest income from customers of $72 thousand, and interest income-noncustomers of $235 thousand. For the three months ended March 31, 2025, revenue that was recognized over time includes other revenue of $233 thousand, management fees of $66 thousand, and interest income from customers of $53 thousand.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2026, and 2025 total revenue and revenue related to contracts with customers within the scope of Topic 606 were ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Revenues</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Underwriting services</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,949</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,606</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Carried interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,490</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,190</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Interest income – customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">230</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">249</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Management fees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">265</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Total revenue from contracts with customers</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">8,150</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Principal transactions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,532</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(910</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Interest income – noncustomer</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total revenue</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">35,805</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,240</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 32949000 5606000 1096000 2490000 2190000 72000 39000 230000 249000 265000 66000 37102000 8150000 -1532000 -910000 235000 35805000 7240000 32900000 1100000 2500000 1500000 600000 2100000 5600000 2200000 900000 300000 1200000 230000 265000 72000 235000 233000 66000 53000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 13. Commitments and Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Legal Proceedings</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be subject to certain legal and other claims that arise in the ordinary course of its business. In particular, the Company and its subsidiaries may be named in and subject to various proceedings and claims arising primarily from the Company’s securities business activities, including lawsuits, arbitration claims, class actions, and regulatory matters. Some of these claims may seek substantial compensatory, punitive, or indeterminate damages. The Company and its subsidiaries may also be subject to other reviews, investigations, and proceedings by governmental and self-regulatory organizations regarding the Company’s business, which may result in adverse judgments, settlements, fines, penalties, injunctions, and other relief. Due to the inherent difficulty of predicting the outcome of litigation and other claims the Company cannot state with certainty what the eventual outcome of potential litigation or other claims will be. Notwithstanding this uncertainty, the Company does not believe that the results of these potential claims are likely to have a material effect on its financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives’ former employer. This notice was filed against the Company’s subsidiary, Dominari Securities. The Company does not agree with the plaintiff’s claims. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of the Company’s technology. Other than ordinary routine litigation incidental to the business, the Company is not aware of any material, active or pending legal proceedings brought against it.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 14. Income Taxes </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s income tax expense (benefit) for the three months ended March 31, 2026 is as follows ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">U.S. Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,537</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,331</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Current income tax expense (benefit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">U.S. Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Deferred income tax expense (benefit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Total income tax expense (benefit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes in accordance with ASC 740, Income Taxes. For interim periods, the Company applies the estimated annual effective tax rate (“AETR”) method in accordance with ASC 740-270. Under this method, income tax expense for interim periods is computed by applying the estimated annual effective tax rate to year-to-date ordinary pretax income (loss) and adjusting for the tax effects of discrete items recognized in the period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2026, the Company recorded income tax expense despite reporting a pretax loss. This result is primarily attributable to a significant permanent difference related to the limitation on the deductibility of certain executive compensation under Internal Revenue Code Section 162(m). The Company currently expects that a substantial portion of executive compensation will not be deductible for income tax purposes for the full fiscal year. As a result, the Company’s estimated annual taxable income is forecasted to be positive, despite an expected pretax book loss. Accordingly, the Company’s estimated annual effective tax rate is negative, as the projected annual income tax expense is divided by an expected pretax book loss. The application of this negative AETR to year-to-date ordinary pretax loss results in the recognition of income tax expense in the interim period, rather than a tax benefit that would otherwise be expected based on the pretax loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company recognized the tax effect of a discrete item during the three months ended March 31, 2026, which further impacted income tax expense in the period. Discrete items are excluded from the determination of the AETR and are recorded in the period in which they occur. During the period, the Company recognized a book loss of approximately $6.9 million related to the sale of the Company’s marketable securities in American Bitcoin Corp (“ABTC”) stock. For income tax purposes, the majority of the approximate $32.5 million of proceeds from the sale of the Company’s ABTC stock resulted in a $32.5 million were taxable ordinary income which is treated as a discrete item in the interim period. The income tax effect of this transaction increased current income tax expense by approximately $9.5 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s effective tax rate for the three months ended March 31, 2026, was (9.0%). The primary drivers of the variance from the statutory rate were state taxes, Sec. 162m disallowed compensation, and valuation allowance. The Company will continue to assess its estimated annual effective tax rate each reporting period. Changes in forecasted pretax income, the amount of non-deductible compensation under Section 162(m), or other factors could result in significant adjustments to the Company’s interim income tax provision in future periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2025, the Company did not record any income tax expense or benefit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company’s history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of all deferred tax assets. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets of approximately $49.4 million as of March 31, 2026 and $38.3 million as of December 31, 2025. For the three-month period ended March 31, 2026, the change in valuation allowance is approximately $11.1 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2026, the Company has federal, state post-apportioned, and foreign net operating loss (“NOL”) carryforwards of approximately $76.7 million, $74.5 million, and $0, respectively. Of the federal amount, $29.8 million have a limited carryforward period and will begin to expire in 2026, and $47.0 million will have an indefinite carryforward period. Of the state post-apportioned amount, $74.5 million have a limited carryforward period and will begin to expire in 2038.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of the U.S. NOL carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed a Section 382 study through December 31, 2025, and concluded that it underwent ownership changes as defined by the Code on September 10, 2013, March 31, 2014, May 24, 2016, December 5, 2019, March 31, 2020, March 31, 2021, and February 10, 2025. The Company had a net unrealized built-in loss (“NUBIL”) position at each ownership change date. As a result, the Company’s utilization of certain tax attributes, including amortization of acquired intangible assets, is subject to the Section 382 limitation. The Company has approximately $76 million of acquired intangible assets capitalized between 2013 and 2023 that are subject to this limitation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any future ownership changes that may occur after December 31, 2025, may limit the Company’s ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company’s effective tax rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s income tax expense (benefit) for the three months ended March 31, 2026 is as follows ($ in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify">U.S. Federal</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,537</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,331</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Current income tax expense (benefit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">U.S. Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Deferred income tax expense (benefit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Total income tax expense (benefit)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 8537000 4331000 12868000 12868000 6900000 32500000 32500000 9500000 0.09 49400000 38300000 11100000 76700000 74500000 0 29800000 47000000 74500000 76000000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 15. Regulatory </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities, the Company’s broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company’s broker-dealer subsidiary is Dominari Securities is subject to SEC Uniform Net Capital Rule (Rule 15c3-1), which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule15c3-1. As of March 31, 2026, Dominari Securities had net capital of approximately $23.4 million in excess of minimum net capital requirement of $0.7 million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dominari Securities customers’ securities transactions are introduced on a fully-disclosed basis with its clearing broker/dealers. The clearing broker/dealers are responsible for execution, collection of and payment of funds and, receipt and delivery of securities relative to customer transactions. Off-balance-sheet risk exists with respect to these transactions due to the possibility that customers may be unable to fulfill their contractual commitments. The clearing broker/dealers may charge any losses it incurs on customers to Dominari Securities. The Company seeks to minimize this risk through procedures designed at Dominari Securities to monitor the creditworthiness of its customers and to ensure that customer transactions are executed properly by the clearing brokers, by monitoring all customer activity and reviewing information it receives from its clearing broker on a daily basis.</p> 23400000 700000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 16. Related Party Transactions </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, the Dominari Holdings engaged the services of Revere Securities, LLC (“Revere”) to assist in the management and building of the Company’s investment processes. Kyle Wool, Chief Executive Officer and one of the Company’s board members, was previously a member of the board of directors of Revere until June 2023 and held approximately 30% of Revere’s outstanding equity until May, 2025. From time to time, the Company participates in offerings of securities as an underwriter in transactions in which Revere also participates as an underwriter. For the three months ended March 31, 2026, there were no such transactions. The Company earned $368,000 in the three months ended March 31, 2025 in transactions, which Revere also participated as an underwriter. As of May 20, 2025, Kyle Wool no longer holds an equity interest in Revere.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year December 31, 2024, the Company entered into employee loans with various employees totaling $2.4 million. The terms of the loan agreements range from 3 years to 7 years, with an average annual interest rate of approximately 3.2%. The total interest received for the three months ended March 31, 2026 and 2025 was approximately $17 thousand and $21 thousand, respectively. As of March 31, 2026 and 2025, the total outstanding balance of the employee loans was $1.7 million and $2.0 million, respectively and are included in loans to employees on the accompanying unaudited condensed consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of the Company’s investments are made through related party special purpose vehicles (the “Series Funds”). Those Company investments in the Series Funds without readily determinable fair values are accounted for using the measurement alternative and are are classified as long-term equity investments. Approximate carrying values of such related party long-term equity investments was $261 thousand and $150 thousand as of March 31, 2026 and December 31, 2025 respectively. Those Company investments in the Series Funds which have readily determinable fair values are classified as marketable securities with an approximate fair value of $2.3 million as March 31, 2026 and December 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company owns 90% of AV Manager and AV Investment Manager, the remaining 10% is owned by non-controlling parties. As such, 10% of any profits earned by these entities are attributable to non-controlling interests and are presented in the unaudited condensed consolidated statements of changes in stockholders’ equity. As of March 31, 2026, the amount attributable to non-controlling interest was $23 thousand. There is $21 thousand payable to non-controlling interests as of March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company earns revenues for managing certain pooled investment vehicles which are related parties. These include the entirety of the management fee revenues totaling $0.3 million and $0.1 million for the three months ended March 31, 2026 and 2025, respectively and are classified as management fees in Note 12 and included in other revenue within the statement of operations. The total amount of contract liabilities disclosed in Note 2 represented amounts received in advance of revenue earned on managing such related party investment vehicles and are listed as contract liabilities in the unaudited condensed statement of financial condition totaling $4.7 million as of March 31, 2026 and $4.5 million as of December 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, Dominari Securities provides underwriting and brokerage services to the Series Funds. As a result of services provided, the Company recognized approximately $0.4 million in underwriting revenue, $1.1 million in carried interest revenue, and $1.0 million of commission revenue during the three months ended 2026.</p> 0.30 368000 2400000 P3Y P7Y 0.032 17000 21000 1700000 2000000 261000 150000 2300000 2300000 0.90 0.10 0.10 23000 21000 300000 100000 4700000 4500000 400000 1100000 1000000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 17. Segment Reporting</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the <span style="-sec-ix-hidden: hidden-fact-126">Chief Executive Officer</span>, in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy Aikido. The Dominari Financial reportable business segment represents the Company’s broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy Aikido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy Aikido.</p> <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CODM has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the “<i>Summary of Significant Accounting Policies</i>”.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The measures of segment profitability that are most relied upon by the CODM are gross revenue and net income (loss), as presented within the table below and reconciled to the unaudited condensed consolidated statement of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Dominari<br/> Financial</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Legacy<br/> Holding Co.</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,805</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Compensation and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,891</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,268</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,159</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Professional and consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">876</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,063</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,329</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,392</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Income / (loss) from operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,182</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,622</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Loss on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,014</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,014</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,845</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,845</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income (/loss) before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,027</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(44,467</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net income (loss)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,895</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,335</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Non-controlling interests</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss attributable to stockholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,918</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,104</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,216</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85,320</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended March 31, 2025</b></span></td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dominari <br/> Financial</b></span></td> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legacy<br/> Holding Co.</b></span></td> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated</b></span></td> <td style="white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         7,240</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,240</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Costs</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation,  benefits and advisory fees</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,595</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,806</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,401</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional and consulting fees</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">775</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">829</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other expenses</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,544</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,348</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,892</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,953</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,929</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,882</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other (expenses) income</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on marketable securities</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(168</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(168</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized loss on note receivable</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">221</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">221</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in carrying value of investments</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">320</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">320</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other (expenses) income</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">394</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">394</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,953</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,535</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,488</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,202</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,103</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,335</span></td> <td> </td></tr> </table> Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is the Chief Executive Officer, in deciding how to allocate resources to an individual segment and in assessing performance. 2 Additionally, the CODM views the expenses listed below to be significant in their analysis.<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended March 31, 2026</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Dominari<br/> Financial</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Legacy<br/> Holding Co.</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,805</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,805</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Operating Costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Compensation and benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,891</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,268</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,159</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Professional and consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">876</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,063</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,329</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,392</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Income / (loss) from operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,182</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,622</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other (expenses) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-left: 9pt">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Loss on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,014</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,014</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,845</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,845</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net income (/loss) before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(53,027</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(44,467</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,868</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net income (loss)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,895</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,335</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Non-controlling interests</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">23</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss attributable to stockholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,560</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,918</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(57,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,104</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,216</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85,320</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended March 31, 2025</b></span></td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dominari <br/> Financial</b></span></td> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legacy<br/> Holding Co.</b></span></td> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap; text-align: center"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated</b></span></td> <td style="white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         7,240</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,240</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Costs</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation,  benefits and advisory fees</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,595</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,806</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,401</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professional and consulting fees</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">775</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">829</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other expenses</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,544</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,348</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,892</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,953</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,929</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,882</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other (expenses) income</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest income</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on marketable securities</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(168</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(168</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unrealized loss on note receivable</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">221</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">221</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in carrying value of investments</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">320</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">320</span></td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other (expenses) income</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">394</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">394</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,953</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,535</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,488</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,202</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,103</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,335</span></td> <td> </td></tr> </table> 35805000 35805000 23891000 44268000 68159000 291000 585000 876000 3063000 1329000 4392000 8560000 -46182000 -37622000 108000 108000 61000 61000 -7014000 -7014000 -6845000 -6845000 8560000 -53027000 -44467000 12868000 12868000 8560000 -65895000 -57335000 23000 23000 8560000 -65918000 -57358000 25104000 60216000 85320000 7240000 7240000 7595000 28806000 36401000 54000 775000 829000 1544000 1348000 2892000 -1953000 -30929000 -32882000 21000 21000 -168000 -168000 -221000 -221000 -320000 -320000 394000 394000 -1953000 -30535000 -32488000 19202000 33103000 52335000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 19. Subsequent Events </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividend</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 4, 2026, the Company’s board of directors authorized a special cash dividend of, in aggregate, approximately $9.0 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to the Company’s common stock shareholders and certain warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2026.</p> 9000000 0.31 false false false false http://fasb.org/srt/2026#ChiefExecutiveOfficerMember 0000012239 false Q1 --12-31 Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly. Investment made in these companies are through both an SPV and direct investments.